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ABSTRACT 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric 
oxide (NO) synthesis and elevated plasma levels associate with poor 
cardiovascular and renal outcomes. The dimethylarginine 
dimethylaminohydrolase enzymes (DDAHs; 1 and 2) metabolise ADMA. A 
DDAH1 gene variant associates with higher kidney tissue mRNA expression, 
lower plasma ADMA but counter-intuitively, a steeper rate of eGFR decline. 
This indicates that renal DDAH1 activity may be deleterious and circulating 
ADMA does not necessarily reflect the NO-ADMA balance (or severity of 
disease) within kidney tissue. This study tests the hypothesis that reduced 
renal DDAH1 activity protects against the progression of kidney function 
decline, independent of circulating ADMA. 
Renal DDAH1 expression predominates within the proximal tubule. A 
novel proximal tubule-specific DDAH1 knock-out (PTD1KO) mouse was 
developed, which demonstrated tubule-specific dysregulation of ADMA and 
NO that was not evident systemically. Phenotyping studies in PTD1KO mice 
did not identify consistent alterations of urinary biochemistry at baseline or 
after salt loading, however, proteomic analysis revealed significant alterations 
of urinary peptides at baseline; including down-regulation of uromodulin and 
collagen. At 12 weeks following folate renal injury, the PTD1KO mouse 
exhibited less kidney function decline, collagen deposition and pro-fibrotic 
gene expression (Col12!, TGF" and ET-1) than controls. Furthermore, ADMA 
and DDAH1 inhibition reduced tubular sodium and fluid reabsorption in rat 
microperfusion studies, although studies in PTD1KO mice failed to reproduce 
this effect. Finally, in vitro studies using a PT cell line and primary PT culture 
indicated an inhibitory effect of ADMA upon PT cell proliferation.  
Consistent with recent human genetic studies, these data provide 
experimental evidence indicating a reduction of renal tubule DDAH1 activity 
can protect against progressive kidney fibrosis and function decline, 
independent of plasma ADMA. This work provides novel insights into the role 
of the NO-ADMA-DDAH axis within the kidney, particularly the tubule.  
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epPCR End-point polymerase chain reaction 
ES Embryonic cell 
ESRD end stage renal disease 
ET-1 Endothelin-1 
EtBr Ethidium bromide 
FACS Fluorescence-activated cell sorting 
FAD Flavin adenine dinucleotide 
FAM 6-carboxyfluorescein 
FCCP carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
FCS Foetal calf serum 
FeNa Fractonal excretion of sodium 
FITC Fluorescein isothiocyanate 
FMN Flavin mononucleotide 
FXR farnesoid X receptor 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GN glomerulonephritis 
GFP Green fluorescent protein 
GFR glomerular filtration rate 
GTP Guanosine triphosphate 
GWAS Genome-wide association study 
HDL high density lipoprotein 
HPLC high performance liquid chromatography 
HPRT hypoxanthine phosphoribosyltransferase 1 
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HTA Human Tissue Act 
HUVECs Human umbilical vein endothelial cells 
IFN-" interferon-"  
Ig Immunoglobulin 
IL-1 interleukin-1 
iNOS 
KDIGO 
KDOQI 
inducible NOS/NOSII 
Kidney Disease Improving Global Outcomes 
Kidney Disease Outcomes Quality Initiative 
IP Intra-peritoneal 
IV Intra-venous 
KAP Kidney androgen-sensitive protein 
KC Kidney androgen-sensitive protein Cre recombinase 
ITS Insulin transferrin selenium 
Jv Tubular absorption rate 
Km Michaelis constant 
LACKABO London Arterial Calcification Kidney and Bone Outcomes study 
LacZ "-galactosidase 
L-NAME N-nitro L-arginine methylester 
LCMS/MS Liquid chromatography mass spectroscopy (dual) 
L-NMMA N(G)-monomethyl-L-arginine 
LPS Lipopolysaccharide 
MA methylarginine 
MAME Methylarginine-metabolising enzymes 
MCP-1 monocyte chemoattractant protein-1 
MDRD modified diet in renal disease 
MRC Medical Research Council 
mRNA messenger RNA 
MS mass spectrometry 
MTS 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
m/z Mass to charge ratio 
Na/H Sodium-hydrogen exchanger  
NADPH Nicotinamide adenine dinucleotide phosphate 
Na/K-ATPase Sodium/potassium-adenosine triphosphate enzyme pump 
NCBI National Center for Biotechnology Information 
NCEPOD National Confidential Enquiry into Patient Outcome and Death 
ND not done 
NF-#! nuclear factor #B 
NHE3 Sodium-hydrogen exchanger-3 
NHS National Health Service 
NHANES North American National Health and Nutrition Examination Survey 
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NHPSTs Normal human proximal straight tubular cells 
NKCC2 Sodium-potassium chloride co-transporter 
NKF US National Kidney Foundation 
NO nitric oxide 
NOS nitric oxide synthase 
NOx nitrogen oxide species 
nNOS neuronal NOS/NOSI 
NRF Nuclear factor 
ns Non-significant 
NSAIDs Non-steroidal anti-inflammatories 
NTN Nephrotoxic nephritis 
NTS Nephrotoxic serum 
OCR Oxygen consumption rate 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PAH Para-aminohippurate 
PAN Puromycin aminonucleoside nephrosis 
PAS periodic acid-schiff 
PBS phosphate-buffered saline 
PCr Plasma creatinine 
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PFA paraformaldehyde 
PRMT protein methyl transferases 
PT(C) Proximal tubule (cell) 
PTD1KO Proximal tubule specific DDAH1 knock-out 
RAS renin-angiotensin system 
RIFLE Risk; Injury; Failure; Loss; End-stage renal disease 
RIPA Radio-Immunoprecipitation Assay 
RNA  ribonucleic acid 
RPMI Roswell Park Memorial Institute (cell culture media) 
RPOL RNA polymerase 
ROCK Rho-kinase; 
RPL13A ribosomal protein 13A 
RRT renal replacement therapy 
rtPCR reverse transcription PCR 
SBP systolic BP 
SCX Strong cation exchange chromatography 
SD standard deviation 
SDMA symmetrical dimethylarginine 
SDS Sodium dodecyl sulphate 
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SEM standard error of the mean 
siRNA small inhibitory RNA 
SNAP S-nitroso-N-acetyl-l,l-penicillamine 
SNO-Hb S-nitrohaemoglobin 
SNP single nucleotide polymorphism 
SPE Solid phase extraction 
SUN Serum urea nitrogen 
SVR systemic vascular resistance 
TAL Thick ascending limb 
TEMED Tetramethylethylenediamine 
TGF Tubuloglomerular feedback 
TGF-! transforming growth factor-!  
TNF-$ tumour necrosis factor-$ 
UCL University College London 
UCP Uncoupling protein 
UMOD uromodulin 
UNx uninephrectomy 
UUO Unilateral ureteric obstruction 
UV Utero-vaginal 
VDR Vitamin D receptor 
VEGF vascular endothelial growth factor 
VSMC Vascular smooth muscle cell 
WT wild-type 
YFP Yellow fluorescent protein 
 
18 
1 INTRODUCTION 
1.1 The kidney in health 
1.1.1 Physiological kidney function 
The central role of the mammalian kidney is to maintain an internal metabolic 
balance by regulating circulatory volume and systemic blood pressure whilst 
removing unwanted solutes. The human kidney is highly vascular and despite 
weighing an average of only 150 grams, it can filter up to 150 litres of blood 
per day [1] (Figure 1A). Each kidney contains 1-2 million functional subunits 
[2] (nephrons; Figure 1B) that interface with the intravascular and urinary 
compartments in order to monitor and regulate the composition and volume of 
circulating plasma. To achieve this, three processes are key; 1) filtration of 
plasma by the glomerulus (ensuring large plasma proteins remain), 2) 
selective reabsorption of filtrate into the tubular epithelial cell lining and finally, 
3) secretion of unwanted solutes and metabolites from peritubular capillaries 
into the tubular fluid.  
 
 Figure 1. Schemata of the kidney and nephron 
A) Whole kidney structure; a protective fibrous capsule envelopes the kidney; cortex houses 
glomeruli and tubular portions of the nephron; medulla contains Loops of Henle, collecting 
ducts and larger vessels; central pelvis contains the bundle of vessels, nerves and urinary 
collecting system. B) The nephron; blood is filtered at the glomerulus; ultrafiltrate passes into 
the proximal tubule where the majority is selectively reabsorbed back into the peritubular 
capillaries and other metabolites are secreted; further water and solute exchange occurs 
through the Loop of Henle (via vasa rectae capillaries) and distal tubule; urine flows down the 
collecting duct. (Images adapted from Wellcome Images, N0026029). 
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In addition to excretion, the kidney has other critical homeostatic 
responsibilities including secretion of the hormone erythropoietin (stimulating 
bone marrow production of red blood cells), and hydroxylation of vitamin D 
into its active form - essential to calcium and phosphorus regulation ensuring 
bone health. 
1.1.2 Measurement of kidney function 
Kidney function is determined by a quantification of the glomerular filtration 
rate (GFR). Creatinine, a metabolite of creatine phosphate from muscle, 
serves as a plasma marker of GFR. After release into plasma it is freely 
filtered at the glomerulus but since it does not undergo tubular reabsorption, it 
reflects GFR under steady-state conditions of dietary intake and muscle 
breakdown. Limitations to its interpretation include; the assumption of steady-
state; individual variability of muscle mass; and variable tubular secretion of 
creatinine (up to 28% of total clearance [3]) resulting in over-estimates of 
GFR. Despite being an imperfect surrogate for GFR, creatinine remains the 
most common clinical marker of renal function, largely due to the convenience 
of automated plasma measurement [4, 5] whilst gold standard tests for 
measuring GFR using radioisotopes or inulin clearance remain impractical. 
The majority of assays to measure creatinine are based on the original 
colorimetric Jaffe reaction [4], although the specific techniques used vary 
widely between laboratories which in turn affects their performance [6]. More 
recently, official working groups such as the National Kidney Disease 
Education Program (NKDEP, USA) have recommended calibration of clinical 
assays against the reference method – isotope dilution mass spectrometry [7]. 
To counter some of the limitations attributed to muscle mass, current 
clinical practice uses a derivation of plasma creatinine proposed by the 
Modification of Diet in Renal Disease study group, which corrects for 
confounding variables such as age, gender and ethnicity and provides a more 
precise value for many individuals [8]. Most laboratories now routinely provide 
estimated GFR (eGFR) values (alongside creatinine values) that are derived 
using a simplified MDRD equation (Figure 2 [9]). 
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A) Complete MDRD-1 equation (mL/min/1.73m2) ! !"#!!!"#!!!!!!!!!!"#!!!!!"#! !!!"#!!"!!"#$%" ! !!!"#!!"!!"#$%! !"# !!!!"#!!!"#!!!!!"# 
B) Simplified MDRD-2 equation (mL/min/1.73m2) ! !"#!!!"#!!!!!"#!!!"#!!!!!"#! !!!"#!!"!!"#$%" !!!!!"!!!"!!"#$%! 
 
Figure 2. MDRD equations for calculating GFR from serum creatinine values 
(A) Complete; (B) Simplified. Where PCr=serum creatinine concentration (mg/dL) (alkaline 
picrate method); SUN=serum urea nitrogen concentration (mg/dL) (urease method); 
Alb=serum albumin concentration (g/dL) (bromocresol green method). 
 
Despite widespread international use of serum creatinine and the 
MDRD equation, debate continues as to the best method to quantify GFR, 
given the limitations of creatinine. Alternative serum markers (such as cystatin 
C and symmetric dimethylarginine; SDMA, see further text [10]) or improved 
creatinine-based eGFR formulae such as that developed by the CKD 
Epidemiology Collaboration (CKD-EPI, [11]) have been proposed but as yet, 
have not been adopted in routine clinical practice.  
Accurate measurement of GFR in experimental animals is not straight-
forward. Performed traditionally using inulin or para-aminohippurate (PAH), 
results can be confounded by anaesthetic agents and volume depletion 
resulting from sequential venesection. Similar to the clinical setting, concerns 
have been raised regarding the specificity of assays based on the Jaffe 
reaction in mice [12]. High pressure liquid chromatography (HPLC) of serum 
creatinine has been reported to be a much more reliable assay that correlates 
well with labelled inulin clearance [13] and more recently, fluorescein 
isothiocyanate (FITC)-labelled sinistrin (a polysaccharide similar to inulin) has 
been used as an injectable marker of GFR that can be quantified 
transcutaneously over time [14].  
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1.2 The kidney in disease 
1.2.1 Mechanisms of kidney injury 
1.2.1.1 Perfusion dependence 
For their size (<2% of body mass), the kidneys require a relatively large 
proportion of cardiac output (~20%) in order to satisfy their metabolic 
demands. This presents a particular vulnerability to injury for if perfusion 
pressure is compromised for instance, by hypovolaemia; vascular disease 
(eg. hypertension or diabetic vasculopathy) or excess vasoactive hormones 
and drugs, then GFR declines as tubules quickly become hypoxic and 
incapable of selecting essential filtrate from waste. 
Other functional and structural factors predispose the kidney to injury 
which are best described in terms of the nephron region affected: glomerular 
or tubulointerstitial. 
 
1.2.1.2 Glomerular disease 
Diabetes is the leading cause of chronic renal disease in the Western World 
and is characterised by progressive glomerular destruction [15]. Sustained 
hyperglycaemia causes micro-vascular disease within the glomerular capillary 
bed leading to failure of sieve function, proteinuria and eventually, irreversible 
glomerulosclerosis. 
The glomerulus is particularly susceptible to immune-mediated damage 
that causes a significant proportion of acute intrinsic kidney injury. Local or 
remote inflammatory responses can precipitate glomerulonephritis due to 
trapping of circulating immune complexes within the small-diameter 
glomerular capillary loops. In addition, the glomerular basement membrane 
contains two antigens that cause specific types of renal disease; the Amyloid 
P component (a glycoprotein) and the Goodpasture antigen (associated with 
type IV procollagen).  
Histological features of primary glomerular disease are classified 
according to: 
1. Distribution of abnormal glomeruli (focal or diffuse). 
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2. Distribution of abnormalities within single glomeruli (global or 
segmental). 
3. Nature of glomerular abnormalities (endothelial, mesangial or 
endothelial cell proliferation; basement membrane appearance; 
presence of immune complexes) [1] 
 
1.2.1.3 Tubulointerstitial disease 
The renal tubule is highly metabolically active and its vulnerability to hypoxia 
is compounded by a low physiological oxygen tension of blood reaching the 
deep medullary peritubular capillaries [16].  Active reabsorption of filtrate and 
secretion of unwanted solutes is not only energy-demanding, but concentrates 
metabolites or exogenous compounds locally, to levels that can cause direct 
cellular toxicity or simply overwhelm tubular cell function. In addition, many 
drugs (eg. non-steroidal anti-inflammatories; NSAIDs) and antibiotics can 
directly trigger a tubulointerstitial hypersensitivity reaction, while compounds 
such as urate precipitate within tubular lumina causing obstruction, 
inflammation and cell death. 
Finally and perhaps most significantly, the tubulointerstitium lies 
structurally and functionally between the glomerular and urinary collecting 
system and is therefore exposed to the migrating insults from glomerular 
protein leak upstream (Chapter 1.2.8) or ascending infection and obstructive 
pressure from downstream within the lower urinary tract. 
Histological features of tubulointerstitial disease include: 
1. Interstitial oedema 
2. Inflammatory cell infiltration (lymphocytes, plasma cells, 
macrophages, neutrophils) 
And later: 
3. Interstitial fibrosis  
4. Tubular atrophy 
5. Persistent lymphocyte-macrophage infiltration [1] 
 
In a clinical setting, the manifestations of renal damage fall into two 
categories defined by chronicity: acute kidney injury (AKI) and chronic kidney 
disease (CKD).   
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1.3 Acute kidney injury (AKI) 
1.3.1 Definition and classification of AKI 
Broadly defined as a rapid loss of renal function, acute kidney injury (AKI) 
replaced the term acute renal failure as part of an international definition and 
classification campaign initiated by the Acute Dialysis Quality Initiative (ADQI) 
[17]. This international collaboration produced the “RIFLE” criteria of AKI 
definition and staging based upon serum creatinine, urine output and the need 
for renal replacement therapy RRT (“RIFLE”: Risk; Injury: Failure; Loss; End-
stage renal disease [17]). Subsequent formal collaborations have developed 
these principles (Acute Kidney Injury Network; AKIN [18]) and most recently, 
the Kidney Disease: Improving Global Outcomes group (KDIGO) published 
definition and staging guidelines that have been adopted by most countries 
including the UK Renal Association (Figure 3) [19].  
 
AKI is defined with ANY of the following: 
a) Increase in serum creatinine #0.3mg/dL (#26.5µmol/L) within 48 hours 
b) Increase in serum creatinine #1.5x baseline within 7 days 
c) Urine volume <0.5mL/kg/h for 6 hours 
 
Stage Serum creatinine Urine output 
1 1.5-1.9 times baseline OR #0.3mg/dL 
(#26.5µmol/L) increase 
<0.5mL/kg/h for 6-12 
hours 
2 2.0-2.9x baseline <0.5mL/kg/h for #12 
hours 
3 3.0x baseline OR #4.0mg/dL (#353.6µmol/L) 
OR initiation of RRT OR in patients <18 
years, decrease in eGFR <35mL/min/1.73m2 
Anuria for #12 hours 
 
Figure 3. Definition and staging of Acute Kidney Injury (AKI) 
As described by the KDIGO guidelines [19] 
1.3.2 Incidence of AKI 
The incidence of community acquired AKI is around 1% but rises significantly 
to 7% following hospital admission [20, 21]. The difference derives from a 
proportion of community AKI events inevitably passing undiagnosed. 
Furthermore, hospitalisation increases the likelihood of developing AKI due to 
consequences of the presenting condition plus exposure to iatrogenic insults 
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such as contrast- or drug-related nephrotoxicity. The recent NCEPOD report 
(National Confidential Enquiry into Patient Outcome and Death, 2009) stated 
that a fifth of all hospital-acquired AKI was both predictable and avoidable and 
only 50% of AKI care was considered by advisors as good [22]. For this 
reason, considerable efforts have been made to produce internationally 
standardised definitions for AKI and guidelines to assist its effective 
management [23, 24]. 
 
Causes / exposures Risk factors / susceptibilities 
Sepsis Volume depletion 
Critical illness Advanced age 
Circulatory shock Female gender 
Burns Black race 
Trauma CKD 
Cardiac surgery Chronic diseases (heart, lung, liver) 
Major surgery (non-cardiac) Diabetes mellitus 
Nephrotoxic drugs Cancer 
Radiocontrast dyes Anaemia 
Poisonous plants / animals  
 Table 1. Causes and risk factors for AKI 
Adapted from KDIGO Clinical Practice Guideline for Acute Kidney Injury [25] 
1.3.3 Causes and risk factors for AKI 
An early study of community-acquired AKI admissions into hospital 
proportionately categorised the underlying causes to pre-renal 
(hypoperfusion, 70%); intrinsic (10%) and post-renal obstruction (20%). The 
vast majority of hospital-acquired AKI occurs in “high-risk” patients who are 
subsequently exposed to multiple sources of injury (Table 1). 
1.3.4 Outcomes in AKI 
1.3.4.1 Short-term 
The most reliable AKI outcome data come from studies of patients admitted to 
intensive care units or following major surgery. Serum creatinine is linearly 
associated with an increased risk of adverse outcomes and in studies of 
patients following cardiac surgery or with heart failure, even small rises predict 
a poorer prognosis [26]. Patients who develop AKI in hospital have increased 
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lengths of stay [25] and depending upon co-morbidities, suffer a 10 to 80% 
risk of mortality [23]. There is reasonable evidence to suggest that AKI is 
more than a consequence of severe morbidity, but it contributes to other 
organ dysfunction. Pathways of inflammation and apoptosis within the kidney 
have been shown to induce maladaptive cellular behaviour in distant organs 
through metabolic disturbances, circulating activated leucocytes, cytokines 
and chemokines [27] thus increasing the likelihood of multi-organ failure and 
associated mortality.  
 
1.3.4.2 Long term 
An episode of AKI predisposes an individual to subsequent AKI episodes, 
established CKD, end-stage renal disease (ESRD) and a higher mortality risk. 
It seems the relationship between AKI and CKD is bidirectional in that CKD 
predisposes to an AKI episode whilst AKI can lead to development of CKD. A 
large systematic review of almost 50,000 AKI survivors reported a CKD 
incidence rate of 7.8 events per 100 patient-years (although data to present 
comparative rates in well-matched control patients without AKI were not 
available) [28]. A retrospective analysis of patients having suffered severe, 
dialysis-dependent AKI had a 28-fold increased risk of developing CKD stage 
4 or 5 over 8-years plus a greater than 2-fold risk of death over hospitalised 
patient controls without AKI [29]. A study of patients with initial renal recovery 
(within 30 days) from dialysis-dependent AKI reported a 3-fold higher risk of 
requiring long-term dialysis over 10 years in comparison to hospitalised age-
matched controls who did not receive acute dialysis [30]. 
Finally, a retrospective study of 3000 patients following cardiothoracic 
surgery reported worse 10 year survival among patients who had developed 
AKI following surgery and this was proportional to severity. Even patients with 
complete renal recovery after AKI had an increased hazard ratio for death of 
1.28 when compared to patients without AKI [31]. 
1.3.5 Treatment of AKI 
The treatment of AKI depends upon the underlying cause(s) and it therefore 
stands that the majority of cases are treated supportively (intra-venous fluids, 
antibiotics as necessary and avoidance of nephrotoxic agents). Primary 
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intrinsic renal diseases such as autoimmune glomerulonephritis are relatively 
rare and dictate their own specific therapies that go beyond the scope of this 
thesis. 
If kidney function declines despite supportive therapy, then renal 
replacement therapy (RRT; in the form of dialysis or extra-corporeal filtration) 
may need to be instituted. There are currently no pharmacological agents 
proven to effectively treat AKI once it is established. Historically, loop diuretics 
(purportedly to reduce tubular metabolic stress), low-dose dopamine [32] and 
fenoldopam [33] (increases in urinary flow by reducing sodium reabsorption or 
through vasodilation, improves renal perfusion) were proposed to be of benefit 
although none have stood the test of a large randomised control trial to 
support their routine use [23]. 
1.4 Chronic Kidney Disease (CKD) 
1.4.1 Definition and classification of CKD 
Chronic kidney disease (CKD) is broadly defined by the KDIGO group as 
“abnormalities of kidney structure or function, present for >3 months, with 
implications for health” [34]. Besides reduced GFR, the most important 
evidence of damage is persistent proteinuria but can also include persistent 
non-visible haematuria and structural abnormalities detected by imaging or 
histology [35]. 
A classification system proposed by the United States National Kidney 
Foundation (NKF) based upon eGFR values [36] has been adopted by the UK 
Renal Association [35] and KDIGO (Table 2) [34] .  
A normal age-related GFR decline occurs that is independent of any 
identifiable disease. Longitudinal human study data of creatinine clearances 
[37] corroborate classic inulin clearance studies in experimental animals [38] 
that demonstrate decline begins from age 30 onwards at a rate of 
approximately 1mL/minute/year. It follows that many elderly people will have a 
GFR in the range of 60mL/min, although often without the other evidence of 
kidney damage required for a diagnosis of CKD. 
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Stage GFR mL/min/1.73m2 Description 
1 greater than 90 Normal GFR with other evidence of kidney damage 
(e.g. proteinuria, haematuria or structural 
abnormalities) 
2 60 to 89 Mild renal impairment with other evidence of kidney 
damage (e.g. proteinuria, haematuria or structural 
abnormalities) 
3 30 to 59 Moderate renal impairment 
4 15 to 29 Severe renal impairment 
5 less than 15 Established renal failure or renal replacement therapy 
Table 2. K/DOQI guidelines for chronic kidney disease: evaluation, classification, and 
stratification. Adapted from [36]. 
1.4.2 Prevalence of CKD 
The North American National Health and Nutrition Examination Survey 
(NHANES) of over 13,000 individuals reported a CKD prevalence of 13% with 
elevated numbers according to increased age and presence of diabetes or 
hypertension [39]. Current UK estimates place CKD prevalence between 4 - 
8.5% [40, 41]. Given the lack of symptomatology with even moderately 
reduced renal function, these figures are likely under-representative as a 
substantial number of cases will not present to medical services and therefore 
remain undiagnosed.  
1.4.3 Causes of CKD 
The causes of CKD are diverse, often multifactorial and definitive data on 
underlying disease is incomplete.  Diagnostic histological examination is 
rarely possible given that most patients present too late in the course of their 
disease, when a kidney biopsy is often not performed, justified or non-
diagnostic (having missed the acute injury). 
Population studies and data collections provide some clues as to what 
conditions underlie the development of CKD although they do not prove a 
direct causal link. A North American prospective study of almost 25,000 
individuals found that diabetes, hypertension and smoking held the strongest 
associative risk to developing CKD over a twenty-year period [42]. Data from 
the UK Renal Registry reveals diabetes as the single most common primary 
renal diagnosis in CKD patients commencing RRT (Table 3). 
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Diagnosis % patients 
Diabetes 24.2 
Glomerulonephritis 11.6 
Pyelonephritis 7.4 
Hypertension 6.7 
Polycystic kidneys 6.6 
Renal vascular disease 7.5 
Other 16.2 
Uncertain aetiology 19.8 
 Table 3. Percentage distribution of primary renal diagnosis in a 2010 cohort of patients 
commencing RRT. Adapted from [43]. 
1.4.4 Complications of CKD 
Although the majority of people with CKD do not develop ESRD, they are at a 
substantially increased risk of mortality relative to the age-adjusted non-CKD 
population - largely due to cardiovascular (CV) disease. A retrospective cohort 
study of over 1000 CKD patients found that only 4% had progressed to RRT 
within 5.5 years but 69% died - of which, 46% were due to cardiovascular 
events such as stroke or myocardial infarction [44]. In addition, a recent inter-
continental meta-analysis including 100,000 individuals with albumin : 
creatinine ratio (ACR) measurements and 1.1 million people with urinary 
dipstick protein measurements found that reduced eGFR and presence of 
albuminuria were associated with all-cause and cardiovascular mortality 
independently of each other and other traditional cardiovascular risk factors 
[45].  
The extra-renal complications of CKD begin to manifest from mild CKD 
(stage 3) and progress with kidney function decline. Patients commonly 
require exogenous iron and erythropoietin to support physiological 
haemoglobin levels and chelating agents to temper the effects of rising 
phosphorus levels and ensuing hyperparathyroidism-related bone disease. In 
CKD, disordered bone metabolism (termed, CKD-MBD; chronic kidney 
disease – mineral bone disorder) directly accelerates vascular calcification 
creating stiff, non-compliant vessels that are narrowed and fail to deliver blood 
to satisfy metabolic demands. Compounded by a reduction in the oxygen-
carrying capacity of the blood (anaemia), the complications of CKD appear to 
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conspire with one another to reduce overall tissue perfusion and thus 
enhance morbidity and mortality. 
The financial cost implications of CKD mirror the impact of morbidity 
upon the individual. When costs directly attributable to CKD are combined 
with the indirect costs (such as RRT, cardiovascular events and hospital stay), 
total UK annual expenditure is estimated to be £1.45 billion. This figure 
represents almost 2% of the entire NHS budget and does not take into 
account spending on complications more discretely related to CKD such as 
heart failure or bone disease [46]. 
1.4.5 Progression of CKD 
Despite resolution or treatment of the underlying disease, many CKD patients 
exhibit accelerated rates of GFR decline beyond the expected fall of 
~1mL/min/year attributed to age. The limited renal specimens taken from 
patients with progressive renal disease confirm advancing glomerulosclerosis, 
tubular atrophy and interstitial fibrosis [47] - in keeping with animal models. 
Furthermore, regardless of the initiating cause, remarkably similar histological 
patterns are exhibited, prompting the proposition of a “final common pathway”.  
Further still, the severity of interstitial fibrosis has been shown to reliably 
predict the development of ESRD [48]. 
1.4.6 Mechanisms of renal fibrosis 
In the aftermath of acute renal injury, inflammation gives way to proliferation 
and repair although as the prevalence and progression of CKD suggests, 
there is often failure to completely switch-off these processes. The persistent 
state of inflammation and fibrosis arises from the interplay between 
maladaptive renal cell-type responses and ageing, genetic and epigenetic 
influences. Specific signalling molecules and pathways have been implicated 
but their relative contribution and interactions are complex and poorly 
understood (Figure 4) [49].  
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Figure 4. Factors implicated in renal fibrosis 
(A) IFN-", Interferon-"; IL-1, Interleukin-1; MCP-1, Monocyte chemoattractant protein-1; NO, 
Nitric Oxide; NF-#!, Nuclear factor #B; PDGF, Platelet-derived growth factor; Rho, Ras 
homolog gene family GTPase; ROCK, Rho-kinase; TGF-!, Transforming growth factor-!; 
TNF-$, Tumour necrosis factor-$; VEGF, Vascular endothelial growth factor. Adapted from 
[50]. (B) The interplay of genetics and cellular responses in renal fibrosis. Histological 
hallmarks include: a persistent inflammatory cell infiltrate with; loss and atrophy of tubular 
epithelial cells; migration and proliferation of myofibroblasts; matrix deposition and peritubular 
capillary rarefaction [48]. 
 
A popular hypothesis integrates theories of renal injury communication 
between kidney regions and how this precipitates a final common pathway of 
worsening fibrosis and functional decline.  
 
1.4.6.1 The final common pathway of CKD 
Animal studies performed during the late 20th century underpin the now widely 
accepted hypothesis that renal function decline is ultimately determined by the 
number of nephrons and their local glomerular pressures [51, 52]. As nephron 
number falls due to disease, existing glomerular and tubular structures 
develop hypertension and hypertrophy in an attempt to maintain the 
glomerular filtration rate (GFR); so called adaptive hyperfiltration. Over time 
however, these compensatory changes have deleterious effects. Raised 
glomerular capillary pressure stretches glomerular walls, enlarging pores that 
allow passage of plasma proteins. The mechanical strain also stimulates 
angiotensin II expression which is vasoactive, pro-fibrotic and impairs 
glomerular sieving function further [53]. 
Renin-angiotensin-aldosterone system 
Kallikrein-kinin system 
Endothelin 
Sympathetic nervous system  
Fibrinolytic system 
Complement cascade 
Cytokines (e.g. IL-1, IFN-", TNF-$) 
Chemokines (e.g. MCP-1) 
TGF-! signalling  
Other growth factors (e.g. VEGF, PDGF) 
NO system 
Intracellular transduction cascades 
(eg. NF-#B, Rho/ROCK) 
! ! 
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The transit of excessive filtrate protein initiates a cascade of pro-fibrotic 
and proinflammatory signals. Podocytes release pro-fibrotic TGF" [54] and 
tubular protein overload induces a tubular epithelial cell stress response to 
produce reactive oxygen species, cytokines, growth factors and vasoactive 
molecules that act both locally and downstream (Figure 4A). Inflammatory cell 
recruitment and activation is triggered and communicated throughout the 
tubulointerstitium resulting in infiltration of lymphocytes, neutrophils and 
macrophages.  
Interstitial ischaemia is a major factor in renal inflammation and fibrotic 
progression. Loss of peritubular capillaries is a histological hallmark feature of 
chronic tubulointerstitial disease and reduced renal parenchyma oxygenation 
has been demonstrated in animal models of CKD [55]. Hypoxia induces 
phenotypic change in tubular epithelial cells, fibroblasts and endothelial cells 
to respectively: drive inflammation, deposit extracellular matrix (fibrosis) and 
become apoptotic. 
Some researchers propose a complete phenotypic transformation of 
resident tubular epithelial cells into functional myofibroblasts occurs - so 
called epithelial to mesenchymal cell transition (EMT) [56]). Although this has 
convincingly been demonstrated in vitro, evidence of such in vivo is lacking. 
More recently, cellular fate mapping studies identify the pericyte (a 
myofibroblast precursor that encircles renal capillaries), as the origin of 
collagen-producing cells seen in fibrosis [57].  
 Further glomerular destruction [58] occurs due to the inflammatory 
milieu and extracellular matrix deposition destroys normal architecture, 
compromising blood flow. The result is a progressive reduction in nephron 
number and a vicious circle of progressive fibrosis and functional decline is 
established.  
1.4.7 Treatment of CKD 
Very few therapeutic agents for CKD are available despite increasing demand 
from an ageing population and intense basic science and clinical research. 
The mainstay of CKD therapy currently lies with renin-angiotensin system 
(RAS) blockade using angiotensin-converting enzyme inhibitors (ACEis) and 
angiotensin receptor blockers (ARBs).  
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Following landmark studies in CKD patients revealing that proteinuria 
reduction achieved by intensified blood pressure (BP) control slowed GFR 
decline [59, 60] a considerable amount of clinical trial activity has been 
devoted to exploiting this further. Many trials have subsequently demonstrated 
GFR protection with BP and proteinuria reduction using ACEi therapy over 
other conventional antihypertensive drug classes such as "-blockers or 
calcium-channel antagonists [61, 62]. The REIN (Ramipril Efficacy in 
Nephrology) study was the first to formally isolate the benefit of proteinuria 
reduction in CKD progression. Despite comparable BP control, ACEi therapy 
slowed GFR decline and progression to ESRD more effectively than non-
ACEi therapy and this effect associated with proteinuria reduction [63]. The 
proposed mechanisms of ACEi reduction of proteinuria and GFR decline are 
several-fold. Aside from reducing systemic BP and hyperfiltration, they can 
boost repair of podocytes, reduce mesangial cell hyperplasia and decrease 
expression of collagen I/IV and TGF" [64]. 
Evidence is now overwhelming for the routine use of ACE inhibitors 
and ARBs in cardiorenal protection for patients with CKD (those with 
proteinuric nephropathies perhaps having the most to gain). Alternative 
mechanisms of CKD progression have been targeted and although drugs 
exist at various stages of pharmacological development, none are yet proven 
to provide additional benefit over current approaches (Table 4). 
 
Drug Mechanism of action 
Aliskiren Renin blocker 
VDR agonist Inhibition of renin synthesis 
Pirfenidone Inhibition of TGF"  
Bardoxolone methyl* Antioxidant (NRF-2 agonist) 
Bindarit Inhibition of MCP-1 (CCL2) 
ET-1 antagonist Inhibition of ET-1 
Sulodexide Restores basement membrane 
Table 4. Novel drug therapies for CKD under development 
Where VDR, vitamin D receptor; TGF", transforming growth factor-"; NRF-2, nuclear factor 
(erythroid-derived 2)-like 2; MCP-1, monocyte chemoattractant protein-1; CCL2, chemokine 
ligand-2; ET-1, endothelin-1. *withdrawn from phase 3 trial in late 2012.  Adapted from [65]. 
 
Although CKD appears to progress along a final common pathway, a 
suitable signalling mechanism to therapeutically exploit is difficult to find.  The 
withdrawal of Bardoxolone from its phase three clinical trial [66] illustrates this 
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and confirms high specificity is required when targeting complex pathological 
pathways to protect renal function whilst avoiding intolerable adverse effects.  
Nitric oxide (NO) signalling stands as a logical candidate for 
investigation in renal injury and fibrosis due to clear roles in vascular tone, 
inflammatory responses and cell signalling. A number of regulatory molecules 
control NO production and it is their pathophysiology that forms the basis of 
this thesis. 
1.5 The Nitric Oxide Signalling Pathway 
Nitric oxide (NO) is a highly reactive molecule present in many different cell 
types with a diverse range of physiological roles. Its significance emerged in 
1987 when the previously described endothelium-derived relaxing factor 
(EDRF) was identified as NO [67]. NO was shown to regulate vascular tone 
(arterial smooth muscle relaxation) through activation of soluble guanylate 
cyclase to catalyse the formation of second messenger cyclic guanosine 
monophosphate (cGMP) [68]. These initial reports launched a whole new field 
of biological research that has subsequently implicated NO in a variety of 
homeostatic systems including neuronal transmission, immune responses, 
clotting cascades and fibrotic pathways [68]. 
1.5.1 Nitric Oxide (NO) production 
NO is generated from the conversion of L-arginine to L-citrulline by the nitric 
oxide synthase (NOS) enzymes (Figure 5). Several co-factors are required for 
NO production; nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), and 
tetrahydrobiopterin (BH4) along with the binding of calmodulin protein. Three 
NOS isoforms exist: nNOS, iNOS and eNOS (respectively: neuronal NOS, 
NOS-1; inducible NOS, NOS-2; endothelial NOS, NOS-3). As their names 
suggest, they were first described within specific cell-types or circumstances 
but have since been identified in a variety of tissue types [69].  
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Figure 5. The production of nitric oxide (NO) 
The NOS catalytic reaction requires the binding of calmodulin protein (not shown) plus the 
presence of five co-factors: NADPH, nicotinamide-adenine-dinucleotide phosphate; FAD, 
flavin adenine dinucleotide; FMN, flavin mononucleotide; BH4, tetrahydrobiopterin; n-, i-, e-
NOS, neuronal-, inducible, endothelial-nitric oxide synthase. 
 
The nNOS and eNOS isoforms constitutively generate NO in pico-
molar concentrations [68]. They are both dependent upon ionic calcium to 
promote calmodulin binding for activity. nNOS produces NO in nervous tissue 
for neurotransmission and in the kidney it exerts tonic control over glomerular 
filtration via expression within the macula densa cells [70]. 
eNOS is predominantly expressed within vascular endothelial cells, 
generating paracrine NO to relax vascular smooth muscle cells (VSMCs) 
thereby regulating tissue perfusion. Vascular eNOS expression increases in 
response to a number of local signals such as ionic calcium, shear stress and 
pulsatile flow, while humoral activators include oestrogen and endothelium-
dependant vasodilators such as acetylcholine, bradykinin and substance P 
[69]. Particularly relevant to atherosclerosis, eNOS further protects against 
vascular injury by inhibiting platelet aggregation, leucocyte adhesion and 
activation [68]. 
In contrast to the “constitutive” isoforms, iNOS does not require calcium 
in order for calmodulin to bind plus it can produce NO in nanomolar 
concentrations (a thousand times greater than the constitutive isoforms). The 
expression of iNOS was first described in activated macrophages but has 
since been reported constitutively in hepatocytes, chondrocytes and renal and 
pulmonary epithelia [69, 71]. Overwhelming iNOS-derived NO synthesis is 
well described in inflammatory conditions such as bacterial sepsis. 
Pathological stimuli such as bacterial lipopolysaccharide (LPS) or 
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endogenous cytokines [72] induce macrophage iNOS to generate NO in 
quantities that are cytotoxic to invading cellular pathogens. Although initially 
advantageous to the host, high concentrations of NO contribute to the 
vascular hyporeactivity and reduced organ perfusion often observed in septic 
shock leading to mortality [73]. Animal models of sepsis suggested a benefit 
from NOS inhibition [74], however disappointingly in human trials, non-
selective NOS inhibition increased mortality [75]. This disparity illustrates that 
global, non-selective NOS inhibition can be detrimental and a more precise 
target of NO signalling is required to temper excessive NO bioavailability 
whilst not completely abrogating activity required for homeostasis. 
1.5.2 Endogenous regulation of NO 
To emphasise the need for intricate NO regulation to maintain homeostasis, 
biologically relevant regulatory pathways have been described at almost every 
molecular level; transcription; post-transcription and protein translation; 
substrate (arginine) and co-factor availability; subcellular localisation, NOS 
enzyme phosphorylation and neutralisation with nitrogen or oxygen free 
radicals [76].  A novel mechanism for the regulation of nitric oxide synthesis is 
via endogenously produced inhibitors of NOS activity: the methylarginines 
(MAs).  These arginine analogues bind to the active site of NOS but inhibit NO 
synthesis, representing one of very few examples of an enzymatic pathway 
regulated by endogenous inhibitors [77].  
1.5.3 Methylarginine biology 
1.5.3.1 Methylarginine production 
Methylarginines (MAs) are derived from the methylation of arginine residues 
within proteins and upon proteolysis, are released as free molecules. The rate 
of methylation is determined by the protein arginine methyl-transferase 
enzymes (PRMTs), which produce three MA subtypes; NG, NG-dimethyl-L-
arginine (asymmetric dimethylarginine; ADMA); NG, NG’-dimethyl-L-arginine 
(symmetric dimethylarginine; SDMA); and NG-monomethyl-L-arginine 
(monomethylarginine; L-NMMA) [78]. The PRMT family has to date, 11 
isoforms identified by amino acid sequence homology but only 9 of these 
have demonstrated activity [79]. The PRMTs have been categorised into four 
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groups according to substrate/product specificity but it is PRMT1 (a Type I 
PRMT) that accounts for approximately 85% of arginine methylation in vivo, 
producing both mono- and di-methylations of the same guanidino nitrogen 
atoms on arginine residues to produce L-NMMA and ADMA [80]. Type II 
PRMTs (including PRMTs 5 and 7) on the other hand can methylate both 
guanidine nitrogen atoms which results in symmetric dimethylation to produce 
SDMA [81]. 
 
1.5.3.2 Methylarginine: handling and actions 
The biological relevance of MAs became apparent when elevated plasma 
concentrations of ADMA (8-fold) were reported in patients on haemodialysis 
compared with healthy controls [77]. In the same publication, administration of 
ADMA into the forearms of healthy volunteers reduced endothelium-
dependent blood flow suggesting inhibition of NOS. Despite numerous 
subsequent observational studies linking elevated circulating ADMA to CV 
and renal disease, the extent to which MAs cause or simply reflect disease is 
yet to be elucidated (discussed further in section 1.6.1). 
Although present in human plasma at a 10-fold lower concentration, 
monomethylated arginine (L-NMMA) can also inhibit NO production but its 
relevance in disease is uncertain [82]. Plasma SDMA concentrations are 
similar to those of ADMA (0.38-0.73 µmol/L in health [83], upto 2.42 µmol/L in 
CKD [84]) but although it does not compete with arginine at the active site of 
NOS, SDMA can compete with L-arginine uptake into cells in millimolar 
concentrations in vitro [85]. Until recently, there has been a paucity of 
evidence to suggest that SDMA is pathogenic in vivo however associations 
have been reported to exist between serum SDMA and inflammation although 
it remains unclear as to whether this is NO-independent [86]. Interestingly, a 
recent study indicated that SDMA may be a chief effector molecule in the 
transformation of healthy to “unhealthy” high-density lipoprotein (HDL) and 
subsequent pro-inflammatory toll-like receptor (TLR) activation seen in CKD-
related CV disease [87]. 
Consistent with the presence of endogenous NOS inhibition is the 
phenomenon described as the “arginine paradox”. Intracellular arginine 
concentrations far exceed the half-saturating arginine concentration (Km) for 
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NOS activity although in vivo or in vitro administration of additional arginine 
increases NO synthesis [88].  
MAs liberated during intracellular proteolysis transit between 
extracellular and intravascular compartments resulting in variable local 
concentrations. For example, intracellular ADMA concentrations in carotid 
artery endothelial cells harvested from rabbits were 10-fold higher than 
plasma levels [89]. Animal studies using radiolabelled methylarginines 
injected peripherally demonstrated intracellular distribution within an hour – 
suggesting a constant state of flux between body compartments [90]. 
 
Figure 6. Formation, distribution, metabolism and actions of endogenous 
methylarginines 
L-arginine (L-Arg) is present in the circulation at >100 times the concentrations of the free 
endogenous methylarginines: ADMA and SDMA. ADMA but not SDMA inhibits all 3 isoforms 
of nitric oxide synthase (NOS), decreasing the production of nitric oxide. L-arginine and the 
free methylarginines are thought to enter the cell (shown on the left) through the y+ 
transporter. ADMA and SDMA are generated intracellularly following the methylation, by 
protein-arginine methyltransferases (PRMT), and subsequent proteolysis, of constituent 
protein arginine residues. ADMA can regulate protein expression through both NO-dependent 
and -independent pathways. ADMA but not SDMA is hydrolyzed by DDAH to form 
dimethylamine (DMA) and L-citrulline (L-Cit), which can be reincorporated into proteins. The 
majority of ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAHs) with 
the product DMA excreted in the urine whereas SDMA is excreted intact. Both SDMA and 
ADMA are substrates for alanine-glyoxylate aminotransferase-2 (AGXT2), which is expressed 
only in kidney (right) and liver (not shown), leading to the formation of symmetrical and 
asymmetrical !-keto-γ-dimethylguanidino valeric acid (DGV) that is also excreted in the urine. 
Dotted arrows show metabolic pathways for which limited in vivo evidence is available. 
Acetylation of ADMA has also been described but is not shown. Monomethylarginine (not 
shown for clarity) is thought to have similar actions, distribution, and degradation pathway to 
ADMA. Reproduced from [91] 
 
Amino acids are transported across cell membranes via solute carrier 
proteins, classified according to their tissue distribution and amino acid 
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selectivity (SLC- prefix). The SLC7 family of y+ cationic amino acid 
transporters (CATs) transport L-arginine and MAs [92]. MAs can compete with 
L-arginine at the CAT transporter, representing an indirect mode of NOS 
inhibition by reducing L-arginine uptake [85].  
The intracellular methylarginine : arginine ratio is a critical determinant 
for NO availability and is dependent upon many factors including protein 
methylation, proteolysis, cell-trafficking and clearance (Figure 6).  Normal 
plasma ADMA concentrations of <1µM [71] may rise several-fold in renal or 
CV disease [77] although this does not define what is happening within 
specific tissues. An appreciation of the time and site specificity of MA handling 
is required if results of in vivo studies are to be correctly interpreted. 
To illustrate this, patients with peripheral vascular disease and 
increased circulating ADMA were supplemented with dietary L-arginine over a 
six-month period [93]. Despite a demonstrated increase in L-arginine to 
ADMA ratio, no benefit in claudication symptoms was found and even a 
possible reduction in flow-mediated vasodilation was suggested. These data 
support the notion that plasma L-arginine : MAs concentrations may not 
reflect those at the site of NOS inhibition and as the authors suggest, counter-
regulatory mechanisms may prevent increased NO production in chronic 
disease states while some suggest an increased amino acid load may even 
exacerbate vascular disease [94]. 
Alternative, NO-independent modes of action of MAs have been 
suggested but remain largely unresolved. There is some evidence to suggest 
that ADMA directly affects gene expression (particularly PRMT3 and bone 
morphogenetic proteins [95] and superoxide-mediated apoptotic pathways 
[96] via NO-dependent and independent mechanisms. 
  
1.5.3.3 Methylarginine clearance 
MAs are eliminated in two ways: renal excretion and enzymatic 
metabolism by methylarginine-metabolising enzymes or MAMEs. MAMEs 
either hydrolyse MAs; the dimethlyarginine dimethlyaminohydroxylases 
(DDAHs: 1 and 2), or deaminate them; alanine-glycoxylate (AGXT2). The 
majority (approximately 80%) of free asymmetric methylarginine (LNMMA and 
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ADMA) is metabolised by DDAH to produce L-citrulline and dimethylamine 
(DMA) (Figure 7).  
 
 
Figure 7. Endogenous regulation of NO synthesis 
Protein arginine methyl-transferase enzymes (PRMTs) methylate arginine residues within 
proteins. Arginine and methylarginines are released during proteolysis and become a 
respective substrate or inhibitor of NO synthase (NOS). The most abundant methylarginine, 
asymmetric dimethylarginine (ADMA) is hydrolysed by dimethlyarginine 
dimethlyaminohydroxylase thus reduced NOS blockade. Both arginine and ADMA are 
metabolised to L-citrulline. ADMA hydrolysis also produces dimethylamine (DMA). 
 
SDMA on the other hand, is not hydrolysed by DDAH and its clearance 
is largely reliant upon renal excretion [97]. The second catabolic pathway 
involving alanine-glycoxylate (AGXT2) has been well described recently [98]. 
This enzyme is principally expressed in the mitochondria of renal epithelial 
cells and to a lesser extent in the liver [99]. Although DDAH hydrolysis 
remains the main metabolic route of methylarginine clearance, AGXT2 has 
the unique ability to metabolise all three subtypes including SDMA by 
deamination. Interestingly, genetic deletion of AGXT2 in mice results in raised 
plasma ADMA and elevated systemic blood pressure suggesting a more 
significant physiological role for AGXT2 than originally thought [98].  
1.5.4 Dimethlyarginine dimethlyaminohydroxylases (DDAH) 
The DDAH enzymes are cytosolic proteins that hydrolyse free ADMA (and 
LNMMA) to form DMA and L-citrulline. DDAH isoforms 1 and 2 share 63% 
open reading frame (ORF; the gene sequence for protein coding) homology 
[100]. Expression patterns of the two isoforms differ markedly and often co-
express with specific NOS isoforms. DDAH1 co-localises with nNOS in the 
40 
brain and kidney while DDAH2 reflects eNOS expression in the heart, 
placenta and kidney [101]. Immune cells such as macrophages almost 
exclusively express the DDAH2 [102]. Further evidence also suggesting a role 
of DDAH2 in inflammatory responses include; the gene maps to the MHC III 
region of chromosome 6 (shared by inflammatory mediators TNF$ and heat-
shock proteins [102]), and the up-regulation of renal tissue DDAH2 protein in 
a rat streptozocin model of diabetic nephropathy (determined by Western 
blotting of whole kidney lysates [103]). 
 
1.5.4.1 The biological relevance of DDAH 
Both DDAH isoforms are expressed in the vasculature and early studies 
demonstrate that pharmacological blockade elevates transient ADMA 
concentrations enough to cause downstream reduction of NO synthesis and 
vascular contraction [104]. Current technical obstacles to the purification of 
active recombinant DDAH2 protein make a direct comparison of respective 
isoform activity impossible however heterozygous deletion of DDAH1 in vivo 
results in a 45-50% reduction in circulating ADMA, indicating that DDAH1 is 
the predominantly active isoform [105]. 
Taken together, these observations indicate that DDAH represents a 
potential mechanism for in vivo control of NO bioavailability.  The highly 
conserved nature of the protein sequence across species would imply an 
important biological role.  Furthermore, the existence of two isoforms 
suggests there is some functional specialisation although the nature of this 
has not been fully explored. 
1.6 The DDAH-ADMA-NOS Pathway and Disease 
As with any homeostatic system, insufficiency or excess of protein expression 
or activity can contribute to pathology. Historically, association studies in the 
field of NO signalling have favoured the notion that elevated ADMA leads to 
reduced NO bioavailability and is therefore always deleterious. However, 
emerging evidence from human genetic studies and transgenic models 
illustrate that too much or too little NO activity has negative pathophysiological 
consequences and it is the timing and site of dysfunction that is of critical 
importance. 
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1.6.1 Disease association studies 
A considerable number of reports have implicated dysregulation of the NO-
ADMA-DDAH axis in human disease states, particularly in the context of 
cardiovascular disease and its risk factors (Figure 8). A community population 
study of 3320 participants in the Framingham Offspring Study identified 
plasma ADMA as being predictive of death over a 10 year follow up although 
it was not adequately powered to assess CV disease incidence [106]. 
Furthermore, a 24 year follow up study of almost 900 healthy women data 
recognized that a 0.15µmol/L rise in baseline plasma ADMA associated with 
approximately 30% increase in incident CV events [107]. Numerous other 
studies report circulating ADMA as a powerful predictor of progressive CV 
disease and CKD (see Section 1.7.3.2), independent of eGFR and other 
traditional risk factors [106, 108-111]. 
Despite this depth of associative data and in most cases, the biological 
plausibility of elevated circulating ADMA altering NO synthesis, none of these 
studies prove causality. Given that plasma ADMA rises with CV and renal 
disease, the potential for confounding remains, even despite adjusting for 
other risk factors. 
 
Figure 8. Conditions associated with elevated plasma ADMA 
CV, cardiovascular; AKI, acute kidney injury [112]; CKD, chronic kidney disease. Adapted 
from [91, 113]. 
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1.6.2 Human DDAH genetic studies 
Population genetic studies provide valuable information on the effects of 
single gene functional variances on risk and progression of human disease. 
Functional variants in the DDAH2 promoter region have been associated with 
improved outcomes in both haemorrhagic stroke and pre-eclampsia [114, 
115] and have even shown predictive power for the requirement of 
vasopressors following cardiac surgery [115]. 
A loss of function DDAH1 gene promoter insertion polymorphism 
identified in the Chinese Han population is associated with a reduced DDAH1 
mRNA expression in vivo, raised plasma ADMA and significantly increased 
risk of thrombotic stroke and coronary heart disease [116]. In a small study of 
1600 middle-aged Finnish men, a DDAH1 mutant variant with a 1% 
prevalence and elevation of plasma ADMA, conferred a 5-fold risk of 
hypertension and a 50-fold risk of coronary heart disease [117].  
1.6.3 Animal studies to manipulate NO signalling 
The timing and tissue-specificity of NO production clearly impacts upon the 
balance between advantageous and deleterious consequences. For example, 
a murine model of pulmonary sepsis showed disease reduction and improved 
survival with early nNOS and late iNOS pharmacological inhibition however, 
genetic knock-down of either isoform or timed non-selective inhibition 
provided no benefit at any time-point [118].  
Advances in transgenic technology have produced targeted DDAH 
gene deletion or overexpressing mouse strains. Together with data from 
studies using transfection and small-interfering RNA (siRNAs), these animals 
have provided further insight into the physiological role of DDAH-determined 
ADMA alterations and their pathophysiological consequences (Table 5). 
Despite different transgenic constructs used to delete DDAH1, hetero- 
or homozygous mice consistently express a hypertensive phenotype with 
elevated plasma ADMA [105, 119]. Furthermore, endothelial-specific DDAH1 
deletion had a significant impact, enough to elevate circulating ADMA and 
reduce endothelial-dependent relaxation [120]. Meanwhile, transgenic DDAH1 
overexpression produces the reverse phenotype, with lower plasma ADMA 
and reduced systemic BP [121].  
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DDAH 
manipulation 
Technique Species ADMA Effect Ref 
! DDAH1 Constitutive exon 1 
haploinsufficiency 
Cre/LoxP exon 4 null 
Endothelium targeted exon 4 null 
siRNA 
Mouse 
 
Mouse 
Mouse 
Rat 
" 
 
" 
" 
" 
"BP, !EDV 
 
"BP 
"BP, !EDV 
#$BP/EDV 
[105] 
 
[119] 
[120] 
[122] 
" DDAH1 Transgenic overexpression 
Adenoviral transfection 
Mouse 
Rat 
! 
! 
! 
! 
[121] 
[123] 
!DDAH2 siRNA Rat #$ #$ BP, !EDV [122] 
"DDAH2 Transgenic overexpression Mouse ! #$ [124] 
!DDAH1/2 Pharmacological Rat " "BP, !EDV  [105] 
Table 5. In vivo effects DDAH modification in rodents 
DDAH, dimethylarginine dimethylaminohydrolase; siRNA, small interfering RNA; ADMA, 
asymmetric dimethylarginine; EDV, endothelium dependent vasodilation; BP, blood pressure; 
" , increase; !, decrease; #$, unchanged. Adapted from [91, 100] 
 
Genetic manipulation of DDAH activity has produced mixed effects in 
disease models. Transgenic or overexpression by transfection of DDAH2 
appears to improve function in models of vascular injury [124, 125]. 
Furthermore, a double transgenic mouse for the proatherogenic 
apolipoprotein E deficiency and DDAH1 overexpression had lower circulating 
ADMA and was protected from atherosclerotic plaque formation [126]. In 
contrast to these findings, DDAH1 overexpression aggravated fibrosis in a 
bleomycin model of pulmonary fibrosis, while pharmacological DDAH1 
inhibition reduced fibrosis and preserved lung function [127]. 
1.7 NO signalling in the kidney 
Many roles of NO within the kidney lead to a common goal: regulation of 
systemic BP. Although this can only be directly achieved by altering GFR or 
tubular reabsorption (particularly sodium), the pathways are complex and 
dynamic, responding rapidly to a host of physiological triggers such as oxygen 
tension, luminal flow, filtrate composition and neurohumoral stimulation. 
1.7.1 Renal expression of NOS and DDAH enzymes 
Immunohistochemical and mRNA localisation studies have identified 
expression and co-localisation of all isoforms of NOS and DDAH in the kidney 
(Figure 9). 
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Figure 9. Expression of NOS and methylarginine-metabolising enzymes along the 
nephron 
NOS, nitric oxide synthase; n-, neuronal; i-, inducible; e-, endothelial;  DDAH, dimethylarginine 
dimethylaminohydrolase; AGXT2, alanine-glyoxylate aminotransferase-2. 
eNOS is expressed throughout the endothelium of glomeruli and the 
renal vasculature, proximal tubular cells, thick ascending limb and collecting 
duct [128], whereas nNOS is expressed in tubular cells of the macula densa 
[70], principal cells of the collecting duct [129] and pelvic renal nerves. 
Constitutive expression of iNOS has been identified throughout epithelial 
regions of the nephron including the proximal tubule, distal convoluted tubule 
and collecting duct [70]. 
 
1.7.1.1 Renal DDAH1 expression in the proximal tubular cell 
The expression of DDAH isoforms is equally specific and with respect to 
DDAH1, it is fundamental to the hypothesis and methods for this thesis. 
The proximal tubule is the principal site of DDAH1 expression 
confirmed by immunohistochemical and micro-Western analysis of micro-
dissected segments from the rat [103] (Figure 10). In the same study, DDAH2 
protein expression was identified in the glomeruli, macula densa, thick 
ascending limb, and distal tubule. 
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Figure 10. DDAH1 protein expression in the normal rat kidney 
A and B. Immunostaining showed reactivity in the cytoplasm of proximal tubular cell (bars = 
50µm). C. Western blot of microdissected nephron segments; glomerulus (GL); proximal 
tubule (PT); proximal straight tubule (PST); thick ascending limb (TAL); distal convoluted 
tubule (DCT); cortical collecting duct (CCD); outer medullary collecting duct (OMCD), and 
inner medullary collecting duct (IMCD). Reproduced from [103]. 
  
 
 
Figure 11. Immunohistochemical staining for DDAH1 in normal human kidney 
A, anti-DDAH1 antibody showing DDAH1 present in the proximal tubule but not other tubules, 
glomerulus or vessels. B, anti-DDAH1 antibody pre-absorbed against DDAH1 peptide 
representing a negative control. Nuclear counter stain with Gill’s haematoxylin. Images 
provided by Dr Ben Caplin (UCL, unpublished). 
B A 
46 
Furthermore, immunohistochemical staining of normal human kidney 
sections within our own laboratory confirms that DDAH1 protein is 
predominantly expressed in the PT cell (Figure 11). Strong expression of 
DDAH1 protein has been confirmed in murine whole kidney tissue lysate [105, 
120], however cell-type localisation patterns have not been reported in the 
mouse kidney.  
1.7.2 Functional roles of NO in the kidney 
1.7.2.1 Renal haemodynamics 
The autoregulatory mechanism that protects GFR despite fluctuations in BP is 
composed of the myogenic and tubuloglomerular feedback (TGF) responses. 
Arterial infusions of a NOS inhibitor (nitro-L-arginine) in dogs elevated 
systemic BP and reduced renal blood and urine flow by 25% while markedly 
increasing renal vascular resistance. These studies reveal that NO maintains 
the basal low vascular resistance characteristic of the kidney and 
interestingly, although glomerular autoregulation was blunted, it remained 
largely intact suggesting that mediators other than NO regulate GFR [130]. 
 
1.7.2.2 Tubuloglomerular feedback (TGF) 
TGF is a renal homeostatic phenomenon whereby delivery of sodium 
and chloride ions to the distal tubule is communicated to regulate GFR via the 
afferent arteriole. The distal tubule of each nephron loops back and positions 
itself intimately with the vascular pole of the glomerulus – a region called the 
macula densa. Sodium-potassium-chloride co-transporters (type 2; NKCC2) 
of the macula densa monitor delivery of chloride [131] and through adenosine 
or ATP signalling, afferent arteriole smooth muscle cells contract and thus 
reduce flow. TGF can be studied by measuring GFR or a surrogate such as 
stop-flow pressure (the PT pressure at which filtration is stopped) during 
microperfusion. The macula densa has consistently been shown to express 
high levels of nNOS and the NO produced appears to blunt TGF responses 
[132]. Microperfusion of individual loops of Henle with all three endogenously-
produced methylarginine isoforms (individually) inhibited uptake of co-
perfused 14C-labelled arginine via the y+ CAT transporter but only ADMA and 
LNMMA inhibits NOS in the macula densa. This suggests that in the kidney, 
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methylarginines not only directly inhibit NOS but can reduce NO production 
via competitive reabsorption of L-arginine substrate [133]. 
 
1.7.2.3 Pressure-natriuresis 
Central to the kidney’s control over systemic BP is the phenomenon of 
pressure-natriuresis. Elevations in arterial BP cause a prompt increase in 
renal sodium and water excretion (natriuresis and diuresis) in an effort to rid 
excess volume and return total body salt and BP to normal. Infusion of NOS 
inhibitor L-NMMA, reduced the pressure-natriuretic response elicited in 
Wistar-Kyoto rats [134] while a study measuring intra-renal NO by cortically-
placed microelectrodes, reported increased NO activity with increments in 
renal perfusion pressure [135]. This NO was postulated to derive from shear-
stress-induced vascular endothelial eNOS up-regulation.  
 
1.7.2.4 Tubular sodium transport 
Isolated tubule microperfusion studies allow direct administration of 
compounds to test effects upon tubular absorption (Jv) of sodium, water and 
bicarbonate. Administration of the NO-donor, nitroprusside in lower 
concentrations (10-6M) stimulated Jv by 50% [136] however at higher doses 
(10-3-4M), it decreased Jv by up to 70% [136, 137]. Similarly, bimodal effects 
upon proximal tubular absorption have been observed using the NOS 
inhibitor, L-NAME, and studies using an nNOS knock-out mouse have 
produced disparate results [138, 139]. These somewhat frustrating results 
may well reflect a bimodal response of tubular absorption to NO availability 
but in addition, are confounded by differences in experimental design, 
allowing extra-renal mechanisms such as humoral responses and renal 
innervation to influence results.  
The inhibitory effect of NO on individual tubular cell transporters is a 
little more consistent. Primary tubular cells from rodents treated with NO-
donors and cGMP analogues have reduced activity of Na/H, Na/K-ATPase 
and NHE3 channels compared to controls [140, 141]. Sodium coupled co-
transport of glucose, phosphate and amino acids are dependent upon the 
electro-chemical gradient generated by basolateral Na/K-ATPase. By NO 
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directly reducing Na/K-ATPase activity, it influences tubular reabsorption of 
most filtered nutrients. 
 
1.7.2.5 Mitochondrial respiration 
Proximal tubular active solute reabsorption is critically dependent upon energy 
produced in the form of ATP through oxidative phosphorylation within 
mitochondria. NO is known to influence mitochondrial function at many levels. 
Firstly, the vasodilatory effect of NO regulates blood flow and delivery 
of respiratory substrates and dissipates heat generated by mitochondria [142]. 
In addition, NO increases blood flow to suit oxygen consumption through the 
generation of nitrosated haemoglobin (NO binds to oxyhaemoglobin to 
produce S-nitrohaemoglobin; SNO-Hb) [143]. SNO-Hb donates NO at a rate 
inverse to the ambient oxygen tension, thereby coupling the regulation of 
blood flow and oxygen delivery to mitochondria [144]. 
Interestingly, NO has a bi-directional influence over mitochondrial 
respiration, determined by chronicity. Acutely, NO reduces oxidative 
phosphorylation by binding to and inhibiting cytochrome c oxidase – the 
terminal enzyme in the electron-transport chain [145]. On the other hand, 
sustained NO exposure has been reported to stimulate mitochondrial 
biogenesis and increases the mitochondrial DNA content of cells in culture 
[146]. The same study reports that eNOS -/- mice have reduced mitochondrial 
mass and both lower basal oxygen consumption and steady state ATP levels.  
Finally, the intracellular localisation of NO signalling enzymes (MAME 
and NOS isoforms) in close proximity to mitochondria supports a regulatory 
effect upon their function. The non-hydrolysing MAME, AGXT2 has been 
localised to mitochondria in rodents. There is evidence to suggest a 
mitochondrial-specific NOS isoform exists, mitochondrial NOS (mtNOS), 
which is sensitive to ionic calcium [147]. Its proposed location, within the 
mitochondrial inner membrane, makes it well-placed to inhibit cytochrome c.  
1.7.3 NO in kidney disease 
1.7.3.1 Acute kidney injury (AKI) 
Endothelial NO dysfunction resulting from cardiovascular disease or more 
acutely, with enhanced iNOS activity during sepsis, can lead to impaired 
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myogenic autoregulation in the kidney. Failure of the kidney to protect its own 
perfusion results in the “pre-renal” mechanism of injury frequently seen in 
clinical practice resulting from sepsis, haemorrhage or following major 
surgery. Progression of other common forms of renal injury such as drug-
related tubulointerstitial nephritis, diabetic renal disease and autoimmune 
glomerulonephritis are all subject to NO dysregulation (often increased) 
causing peroxynitrite formation, and inflammatory cell activation leading to 
chemokine production. The production of NO from iNOS during renal 
inflammation occurs in glomerular mesangial cells, proximal tubular cells and 
activated macrophages. The question remains as to whether increased NO 
bioavailability is chiefly a physiological or pathological response to injury. 
Animal studies designed to interrupt NO signalling in acute renal 
disease have produced disparate results. The administration of NOS inhibitors 
(L-NIL and L-NAME) intensified cytokine and immunoglobulin responses 
disease in a rodent model of autoimmune interstitial nephritis [148]. NOS 
inhibition by depletion of arginine substrate (through administration of 
arginase) also exacerbated disease in a nephrotoxic nephritis model of 
glomerular injury [149]. In contrast to these reports, NOS inhibition achieved 
through restricted dietary L-arginine or L-NMMA administration, reduced acute 
glomerular injury in an anti-thymocyte model of glomerulonephritis [150]. 
Results using an iNOS knock-out mouse in a model of glomerulonephritis 
failed to resolve this controversy. No difference in disease severity was 
observed, although control animals used in this study were heterozygotes for 
the transgenic iNOS deletion which restricts the interpretation of these data 
[151].  
 
1.7.3.2 Chronic kidney disease and fibrosis 
While much of the damage relating to AKI inflammation is thought to result 
from excessive NO activity, the progression of CKD and cardiovascular 
disease is often attributed to NO deficiency [152]. The kidney is responsible 
for a large proportion of ADMA clearance through metabolism by DDAH and 
excretion of the unmetabolised fraction (~20%) in the urine.  It is therefore no 
surprise that plasma ADMA levels rise with declining kidney function although 
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it is not clear whether this is pathogenic or simply a marker of renal 
dysfunction. 
A number of human population studies correlate plasma ADMA 
concentrations with CV disease severity and poor outcomes in CKD. One of 
the largest population studies using data from the Modification of Diet in Renal 
Disease study, revealed plasma ADMA being not only associated with the 
presence of CV disease at baseline but a powerful predictor of CV mortality at 
10 year follow-up [110]. 
In patients with IgA nephropathy, higher plasma values of ADMA were 
associated with severe glomerular and tubulointerstitial damage and a faster 
rate of eGFR decline. In patients undergoing coronary angiography with CKD 
stage 3 or 4, plasma ADMA correlated with low GFR, albuminuria and risk of 
all cause death and CV events [153].  
Data from our own group however, questions the notion that raised 
plasma ADMA is always indicative of ill-health and directly pathogenic. We 
have previously published work showing a gain-of-function DDAH1 
polymorphism that is associated with higher DDAH1 mRNA expression in 
kidney allografts, lower plasma ADMA levels but a steeper rate of eGFR 
decline in two independent CKD patient cohorts [154]. These results on the 
face of it, contradict many association studies that suggest elevated plasma 
ADMA may not be causal of disease and that more specifically, CKD 
progression is subject to DDAH1 activity.  
Studies using rodent models of CKD report a relative renal NO 
deficiency. Reduced urinary nitrite and nitrate has been detected in a variety 
of CKD models of 5/6 nephrectomy, ageing, chronic glomerulonephritis and 
puromycin aminonucleoside nephrosis (PAN) [155]. Furthermore, 
interventions to reduce NO availability exacerbated disease in a renal mass 
reduction model of CKD (single nephrectomy and cautery to the one 
remaining). In this study, a non-selective NOS inhibitor (L-NAME), an nNOS 
selective inhibitor (7NI) and genetic eNOS deletion all produced the same 
deleterious effect [156]. 
Only a minority of animal studies have attempted to influence CKD 
progression by manipulation at the level of ADMA-DDAH activity. Direct 
osmotic pump infusion of ADMA exacerbated renal fibrosis although this 
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finding was confounded by impressive elevations of systolic blood pressure 
and were no different from L-NAME infusion suggesting a non-specific 
hypertensive injury [157]. More convincing are studies in which rodents 
overexpressing DDAH1 were protected against renal fibrosis and collagen 
deposition in both angiotensin-induced and nephron-reduction models of CKD 
[158, 159]. A criticism of these studies however, is their relatively short 
duration of 4 and 6 weeks respectively, which is arguably too short a period to 
genuinely reflect the natural history of fibrosis witnessed in human CKD. 
Furthermore, DDAH1 overexpression was not tissue-specific therefore the 
positive renal effects may be in part, due to improved systemic BP and 
vascular reactivity. 
1.7.4 The balance of NO: health versus disease 
In summary, NO signalling plays a significant role in many homeostatic 
processes and disease. More specifically, it is implicated in kidney 
physiological function and responses to acute injury, inflammation and 
subsequent progressive fibrosis. The proximal tubular cell plays a pivotal role 
in this pathophysiology and expresses many components of the NO signalling 
pathway, particularly DDAH1. The overall influence of DDAH upon NO 
signalling is well understood however the circumstances under which it 
contributes to renal health and disease remain to be established.  
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2 HYPOTHESIS 
2.1 Hypothesis 
“Reduced renal DDAH1 activity protects against kidney function decline” 
 
Objectives 
2.1.1 Transgenic model development 
To develop and characterise a novel transgenic mouse with conditional 
DDAH1 deletion in the proximal tubule cell.  
2.1.2 Disease model development 
To characterise a valid experimental model of kidney disease, manifesting the 
acute and chronic elements of disease exhibited in humans. 
2.1.3 Microperfusion and in vitro studies 
(a) Through collaborative isolated tubule microperfusion studies, 
investigate the impact of ADMA-NO manipulation upon renal tubular function. 
(b) To use a proximal tubule cell line and primary culture for in vitro studies 
to demonstrate a physiological effect of ADMA-NO manipulation and 
investigate underlying mechanisms of in vivo phenotypes. 
2.1.4 A parallel study of renal DDAH2 in Acute Kidney Injury (AKI) 
To test the effect of global DDAH2 deletion in an in vivo model of acute renal 
inflammation. 
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3 MATERIALS AND METHODS 
3.1 In vitro methods 
3.1.1 Cell line culture 
3.1.1.1 Proximal tubular cell line 
Normal Human Proximal Straight Tubular Cells (NHPSTs) were a kind gift 
from Professor Patricia Wilson. To develop immortalised cells, normal 
proximal tubular cells (derived from male and female human kidney tissue) in 
culture were exposed to an immortalising vector, containing pZiptsU19 with 
the temperature sensitive SV40 T-antigen allele tsA58U19 and a neomycin 
resistance gene. Neomycin-resistant tubular cells were selected for 
propagation [160]. For these studies, cells were used from -80°C frozen stock 
at passage number range 5-9. Initially grown to proliferate at 33°C (permissive 
temperature for the immortalising T-antigen) they required a further 72 hours 
at 37°C to switch off the T-antigen before use in experiments. NHPST cells 
were grown in collagen-coated (50ug/mL Rat tail type I collagen; Beckton 
Dickinson, one hour incubation and dried overnight) plastic culture plates 
(Corning) and cells were quiesced by serum-starving for 48 hours prior to 
treatment. Growth media; 1:1 mix of Click’s medium and RPMI medium 
(Invitrogen) containing; human transferrin (5ug/mL; Sigma); dexamethasone 
(50nM; Sigma); insulin (0.5ug/mL; Gibco); 1% fetal calf serum (FCS); penicillin 
/ streptomycin (2mM; Sigma). Cells were fed every 2-3 days and passaged in 
a 1 to 3 split. 
3.1.2 Primary PTC extraction and culture 
The development of this technique is discussed in detail in the Results 
chapter. In brief, mice were sacrificed by cervical dislocation and the renal 
arterial circulation isolated from proximal branches using suture ligation. 
Suspended magnetic beads (Invitrogen) were infused via an aortic catheter 
placed distally to the renal arteries and kidney perfusion confirmed by rapid 
blanching. Once perfused, both kidneys were dissected out, decapsulated 
and minced with a scalpel before incubation in a collagenase (Sigma) solution 
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at 37°C. The resulting homogenate was successively sieved (100µ and 50µ 
pore size) and fragments caught by the latter were magnetically separated 
into glomerular and tubular fractions. Microscopic examination of tubular and 
glomeruli fractions confirmed purity and magnetic bead entrapment within 
glomerular capillary loops. Purified tubules were pelleted by centrifugation at 
1,000rpm for 5mins before resuspension in media and then plated in 
uncoated plastic (Corning). Media contained; DMEM/F12 (Invitrogen 21331); 
0.5% FCS; 100 iu/mL penicillin; 100ug/mL streptomycin; 0.25ug/mL 
amphotericin B; 2.2 mM L-glutamine; 10ug/mL insulin or ITS (Sigma I3146 
5mL); 5.5ug/mL transferrin; 5ng/mL sodium selenite; 10ng/mL EGF; 5 pg/mL 
tri-iodothyronine; 5ug/mL dexamethasone.  Cells were allowed to settle for 
24hrs at 37°C, half volume media change at 48hrs and fed every 2-3 days. 
3.1.3 Apoptosis and EMT experiments 
Cells were treated with combinations of TGF! (5ng/mL; Sigma), ADMA 
(Calbiochem) or DDAH1 inhibitor (L-257; produced by supervisor Dr James 
Leiper [105]). Experimental groups were harvested from 24 to 96 hours. 
Western blotting was performed to identify changes in expression of cell 
phenotype markers and apoptosis. Antibodies to $SMA; E-Cadherin; cleaved 
Caspase 3; all supplied by Abcam. 
3.1.4 Proliferation assays 
3.1.4.1 Scratch wound assay 
This assay is designed to identify the rate of growth (proliferation and 
migration) into a deliberate wound scratched across the monolayer of cells in 
culture. Mitomycin C is a cellular-toxic drug that inhibits cell proliferation 
allowing the observer to distinguish between that and migration. NHPST cells 
were grown in 6 well plates as outlined previously. A cross-shaped scratch 
was drawn across each monolayer using a pipette tip. Cells were washed in 
PBS prior to incubation with treatment media. Treatment groups included 10% 
FCS, mitomycin C (2ug/mL, Sigma-Aldrich), DDAH1 inhibitor (L-257; 
1,10,100uM), ADMA (1,3,10uM), L-arginine (1mM; Sigma). Cells were 
photographed over the scratch intersection at time zero, 24 hours and 48 hrs. 
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Images were quantitatively analysed for percentage growth into the wound 
using Image J software. 
 
3.1.4.2 Bromodeoxyuridine (BrdU) assay 
Bromodeoxyuridine (BrdU) is a nucleoside analogue of thymidine that is 
incorporated into cellular DNA when dividing in S phase. An indirect antibody 
system detects incorporated BrdU using a colorimetric plate reader at 450-
550nm. Cells were grown in 96 well plates as described previously. BrdU 
proliferaton assay kit (Calbiochem) was used according to the manufacturers’ 
protocol. 
 
3.1.4.3 MTS assay 
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay gives a measure of mitochondrial 
reductase activity by colorimetry. Mitochondrial activity is taken as a surrogate 
measure for cell proliferation. Cells were grown in 96 well plates as described 
previously. MTS assay kit (Promega) used according to the manufacturers 
protocol. 
3.1.5 Cell sorting: ImageStream analysis 
ImageStream (Amnis, WA, USA) is a cell-sorting system that integrates flow 
cytometry with fluorescence microscopy - applied in this study to identify YFP-
expressing cells in the KAPiCre reporter mouse. Images are taken by 
automated capture for each cell as they are sorted according to size, shape 
and fluorescence. Tubular cells were isolated as described previously and 
subjected to further digestion to obtain a single cell suspension for analysis 
(Accumax; a protease / DNAse solution; Innovative Cell Technologies Inc, 
CA, USA). 
3.1.6 In vitro metabolism: Seahorse analysis 
Real-time aerobic and anaerobic respiration in the NHPST cell line was 
measured using the Seahorse XF Extracellular Flux Analyzer (Seahorse 
Bioscience, Copenhagen, Denmark). This automated system quantifies the 
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cellular respiration rate in basal conditions and when tested using compounds 
to stress parts of the mitochondrial respiratory chain. Culture plates (24-well) 
are specially designed to accommodate sensor probes that are lowered into 
the wells to isolate a 7µL media volume just above the cell monolayer surface. 
Optical sensors simultaneously measure hydrogen ion production (anaerobic 
glycolysis) or oxygen disappearance (oxidative phosphorylation) within the 
confined media volume over several time-points. Compounds can be 
administered during the assay in order to test maximal respiratory capacity 
and responses to metabolic stress (Figure 12).  
The Seahorse growth plates were collagen-coated and NHPST cells 
were grown as previously described. NHPST cells were seeded to achieve 
confluence within 48hours. After preliminary experiments performed to identify 
optimal working concentrations for the compounds to be added, cells were 
treated with ADMA 10 µM, L-257 100 µM and NO donor 100 µM (S-nitroso-N-
acetyl-l,l-penicillamine, SNAP) at different time-points; 2, 24 and 48 hours. 
Protocols were used according to the manufacturer’s guidance notes. 
Analysis was initially performed using the Seahorse XF24 software, followed 
by transfer to Microsoft Excel. 
 
 
Figure 12. Example bioenergetics profile using the Seahorse Analyser 
Compounds are added sequentially to modulate mitochondrial function and their effect on 
oxygen consumption rate (OCR) is measured. (A) control medium; (B) oligomycin to inhibit 
ATP synthase; (C) FCCP (carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone), an 
uncoupler to short-circuit the proton circuit and allow maximal respiration; (D) rotenone to 
inhibit total mitochondrial respiration. Production of lactic acid (hydrogen ions; extracellular 
acidification rate (ECAR)) can also be measured to quantify anaerobic glycolysis. 
(Reproduced from Seahorse Analyzer Brochure; www.seahorsebio.com) 
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3.1.7 Harvesting protein from cell culture 
Following treatment, 1.5mL of media was aspirated from each well, 
centrifuged (14,000 rpm for 15 minutes) and the supernatant stored at -80°C. 
Cells were washed in PBS, lysed in (RIPA) buffer composed of the following; 
Tris 50mM; NaCl 150 mM; SDS 0.1 %; sodium deoxycholate 0.5 %; Triton X 
100; 1mM PMSF; Complete Protease inhibitor (Roche). Samples were, 
homogenized using a needle and syringe, centrifuged (14,000 rpm for 15 
minutes) and stored at -80°C for future use. 
3.1.8 Harvesting RNA from cell culture 
At the end of treatment, 1.5mL of media was aspirated from each well, 
centrifuged (14,000 rpm for 15 minutes) and the supernatant stored at -80°C. 
Cells were washed in PBS, lysed in Buffer RLT (Qiagen) and stored at -80°C 
for future use. RNA extraction was performed using column purification kits 
(Qiagen Ltd, W Sussex). 
3.2 Molecular biology methods 
3.2.1 Tissue homogenisation 
Tissues were lysed by ball-bearing grinding (5mins at 20Hz; TissueLyser II, 
Qiagen) or a Dounce pestle and mortar homogeniser. Lysates were 
centrifuged to remove the debris pellet and supernatants stored at -80°C until 
further analysis. 
3.2.2 Tissue protein extraction 
Tissue was suspended in PBS containing protease inhibitor (Complete 
Protease Inhibitor Cocktail Tablets, Roche) and lysed as described above. 
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3.2.3 Tissue RNA / DNA extraction 
Nucleic acids were extracted from animal tissue lysates using column 
separation kits according to the supplier’s protocols (Qiagen RNeasy mini kit 
for RNA; DNeasy Blood and Tissue kit for DNA).  
3.2.4 Protein / RNA quantification 
3.2.4.1 Bradford assay 
Protein quantification was performed using either a Bradford’s assay or a 
NanoDrop analyser. The Bradford’s assay is a colormetric technique for 
protein quantification.  In acidic conditions, Coomassie Blue dye appears red 
however turns blue as it binds to amino acids. This absorbance shift 
correlates with protein quantity which can be measured by spectrophotometry 
[161]. 
5µL of protein sample was added to 795µL of distilled water and 200µL 
Bradford dye (BioRad) to a total of 1mL. Controls to generate a standard 
curve contained bovine serum albumin (BSA) (in serial dilutions of 0; 2; 4; 6; 
8; 10; 12 µg/mL) with 5µL of lysis buffer and water made up to 1mL. 100µL of 
samples and controls was pipetted into a 96 well plate and read by 
spectrophotometry at 595nm. 
3.2.4.2 NanoDrop % 
NanoDrop technology (Thermo Scientific) allows quantification of protein, 
RNA or DNA using spectrometry at specific wavelengths. It is useful when 
only small volumes of sample are available as only 1-2uL are required for 
analysis. Samples (2uL loaded) were measured in triplicates and averaged. 
3.2.5 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a molecular biological technique used for 
amplifying nucleic acids in order to assist sequence analysis. Developed in 
the early 1980s by American Kary Mullis [162], it earned him the Nobel Prize 
in Chemistry in 1993. The basic technique has since been adapted to serve a 
variety of applications including genotyping; quantification of gene 
transcription; identification of infectious diseases and forensic DNA finger-
printing. In addition to a starting sample of nucleic acid, the components 
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required for a PCR reaction include complementary DNA fragments or 
primers (serving as targeted start-points for DNA replication); 
deoxynucleoside triphosphates (dNTPs) and a heat-stable DNA polymerase. 
Over a range of temperature increments DNA is denatured into single strands, 
primers anneal to complementary sequences and DNA polymerase catalyses 
binding of free dNTPs to form new double-stranded DNA. By repeated 
subsequent cycles, all new DNA double strands themselves act as templates 
giving rise to logarithmic amplification. Using this method, samples of nucleic 
acid can be analysed according to sequence (determined by known primer 
sequences) and amount (according to rate of replication).  
 
3.2.5.1 End-point polymerase chain reaction (end-point PCR) 
End-point PCR assesses the products of PCR after the exponential phase of 
replication has been reached, at either a pre-defined cycle number or when 
the DNA polymerase and substrates have been exhausted. For that reason its 
application is largely qualitative and useful for assessing presence or absence 
of a sequence (genotyping). Tissue genotyping was performed using a heat-
stable DNA polymerase (Taq; a recombinant form of polymerase from the 
bacterium Thermus aquaticus) to exponentially amplify target regions of DNA. 
A ready made PCR mix containing Taq polymerase, dNTPs 
(deoxyribonucleotide triphosphate) and a red dye for loading was used 
(ReadyMix Taq PCR Reaction Mix, Sigma). 
 
DNA  1 µL  
RedTaq PCR Master Mix (2x), 6 µL  
Primers 0.5 µL each  
DNase-free water 4 µL  
Cycling protocol:   
Hold  2 minutes 94°C 
40 Cycles: 20 seconds 94°C 
 40 seconds 60°C 
 1 minute  72°C 
Final extension 5 minutes 72°C 
Table 6. Conditions used for end-point PCR genotyping 
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A standard PCR protocol is set out above in Table 6. New primers 
were tested across an annealing temperature gradient (upto 10°C either side 
of the DNA dissociation temperature; Tm) to find the optimum conditions for 
polymerisation. Primer sequences are listed in the appendix. 
PCR products were separated by agarose gel (1.5%, containing 
ethidium bromide (EtBr) 0.01%) electrophoresis and EtBr-stained DNA bands 
were visualised under ultraviolet light (Figure 13). 
 
 
Figure 13. Example image of PCR products run on agarose gel 
Performed for KAPiCre / DDAH1 floxed mouse genotyping. KAPiCre genotyping defines only 
presence or absence of the gene and cannot distinguish heterozygosity. DDAH1 floxed 
genotyping reveals an upper band for the floxed allele and a lower band for the WT allele. For 
instance; H35 is KAPiCre positive and heterozygous for the DDAH1-floxed allele whereas 
H37 is homozygous. 
 
3.2.5.2 Reverse transcription quantitative PCR (RT-qPCR) 
Tissue mRNA transcription was determined using a two-step PCR approach 
first involving reverse transcription to create cDNA from the RNA template 
followed by quantitative (qPCR) real-time PCR. 
Extracted RNA was quantified by nanodrop and 100ng loaded into 
each PCR reaction using a commercial dNTP/primer/RTase mix (iScript cDNA 
synthesis kit, BioRad) as outlined in Table 7. 
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iScript mix 4   µL 
Reverse transcriptase 1   µL 
RNA 100ng + water 15 µL 
  
PCR protocol (x1 cycle)  
Reverse transcription 30 min at 42°C 
RTase inactivation 5 min at 85°C 
Table 7. Protocol used for reverse-transcription PCR 
 
3.2.5.3 Quantitative polymerase chain reaction (qPCR) 
The 7900HT Fast System (Applied Biosystems) was used for real-time 
quantitative PCR (RT-qPCR). Sybr Green is a cyanine fluorescent dye that 
emits light in the green spectrum once incorporated into nucleic acid. A 
commercial Sybr Green-based PCR mix (iTaq Fast SYBR Green Supermix 
with ROX, BioRad) was used according to Table 8.  
 
Sybr Green mix 5   µL 
Primers 0.2  µL 
Water 3.6  µL 
cDNA (1:10) 1     µL 
PCR cycling protocol:  
Initial step 95°C   2min 
Thermal cycling x 40  
Denaturation 95°C   3 secs 
Annealing 60°C   30secs 
Disassociation step  
Table 8. Protocol for quantitative PCR 
 
Samples were amplified in duplicate. Amplification curves were 
examined for each set and a fluorescence threshold (CT) set manually at the 
base of the exponential phase of the curve. Amplification efficiency for each 
primer mix was assessed by running serial dilutions of cDNA (1:4; 1:8; 1:16; 
1:32). Standard curve CT values were plotted on a logarithmic scale and the 
slope of linear regression used to calculate relative sample sequence 
transcription. Duplicate CT values were averaged for each sample and 
normalised to a housekeeper gene ($$ CT method) to correct for amount and 
quality of cDNA put into the reaction. Several “housekeeper” sequences were 
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optimised for different types of biological sample and the most stably 
expressed gene was selected. Housekeeper genes commonly used included 
Pol2a, GAPDH, "-actin and !-tubulin. Negative controls were run for each 
primer set using water instead of template DNA. 
3.2.6 Liquid chromatography-mass spectrometry / mass spectrometry (LC-
MS/MS) 
Liquid chromatography-mass spectrometry (LC-MS/MS) is a sensitive 
technique for the high-throughput detection of substances down to pico-molar 
concentrations within complex solutions. The combination of high-pressure 
liquid-chromatography (HPLC) and sequential mass spectrometry confers 
heightened specificity.  
HPLC. Samples in solution are pumped at high pressure down a 
chromatography column containing adsorbent material such as silica. Solutes 
bind to the column through hydrophobic and ionic interactions. Elution buffers 
then wash the column across a pH or salt gradient thus by exploiting 
differences in column-binding affinity, compounds are separated.  
Mass spectrometry. Eluted substances pass into the triple quad mass 
spectrometer where they are first vaporised before ionisation with an electron 
beam. The ions then travel through an electro-magnetic field (quad or Q1) and 
separated according to their mass-to-charge ratio (m/z). In the collision cell 
(Q2) an inert gas such as nitrogen fragments the ions as they are accelerated 
towards a second m/z ratio-selecting field (Q3) before detection. When the ion 
and fragment m/z is known for a given compound, the filters can be set to 
scan specifically for these values. Substances are thus reliably distinguished 
according to their elution time and subsequent precursor to product m/z ratios 
(Figure 14).  
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Figure 14. Schematic diagram of the LCMS/MS system 
 
The Agilent 6400 Series Triple Quadrupole LCMS/MS System was 
used for this study. Biological compounds optimised for detection include 
methylarginines (Calbiochem), amino acids; creatinine and lactate (all Sigma). 
Biological samples including plasma, urine and tissue lysates were 
prepared by methanol protein precipitation in a 1:5 dilution, vortexed and the 
pellet removed by centrifugation. Sample solutions were evaporated to dry in 
a heat-block and resuspended in mobile phase (0.1% formic acid). An internal 
standard was added (7-deuterated ADMA; Cambridge Isotope Laboratories, 
Andover, USA) before precipitation to allow correction for extraction efficiency 
and ion suppression at the point of detection (ions in large abundance can 
out-compete minority ions at the detector). 
A hypercarb (Thermo Scientific) chromatography column was used and 
the mobile phase consisted of 0.1% formic acid, 1% acetonitrile (increasing to 
50% between 5 and 10 minutes) over a total run time of 15 minutes. The 
mass spectrum parameters are listed in the appendix. Data was collected 
using Agilent MassHunter Data Acquisition Software and analysed with 
MassHunter Qualitative Analysis Software before downloading raw data into 
MicroSoft Excel for processing. 
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3.2.7 Urinary proteomics 
The urinary peptide profiles of transgenic mice were investigated in a 
collaborative project with Drs Peter Faull and Pedro Cutillas in The 
Proteomics Laboratory, MRC Clinical Sciences Centre. The following 
methodology was written and performed by Peter Faull. 
Samples were thawed by removing them from the freezer & placing 
them into an Eppendorf Thermomixer Comfort mixing instrument set to 22ºC, 
900rpm for 10 minutes, and then centrifuged at 5ºC, 13000g for 3 minutes. 
200%L of sample was transferred to a 1mL volume Eppendorf Protein LoBind 
tube where 800%L of 0.1% trifluoroacetic (TFA) acid was added to each to 
adjust the volume to 1mL. Tubes were mixed at 22ºC, 900rpm for 2 minutes. 
Samples were then subjected to two different solid phase extraction (SPE) 
steps. Step 1: Reverse-phase SPE using Waters Oasis HLB cartridges 
(product code 186000383). Step 2: Cation exchange SPE using Waters Oasis 
MCX cartridges (product code 186000252). SPE was performed using a 
manual vacuum manifold (Thermo Scientific, 24 port vacuum manifold) & LC-
MS grade solvents from Fisher Chemical. 
Reverse-phase SPE method. Columns were conditioned with 1.5mL of 
100% acetonitrile then equilibrated with two successive 1mL washes of 98% 
water, 2% acetonitrile, 0.1% TFA. Each 1mL volume of sample was loaded 
onto individual columns & permitted to bind to the column media. Two 
successive 1mL washes of 98% water, 2% acetonitrile, 0.1% TFA were added 
to the column to remove small organic molecules, salts or detergents that 
could potentially affect ion signal in the mass spectrometer. The media-bound 
sample was eluted with a single 1mL volume of 40% water, 60% acetonitrile, 
0.1% TFA. Cation exchange SPE was performed immediately after collection 
of eluate. 
Cation exchange SPE method. Columns were conditioned with 1.5mL of 
100% methanol then equilibrated with two successive 1mL washes of 40% 
water, 60% acetonitrile, 0.1% TFA. Each 1mL volume of sample was loaded 
onto individual columns & permitted to bind to the media. Two successive 
1mL washes of 40% water, 60% acetonitrile, 0.1% TFA was added to the 
column to remove anionic species that could potentially affect ion signal in the 
mass spectrometer. The media-bound sample was eluted with a single 1mL 
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volume of 60% acetonitrile, 35% water, 5% ammonium hydroxide. 1mL 
sample eluates were transferred to a Thermo Scientific Savant SPD121P 
SpeedVac Concentrator & dried overnight. 
Sample preparation for mass spectrometry. Dried samples were 
solubilised in 40%L of 0.1%TFA, sonicated for 10 minutes and then 
centrifuged at 5ºC, 13000g for 10 minutes. 10%L of supernatant was 
transferred to a Bioquote Limited 0.2mL lubricated hydrophobic PCR tube 
which was placed into an autosampler vial ready for LC-MS injection and 
analysis. 
Liquid chromatography and mass spectrometry methodology. A Thermo 
Scientific (Dionex) Ultimate 3000 nano liquid chromatography system was 
used to separate peptides prior to mass spectrometric analysis. An injection 
volume of 4%L was removed from the insert vial and loaded onto a trap 
column (Thermo Scientific Acclaim Pepmap 100 with dimensions 100%m 
internal diameter and 2cm length, C18 reverse phase material with 5%m 
diameter beads and 100Å pore size, product number 164564) at 8%L/min in 
98% water, 2% acetonitrile, 0.1% TFA. Peptides were then eluted on-line to 
an analytical column (Thermo Scientific Acclaim Pepmap RSLC with 
dimensions 75%m internal diameter and 50cm length, C18 reverse phase 
material with 2%m diameter beads and 100Å pore size, product number 
164540) and separated using a ramped gradient with conditions: initial 5 
minutes with 4% B (96% A), then 90 minute gradient 4-55% B, then 10 minute 
isocratic at 100% B, then 5 minute isocratic at 4% B (solvent A: 98% water, 
2% acetonitrile, 0.1% formic acid; solvent B: 20% water, 80% acetonitrile, 
0.1% formic acid). Eluted peptides were analysed using Thermo LTQ XL 
Orbitrap operating in positive polarity, top 4 CID (collision-induced 
dissociation) method. Ions for dissociation were determined from initial 15000 
resolution MS scan (event 1) followed by CID on the top 4 most abundant 
ions. CID conditions: default charge state 2, 2.0 m/z isolation width, 
normalised collision energy 35.0, Activation Q value 0.25, activation time 
30ms, lock mass value of 445.120030 m/z used. 
Data analysis. Raw files were searched against UniprotKB/Swiss-Prot 
database (version 10032012) restricted to mouse entries using Mascot 
v2.3.01 [163]. Relative quantification of peptides was performed by extracted 
66 
ion chromatograms of parent ions using an in-house developed software 
(PESCAL, [164, 165]). 
3.2.8 Biochemical analysis of plasma and urine 
Urinary protein measurements were performed using the Bradford’s assay as 
described above. Urinary glucose was measured with a 96-well plate 
colormetric assay using commercially available glucose oxidase reagent 
(Infinity Glucose (Ox), Thermo Scientific; 50µL of sample plus 200µL reagent, 
10min room temperature incubation, read at 490nm). In the reaction, glucose 
is oxidized by glucose oxidase to gluconic acid and hydrogen peroxide. 
Hydrogen peroxide reacts in the presence of peroxidase with hydroxy-benzoic 
acid and 4-aminoantipyrine to form a red quinoneimine dye. Colour intensity is 
proportional to the glucose concentration and quantified with a plate-reader.  
Plasma and urinary content of protein, electrolytes and creatinine was 
performed by automated analysis in the National Health Service laboratory, 
Hammersmith Hospital. 
3.2.9 Western blotting 
Proteins were separated and identified using Western Blotting [166] 
and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Gels (12%) were made according to the following recipe. Resolving gel (10mL 
of 12%); 4.35mL dH2O; 3mL 40% acrylamide/Bis 37.5:1; 2.5mL 1.5M Tris-Hcl 
pH8.8; 100uL 10% SDS; 5uL TEMED; 50uL 10% APS (all from Biorad). 
Stacking gel (10mL of 4%); 6.32mL dH2O; 1mL acrylamide/Bis 37.5:1; 2.52mL 
0.5M Tris-Hcl pH6.8; 100uL 10% SDS; 10uL TEMED; 50uL 10% APS. See 
Table 9 for the detailed protocol. Antibodies for DDAH1 and 2 were developed 
within our group in conjunction with Sigma Aldrich (goat anti-mouse). GFP 
antibodies purchased from Abcam and Clontech. Licor secondary antibodies 
were used for Odyssey fluorescent detection. All other antibodies were 
purchased from Abcam unless stated otherwise.  
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Run SDS PAGE 10-20uL protein/well plus 2uL protein marker (All 
Blue; BioRad). 150V for upto 90mins 
Transfer to membrane Using BioRad Mini-Transblot onto nitrocellulose or 
Hybond-P (Immobilon), 100V 1 hour, ice cooled 
Rinse in PBS Tween 0.1% 10mins 
Block in 5% milk (in PBS-T) Room temperature 1 hour 
Primary antibody incubation 
(In 5% milk with PBS-T) 
4°C overnight in 5% milk PBS-T with agitation, see 
below for concentrations 
PBS-T washes x 6 X3 quick swills, x3 5 min washes with agitation 
Secondary antibody incubation 
(In 5% milk with PBS-T) 
Room temperature 1 hour with agitation 
PBS-T washes x 6 X3 quick swills, x3 5 min washes with agitation 
Visualisation either:  
Chemiluminescence Amersham ECL kit 
Fluorescence detection Licor Odyssey detection and quantification system 
Table 9. Western blotting protocol 
3.2.10 DDAH antibody purification 
Reliable antibodies specific to DDAH1 and 2 are difficult to produce and 
outcomes with commercial preparations are variable. Our group successfully 
generated polyclonal goat antibodies against peptides DDAH1238-252 and 
DDAH2241-255 [167]. It was necessary to purify working solutions of antibody 
from the sera of peptide-inoculated goats using affinity purification through 
columns containing beads with covalently bound DDAH peptides. The 
protocol detailed in Table 10 was adapted from “Using Antibodies – A 
Laboratory Manual” (Harlow, E. Lane, D [168]). A fraction collector, low-
pressure (LP) chromatography system and LP data view software 1.03 were 
supplied by BioRad. 
The eluate was passed through a UV filter set at 280nm to detect 
protein and allow identification of the antibody-containing fractions that were 
subsequently run separately through an SDS-PAGE gel and stained with 
Coomassie Blue to confirm presence of eluted protein. Antibodies were tested 
against liver and kidney lysates from WT animals and global DDAH1 and 
DDAH2 knock-out animals for negative controls. As expected from non-
homologous peptide sequences to which they were raised – DDAH1 and 2 
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antibodies exhibited no cross-reactivity and in addition, observed band sizes 
were different; DDAH1 ~37kDa, DDAH2 ~28kDa. 
 
 
Column washing Sequential 20mL volumes at 2mL/min: 10mM 
Tris (pH=7.5); 100mM glycine (pH=2.5); 
10mM Tris (pH=8.8); 100mM triethylamine 
(pH=11.5); 10mM Tris (pH=7.5) 
Serum 20mL goat serum in 20mL Tris (pH=7.5), 
spun 5min, 4000rpm. Supernatant ran at 
0.5mL/min 
Washing column (to clear non-specific bound 
protein) 
40mL volumes at 2mL/min: 10mM Tris 
(pH=7.5); 500mM NaCl/Tris (pH=7.5)  
Acid elution (of bound antibody) 20mL of glycine (pH=2.5) at 1mL/min. 
Fractions collected into tubes containing 
200uL Tris (pH=8.8) to immediately neutralize 
acid 
Washing 20mL of Tris (pH=8) 
Base elution 20mL of triethylamine (pH=11.5) 
Washing 40mL of Tris (pH=7.5) 
Table 10. Detailed protocol for DDAH antibody affinity purification 
 
3.3 Biochemical methods 
3.3.1 Nitric oxide quantification 
As previously described NO is highly reactive, making direct measurement in 
ex vivo samples impractical. Assays are therefore designed to detect levels of 
stable end products of NO metabolism; nitrite (NO2-) and nitrate (NO3-). 
Assessments of NO activity in vivo using nitrite and nitrate species (NOx) as 
surrogates is an accepted approach, however a significant effect of dietary 
nitrate has to be considered. Ideally, in vivo experiments using NOx as an 
end-point measure should be performed whilst subjects are fed a low 
nitrite/nitrate diet to reduce variability and better expose genuine effects of 
intervention [169, 170]. In these studies, a low nitrite/nitrate diet was not used 
and therefore results have to be interpreted with this as a consideration. 
69 
3.3.2 Nitric Oxide Analyser 
The Sievers NOA 280i (GE Analytical Instruments, Colorado, USA) was used 
to measure the NO content of small volumes of biological samples. Nitric 
oxide is re-derived from nitrites and nitrates (stable end-products of NO 
activity) by reduction in heated vanadium chloride. NO is detected and 
quantified in a gas-phase chemi-luminescent reaction with ozone which emits 
in the red/infra-red spectrum.  
The lower limit of detection is around 0.2µM for a volume of only 5µL.  
Samples prepared by methanol protein precipitation (1:5 volume mix; vortex; 
high speed 10min centrifuge to remove pellet), run in triplicate volumes of 
20µL, averaged and NO quantified by calculation against a standard curve of 
sodium nitrate (0-200µM). Data was recorded using Sievers NOAnalysis 
Liquid software. 
3.3.3 Griess reaction 
This method quantifies organic nitrite and utilizes the chemical diazotization 
reaction originally described by Peter Griess in 1879. Sulfanilamide forms a 
diazonium salt with organic nitrites and subsequently N-1-
napthylethylenediamine dihydrochloride (NED) reacts under acidic conditions 
(phosphoric acid) to form a pink colour, which can be read by colorimetry at 
540nm.  
The Griess assay is less sensitive than chemi-luminescence with a 
lower limit of detection of approximately 1µM. In addition, at least ten-times 
the volume of sample is required (50µL) however the assay is fast, 
inexpensive and allows high numbers of samples (in 96 well plates) to be 
tested simultaneously. 1% (w/V) sulphanilamide / 5% phosphoric acid is 
mixed in a 1:1 ratio with; 0.1% (w/v) N-(1-napthyl) ethylenediamide and added 
to an equal volume of sample (50-100µL/well). A standard curve of known 
sodium nitrite concentrations (0-100µM) was used for quantification. (All 
chemicals purchased from Sigma). 
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3.4 Histological methods 
3.4.1 Frozen section histology 
Tissue harvested from the ROSAYFP reporter mouse was fixed overnight in 
4% PFA and then 30% sucrose in PBS until the tissue sank (around 4 hours). 
Specimens were then embedded in OCT and snap frozen onto cork discs in 
either isopentane cooled in liquid nitrogen or methanol cooled in dry ice and 
stored at -80°C. 
For frozen sectioning samples were warmed to -20°C in the cryotome 
(CM 1850 Leica Microsystems, Germany) before cutting 5 µm sections onto 
poly-L-lysine-coated glass slides. Sections were dried at room temperature 
and coverslips mounted using a reagent containing DAPI for nuclear staining 
(Prolong® Gold, Life Technologies™). Slides were studied using a Leica SP5 
microscope. 
3.4.2 Immunohistochemistry 
3.4.2.1 Tissue preparation 
Harvested organs were fixed in 4% paraformaldehyde (PFA) overnight and 
then stored in 70% ethanol.  For kidney specimens, half of the right kidney 
was transected in the sagittal plane. Samples were processed and stained by 
staff at the Department of Histopathology, Imperial College at South 
Kensington, London, unless stated otherwise.  Tissues were embedded in 
paraffin blocks by an automated processor and 5µM sections cut on a 
microtome and attached to poly-L-lysine-coated glass slides.  
 
3.4.2.2 DDAH1 staining 
The detailed protocol in Table 11 was used for DDAH1 staining. Initial staining 
for DDAH1 in mouse and human kidney was performed upon sections 
previously prepared and kindly donated by Dr Ben Caplin (UCL, London). 
 
3.4.2.3 Periodic Acid Schiff (PAS) Stain  
Periodic acid reacts with carbohydrate molecules to create aldehydes giving a 
purple colour upon reaction with Schiff reagent. PAS staining is therefore 
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useful for the histological assessment of carbohydrate-rich structures such as 
the tubular and glomerular basement membranes in kidney sections. 
Sections were rehydrated through xylene and graded ethanol (100%, 
95% 70%) solutions to water. Following rehydration, slides were submerged 
in periodic acid for 5 minutes, washed and then exposed to Schiff’s reagent 
for 1 hour.  Following further washing, sections were counter-stained with 
Gill’s haematoxylin for 3 minutes, soaked in tap water for 5 minutes and 
destained in acid alcohol.  Slides were dehydrated in xylene and coverslips 
applied using DPX mountant.  
 
 
Wax removal 10 min xylene soak, then xylene washes x2 
 100% ethanol washes x3 
 5 min water soak 
 10 min soak in methanol plus 6% hydrogen peroxide 
 Water wash 
Antigen retrieval Citrate buffer (0.021%) 5 min then 20mins on “HIGH” in microwave 
 Water wash 
Blocking 5 min PBS soak 
 20 min normal horse serum incubation (3 drops; Vector) 
 PBS wash 
 15 min Avadin (3 drops; Vector), PBS wash 
 15 min Biotin (3 drops; Vector), PBS wash 
Primary antibody DDAH1 goat polyclonal (1:50; Dr J Leiper), 1 hour at room 
temperature 
  
Secondary antibody Biotinylated horse anti-goat IgG (1:200; Vector), 30 min room 
temperature. PBS wash 
Tertiary antibody ALP ABC kit (1:100; Vector), 30 min room temperature. PBS wash 
Substrate staining ALP substrate kit (Vector), upto 30 min room temperature, stopped 
by water wash when staining clear 
Counter-stain Mayer’s haematoxylin 5 min 
Washing x 3 sequential washes in ethanol and xylene 
Mounting DPX and coverslip, dry overnight 
Table 11. Protocol for DDAH1 immunohistochemical staining 
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3.4.2.4 Picrosirius Red Stain 
Following rehydration, slides were stained with picrosirius red (Direct Red 80 
0.5% in saturated picric acid) for 1 hour.  Slides were then washed and 
counter-stained with Weigert’s haematoxylin (an acid-resistant nuclear stain) 
for 2 hours before washing, dehydration and coverslipping.  
Although collagen fibre deposition is frequently demonstrated with 
picrosirius red staining, there is a lack of consensus as to the best method of 
visualisation [171]. Bright field visualisation allows detection of red-stained 
collagen but lacks specificity and although linearly-polarised light improves 
upon this, a proportion of fibres lying parallel to the transmission axis will 
inevitably be invisible. Circular polarised light removes this problem and 
allows all collagen fibres to be visualised. 
The sections were analyzed using a Manual Zeiss Axiophot 
microscope (Zeiss, NY, USA) equipped with filters to provide circularly 
polarized illumination. The lower filter (3M circular polarizer; Edmund 
Industrial Optics, Barrington, NJ, USA) was placed above the microscope’s 
field iris diaphragm ring, while the upper filter was constructed from a 
combination of a quarter-wave plate (U-TP137, Olympus) placed below a 
linear polarizer aligned such that its transmission axis was at 45 ! to the fast 
axis of the wave plate. These two filters were aligned and fixed to maintain a 
field background as dark as possible (that is, the filters were “crossed”). 
Tissue images were obtained with a 2.5X objective lens, recorded on a digital 
camera (Canon EOS-40D digital SLR; Canon Inc, Tokyo, Japan) and viewed 
through Canon Utilities EOS software. 
Images were subsequently analysed using a Fiji software macro written 
by Dr Dirk Dorman, Head of Microscopy, MRC Clinical Sciences Centre, 
Imperial College, London, which automated the following steps to quantify 
collagen in each whole kidney slice: individual images of each section were 
stitched together to form a whole kidney image; a plane slide image was used 
to correct for background; whole kidney area in pixels was recorded using 
texture thresholding; whole collagen area (yellow-green birefringence) was 
recorded by colour intensity thresholding. Relative collagen deposition per 
total section area (pixels) could then be reported. Using the whole kidney 
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section and automated analysis removes potential bias and therefore the 
need for observer blinding. 
3.5 In vivo methods 
3.5.1 Regulatory Approval 
Animal experimentation was undertaken only in accordance with the 
3R principles of replacement, refinement and reduction.  In vivo procedures 
were used only where no appropriate in vitro methodology was available and 
experiments were designed to minimise suffering to the animals involved. All 
animal procedures were conducted under the terms of Home Office Project 
and Personal Licences. 
Where possible, power calculations were used to guide what minimum 
number of animals would be adequate for experiments. An online power / 
sample size calculator was used (http://www.stat.ubc.ca/~rollin/stats/ssize). 
As an example, using the relative percentages of DDAH1 protein expression 
between tubular and glomerular lysates; a power of 80% was deemed 
adequate to detect a minimum 25% difference between the two groups. An 
estimated standard deviation size (&) of 15% was derived from values gained 
in previous Western blotting assays using the DDAH1 antibody. Statistical 
significance (!) was set at 0.05 for a two-sided test. 
3.5.2 Housing Conditions 
Animals were maintained in social groups where possible with appropriate 
environmental enrichment (e.g. bedding materials, mouse tunnels).  Animals 
were kept in rooms at a constant temperature and maintained on a 12-hour 
light/dark cycle. They were fed on standard rodent chow and water ad libitum 
unless stated otherwise. 
3.5.3 Experimental animal strains 
The transgenic constructs and breeding strategies are described in further 
detail in Chapter 4: “Targeted gene deletion in the renal proximal tubule”.  
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3.5.3.1 The floxed DDAH1 mouse 
The DDAH1 floxed mouse strain was bred on a mixed B6/129 background. 
The construct was developed in-house by our own group, wherein LoxP sites 
were inserted to flank exon 1 of DDAH1, which encodes the initiating 
methionine residue and the first 100 amino acids of the protein (see Chapter 
4.4). 
 
3.5.3.2 The KAPiCre mouse 
The KAPiCre transgenic mouse developed by Li et al [172] was purchased as 
a male heterozygote on a C57BL/6J background from Jackson Laboratories 
(strain name: B6.Cg-Tg(Kap-cre)29066/2Sig/J). (See Chapter 4.2.1).  
 
3.5.3.3 The ROSAYFP mouse 
The ROSAYFP (heterozygote male) mouse on a mixed B6/129 background 
was a kind gift from Professor Graham Williams. (See Chapter 4.3).  
 
3.5.3.4 The DDAH2 global knock-out mouse 
The DDAH2 global knock-out transgenic mouse line was created through the 
Texas Institute for Genetic Medicine (TIGM, Houston, Texas, USA) and bred 
on a mixed B6/129 background. DDAH2 gene disruption was achieved by the 
insertion of a long terminal repeat into the first exon of the gene using a 
retroviral vector (http://www.tigm.org/). (See Chapter 11). 
3.5.4 Transgenic Animal Genotyping 
At approximately 4 weeks of age, mice were genotyped using tail-clipped 
tissue and ear-notched for identification. DNA extraction was achieved using 
“GNK” lysis buffer (Triz base 10mM; MgCl2 1.5mM; KCl 50mM; gelatin 0.01%; 
Igepal Ca-630 0.45%; Tween 20 0.45%) with fungal proteinase K. Samples 
were digested overnight at 53 °C and the proteinase K deactivated by a 10 
minute period at 100 °C. End-point PCR using 1µL of DNA per reaction mix 
was performed as described previously.  Primer sequences for transgenic 
genotyping were obtained from Dr J Leiper (DDAH1 floxed, DDAH2 KO) and 
the Jackson Laboratory (KAPiCre) (see appendix).  
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3.5.5 Urine Collection 
Animals were place in metabolic cages for a maximum of 24 hours. Collected 
urine was centrifuged at high speed for 10 minutes, the pellet discarded and 
stored at -80°C. 
3.5.6 Testosterone pellet insertion 
Exogenous testosterone was administered in the form of a pellet placed 
subcutaneously. The original investigators used pellets containing 5mg of 
testosterone designed to release over 21 days, equivalent to 0.24mg/day 
[172]. To cover a 12 week CKD model, testosterone pellets for this study were 
made to request for a similar daily dosage of 0.24mg/day; 22mg continuous 
release over 90 days (13 weeks; supplied by Innovative Research of America, 
Florida, USA). Mice were anaesthetised under oxygen (2L/min) delivered 
isoflurane and placed on a warming mat. After shaving, a small 3-5mm 
incision was made in the nape of the neck to the right of midline. A 
subcutaneous pocket was created by blunt forcep dissection, the pellet 
inserted and the incision closed with two sutures using 5-0 Mersilk (Ethicon, 
Johnson and Johnson Medical Ltd. UK). Animals were allowed to recover in a 
heated chamber (32°C) and checked daily for two days following surgery. 
3.5.7 Salt-feeding 
In some experiments, selected mice were given low- or high-sodium chow 
(0.03% or 3.15%; TestDiet®, IN, USA) with ad libitum access to normal water. 
Urine was collected in metabolic cages before and after 8 days of salt-feeding 
before blood pressures were recorded under terminal anaesthesia. Plasma 
and kidney tissue was harvested as described elsewhere. 
3.5.8 Models of renal injury 
3.5.8.1 Folate model 
The use of intraperitoneal (IP) folate (folic acid or pteroylglutamic acid) to 
model renal injury is a well-established experimental technique [173, 174]. 
Folate induces a dose-dependent nephrotoxicity as crystals precipitate within 
renal tubule lumina.  Acute tubular necrosis ensues within 48 hours, followed 
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by a period of epithelial regeneration and from 8 weeks following injury, 
kidneys exhibit loss of function and by 12 weeks, progressive fibrosis (Figure 
15). 
 
 
Figure 15. Progressive fibrosis in experimental mouse folate nephropathy  
Female mice on a CD1 background received a single IP folate dose of 200mg/kg at T0. 
Assessment of fibrosis performed by semi-quantitative analysis. Reproduced from [175]. 
 
Folate injury thus provides a reproducible model with which to 
investigate the natural history of inflammatory pathways from initial acute 
tubular injury through to chronic kidney disease. Time points of 2, 14 and 84 
days were chosen for this study to permit assessment of the acute injury 
phase, recovery and eventual progression to chronic fibrosis respectively. 
Mice received a single intra-peritoneal injection of folate (240µg/g of 
body weight) dissolved in 0.3M NaHCO3 vehicle (20mg/mL) or vehicle control 
alone (both from Sigma). Mice were sacrificed by CO2 narcosis followed by 
cervical dislocation at day 2, day 14 or day 84 (12 weeks). Blood was 
collected by direct cardiac puncture and stored on ice before high-speed 
centrifugation to remove the plasma. The right kidney was halved (sagittal 
plane) for histology, and quartered for future RNA and protein extraction while 
the left kidney was weighed. Samples were stored at -80°C prior to further 
processing. Prior to sacrifice, urine was collected in metabolic cages for the 
14 and 84 day time-points. 
 
77 
3.5.8.2 Nephrotoxic nephritis model 
Nephrotoxic globulin and expertise with this model was kindly provided by Dr 
Ruth Tarzi. The following is a description of how this was prepared [176]. 
Sheep were immunized with murine glomerular lysate initially in complete and 
then incomplete Freund’s adjuvant (Sigma, Dorset, UK). Ammonium sulfate 
precipitate was dialyzed against sterile PBS (Invitrogen, Paisley, UK) and 
stored at -80°C. (The endotoxin content of the nephrotoxic globulin was 
undetectable after using a Biowhittaker QCL-1000 LPS assay kit 
(Biowhittaker, Walkersville, MD). 
Mice were pre-immunized with intra-peritoneal sheep IgG (0.2 mg) in a 
1:1 volume mix with complete Freund’s adjuvant (Sigma). Five days after the 
immunization, 5 mg of nephrotoxic serum (NTS) was injected through a tail 
vein.  The mice were monitored clinically; 10 days after NTS injection, the 
mice were sacrificed and harvested as described above.  
3.5.9 Invasive Blood Pressure Measurement  
Invasive blood pressure recordings were performed with the assistance of Dr 
Zhen Wang.  Animals were anaesthetised under oxygen (2L/min) delivered 
isoflurane anaesthesia and placed on a warming mat.  The carotid artery was 
isolated and a ‘Mikro-Tip’ pressure transducer catheter (Millar Instruments, 
TX) was introduced.  Recordings were obtained using the Powerlab system 
and data recorded and analysed using Chart software (both from 
ADInstruments, Oxfordshire). Isoflurane anaesthesia was minimised to 1% 
and after a 3-minute stabilisation interval, blood pressure was recorded and 
sampled for approximately 50 cardiac cycles. All measurements were blinded 
to genotype and performed between 0800 and 1300 to maintain diurnal 
consistency. 
3.5.10 Isolated proximal tubule microperfusion 
These studies were done in collaboration with Professor Chris Wilcox’s group 
at the Kidney and Vascular Research Center, Georgetown University, 
Washington, USA. Dr William Welch and Professor Wilcox supervised the 
work whilst Miss Tracy Bell provided the surgical expertise. This technique 
measures intrinsic tubular epithelial transport in vivo and historically, data 
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gathered in this way forms the basis of renal tubular physiology. Single 
proximal tubule (PT) segments are isolated by cannulation and by 
administering various compounds, the roles of key regulators of PT function 
can be tested. The technique permits control of flow rate, sodium 
concentration, osmolality, and extracellular pH. The methods, performed in 
both rats and mice, have been described previously [177, 178] but a brief 
outline follows. 
 
3.5.10.1 Animal preparation 
Animals were anesthetized with thiobarbital (Inactin, 80 g/kg IP; Research 
Biochemicals Inc) and cannulae were placed in a jugular vein for infusion of 
fluids and in a femoral artery for the recording of mean arterial pressure 
(MAP; Powerlab, AD Instruments Inc). A tracheotomy tube was inserted and 
animals ventilated room air spontaneously. A catheter was inserted in the 
bladder and another in the left ureter to collect urine. The left kidney was 
exposed by a flank incision and stabilized in a Lucite cup (Vestavia) mounted 
on a heated surgical table and bathed in mineral oil maintained at 37°C 
(Figure 16).  
 
Figure 16. Renal proximal tubule micro-perfusion in rodents 
A. The animal is anaesthetized on a heat mat and cannulated as labeled. B. The left kidney is 
held in a cup and bathed in mineral oil heated to body temperature. C. A glass micropipette is 
advanced into a superficial tubule under microscopic guidance and optic light source (dye is 
visible in the tip which is used to confirm successful cannulation). 
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 After surgical preparation, rats were infused with a solution of 154 
mmol/L of NaCl and 1% albumin at 1.5 mL/h to maintain euvolemia. Studies 
began after a 60-minute of stabilization period. 
 
3.5.10.2 Microperfusion of PTs 
The kidney surface was examined microscopically and a PT segment of 
appropriate visible length was injected with a “finding” pipette containing dye-
stained artificial tubular fluid. The flow was blocked by injection of T grease (T 
grade, Apiezon Products) via a micropipette (10 to 12 µm OD) proximal to the 
perfusion site. The tubule was perfused with a micropipette (8 to 10 µm OD) 
connected to a micro-perfusion pump (model A1400, World Precision 
Instruments Inc) at 18±3 nL/min. The perfusion solution contained 14C inulin 
(New England Nuclear) as volume marker and 0.1% FD&C green dye for 
identification of the perfused loops. 
 Tubules were perfused for 2 to 8 minutes before fluid collections, which 
were made at a downstream site with a micropipette (7 to 10 µm OD) after 
placement of a column of oil to block downstream flow. Samples were 
collected for 3 to 5 minutes and transferred into a constant-bore capillary tube 
for which the length was measured with a micrometer to calculate the tubular 
fluid volume. Thereafter, the samples were injected into scintillation fluid and 
the 14C activity counted. Collected samples with <95% and >105% of 
microperfused inulin were discarded. The amount of microperfused inulin was 
estimated by the average of 14C-activity in 4 samples microperfused directly 
into capillary bore tubes at the end of the experiment. To determine the 
lengths of the perfused segments, tubules were filled with high-viscosity 
microfil (Flow Tech, Inc). 
 At the end of the experiments, the kidney was partially digested in 20% 
NaOH, and the casts were measured under a dissecting microscope. The Jv 
was calculated by the difference in the perfusion rate and the collection rate 
factored by the length of the nephron: Jv = Vperf (nL/min) ' Vcoll (nL/min) / 
PT length (mm) where Vperf indicates perfusion rate and Vcoll indicates 
collection rate and expressed as nL/min/mm. The composition of the 
perfusion fluid was as follows (mM): 125 NaCl, 20 NaHCO3, 5 KCl, 1 MgSO4, 
2 CaCl, 1 NaHPO4, 5 glucose, and 4 urea.  
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5.10 Data analysis 
Statistical analysis was performed using the Prism software package (Graph 
Pad Inc., UK). All data are presented as means ± SEM. Distribution of data 
was determined by skewness and D’Agostino and Pearson omnibus normality 
test for group sizes of more than 7 (below which normality testing is 
inaccurate). For comparisons between two groups for a single variable, an 
unpaired two-tailed t-test (parametric data) or a Mann-Whitney U test (non-
parametric data or where a normal distribution could not be assumed) was 
used. Differences between multiple groups were assessed by one-way 
analysis of variance (ANOVA) followed by Bonferroni’s post test for multiple 
comparisons. Two-way ANOVA was used where comparisons were being 
made between groups subject to two experimental variables, followed by 
Bonferroni’s post test for multiple comparisons. P values of <0.05 were 
considered statistically significant. 
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4 TARGETED GENE DELETION IN THE RENAL PROXIMAL TUBULE 
4.1 DDAH1 expression within the proximal tubule 
As discussed in Section 1.7.1.1, the proximal tubule has been demonstrated 
to be the principal cell type to express DDAH1 protein in both the rat and 
human kidney. Further immunohistochemical staining of human kidney tissue 
for this study reproduced a similar pattern of expression (Figure 17). 
Figure 17. Immunohistochemical staining for DDAH1 in normal human kidney. 
A, DDAH1 staining is seen in the epithelial cells of the proximal tubule (arrows) and not in the 
glomerulus (g) or control (B; DDAH1 antibody pre-incubated with DDAH1 peptide). 
 
In the mouse, qPCR and Western blotting analysis of extracted tubular 
cells indicated that DDAH1 transcription and protein expression is 
approximately 95% higher in kidney tubule lysates when compared with 
glomerular lysates (Figure 18). 
Figure 18. DDAH1 expression in murine tubular cells 
A, DDAH isoform protein expression and B, MAME transcription. DDAH1 protein expression 
predominates in tubular fractions. Consistent with previous reports, DDAH2 expression is 
stronger in the glomeruli, and AGXT2 in the tubules. Comparisons are made between tubular 
(white bars) and glomerular fractions (black bars) of WT mouse kidney tissue (corrected 
relative percentages). Mann-Whitney U test, n=5, *** p<0.001. 
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4.2 Transgenic technology 
Genetic modification or transgenic technology developed over the last two 
decades has revolutionised the study of the roles specific genes play within 
whole organisms. Transgenic techniques are most well developed in the 
mouse, owing to advanced knowledge of its genetics, ability to manipulate 
embryonic cells (ESs), rapid breeding times and relative small size with low 
maintenance costs. Two basic approaches are used to either overexpress or 
delete a gene; random chromosomal integration and homologous 
recombination. 
4.2.1 Random chromosomal integration 
DNA sequences (a promoter element and gene of interest) are microinjected 
into a fertilised oocyte that is subsequently inserted into a pseudopregnant 
female. This technique is most often used to achieve de novo or exaggerated 
expression of a gene whose product may either be functional or dominantly 
inactivating against a native protein. In addition, this technique can be used to 
introduce a “reporter” protein, such as green fluorescent protein (GFP), that is 
functionally innocuous but expression is driven by upstream regulatory 
elements. By using immunohistochemistry or biochemical assays to 
determine the expression pattern of GFP, insights can be gained into the 
presence and functional role of upstream control sequences. Similar random 
DNA integration can also be achieved using a viral vector to transfect the 
target cells in order to express a new gene product. 
Interpreting the phenotypes of animals created in this way requires 
caution. New DNA insertion is random and can occur within inactive sites of 
the chromosome or interrupt native gene sequences. Furthermore, a 
transfected cell overexpressing protein in supra-physiological concentrations 
may undergo adaptive changes to the expression and function of other genes 
resulting in a phenotype not necessarily reflective of the function of the gene 
under scrutiny. 
4.2.2 Homologous recombination 
Homologous recombination is a normal biological phenomenon of nucleotide 
sequence exchange between similar DNA strands that repairs harmful breaks 
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and produces small genetic variations. The process can be exploited for the 
targeted introduction of new gene sequences using a technique developed by 
Capecchi, Evans and Smithies for which they won the 2007 Nobel Prize in 
Physiology or Medicine [179]. 
A specifically designed DNA construct flanked by sequences identical 
to the targeted locus is introduced into embryonic stem (ES) cells. After 
translocation to the nucleus, the construct replaces the targeted locus through 
homologous recombination. ES cells containing the recombined DNA are then 
injected into developing embryos and if integration is successful, the 
developing fetus is chimeric: composed of two different cell populations – 
some containing all native DNA and others, the new DNA construct. If the 
fertilised oocyte is from the transgenic sub-population, subsequent breeding 
will produce heterozygotes for the new genotype, allowing generation of 
homozygotes from successive mating. This technique is commonly used to 
delete or disrupt selected genes to create a null or “knock-out” animal. The 
approach also allows for the study of gene expression “dose” effects, by 
comparing the phenotypes of wild-type and transgenic homozygous 
organisms against those with haploinsufficiency. 
A number of limitations exist with homologous recombination. Many 
genes are crucial for embryonic development and their deletion results in 
lethality. Even in viable offspring, absence of a gene throughout development 
to adulthood can provoke adaptions to the expression of other genes that lead 
to a phenotype not necessarily representative of the deleted sequence. In 
addition, non-specific tissue type gene deletion makes phenotype 
interpretation difficult. For example, global DDAH1 deletion increases 
circulating ADMA, elevates systemic BP and may influence renal 
autoregulation - introducing strong confounding variables when trying to 
define the specific pathophysiological roles of renal proximal tubular DDAH1 
activity. Cre-Lox recombinase technology circumvents these issues and 
allows conditional gene knock-out in a time and cell-type specific nature. 
4.2.3 Cre-Lox technology 
Cre (cyclisation recombinase) is an enzyme derived from the bacteriophage 
P1, that excises DNA sequences flanked by “LoxP” sites: unique 34 base-pair 
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nucleotide sequences that serve as points for recognition and reintegration, 
allowing Cre to ligate the DNA back together [180]. The Cre-Lox system was 
developed for use in eukaryote organisms throughout the 1990s [181] and is 
now a well-established method for achieving conditional, cell-type specific 
gene deletion. 
For inducible cell-specific gene deletion, two transgenic constructs are 
required to be integrated using homologous recombination. One contains the 
gene of interest flanked by LoxP sites (floxed), whilst the other must have Cre 
recombinase fused with a promoter region that is hormone (eg. testosterone) 
or drug-sensitive (eg. doxycycline). When both alleles co-exist in the same 
cell, and in the presence of the specific inducing factor, active Cre 
recombinase is expressed and the gene of interest excised (Figure 19). 
 
Figure 19. Cre-Lox mouse breeding 
Mice with the Cre protein expressed in a specific cell type are bred with mice that contain a 
gene of interest flanked by LoxP sites. When the mice are bred, cells expressing Cre will have 
the target gene excised. Reproduced from [182]. 
 
Although commonly used for gene deletion, de novo gene expression 
can also be achieved with the Cre-Lox system. If a transgene is fused with a 
ubiquitous promoter and a floxed STOP sequence, active Cre removes the 
STOP insertion, permitting expression of the new gene (Figure 20). This 
technique is frequently used to create “reporter” cells or organisms that allow 
rapid identification of successful transgene integration and expression (eg. 
LacZ or yellow fluorescent protein (YFP)). 
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Figure 20. Cre-Lox construct for de novo gene expression 
The STOP sequence is a short sequence of transcriptional STOP codons or terminators that 
prevent gene transcription. Activated Cre excises the STOP sequence allowing gene 
transcription and expression. Reproduced from [182]. 
 
Cre activity is very efficient and the main limitation to this system is 
promoter specificity, as very few are perfectly cell-type specific and even low 
levels of Cre expression can lead to recombination [183]. 
4.3 Study design 
4.3.1 Kidney androgen promoter 2/ improved Cre (KAP2iCre)  
The kidney androgen-inducible protein (KAP) was first identified by in vitro 
translation of male mouse kidney mRNA in 1979 [184]. The function of this 20 
kiloDalton (KD) protein remains unknown, but in-situ hybridisation studies 
show highly-specific proximal tubular expression and exquisite androgen 
sensitivity [185]. In comparison to normal males, female and castrated male 
mice express 10 and 200 fold less KAP mRNA respectively. 
The KAP2iCre (KC) construct was developed and used by the original 
investigators through their work assessing the role of renin and angiotensin 
expressed within the proximal tubule [172, 186]. By fusing regulatory 
elements of both the KAP promoter and angiotensinogen genes, enhanced 
high level, PTC-specific, codon-optimised Cre (iCre) expression could be 
achieved with administration of exogenous testosterone (without functional 
KAP or angiotensinogen production). Low level Cre expression was detected 
in brain and liver extracts using RNase protection assays, although <1% of 
hepatocytes stained positively in their LacZ reporter mouse. The same group 
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has since published work using the KC construct to either overexpress or 
deplete the proximal tubular angiotensin receptor type-1A (AT1A), resulting in 
an increase and decrease of systemic BP respectively, independent of 
testosterone administration alone [187]. 
The KC transgenic mouse is commercially available and was 
purchased from the Jackson Laboratory, Maine, USA (strain name: B6.Cg-
Tg(Kap-cre)29066/2Sig/J). Male KC+ mice exhibit variable levels of KC 
expression during adulthood due to endogenous testosterone production 
whereas female mice do not [172]. To achieve complete temporal control over 
KC expression, only female mice were used for experiments (see final 
discussion). Administration of a subcutaneous testosterone pellet for a 
minimum of ten days [186] was necessary to induce functional KC expression 
and subsequent floxed gene deletion - evidence of which was examined 
through expression analysis of genes, proteins and enzyme activity. 
Two KC double transgenic mice were bred: the first, a ROSA26eYFP 
reporter mouse to confirm cell-type specific KC induction with exogenous 
testosterone, the second, a DDAH1-floxed mouse designed to test the study 
hypothesis (Figure 21). 
 
Figure 21. KAPiCre mediated YFP expression and DDAH1 deletion 
Following 10 days of exogenous testosterone treatment in female mice, expression of renal 
proximal tubular cell-specific active KAPiCre causes recombination events between loxP sites 
and excision of intervening gene sequences. A, the YFP reporter mouse and B, the PT-
specific DDAH1 knock-out (PTD1KO) mouse. 
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4.4 The ROSA26eYFP reporter mouse 
ROSA26 is a gene locus on murine chromosome 6 that is widely expressed in 
different cell-types but its function is unknown. It was first identified in mouse 
embryonic stem cells (ECs) in 1991 [188] and has since been used as a locus 
for the insertion of transgenic constructs through homologous recombination 
to generate over a hundred transgenic mouse lines. Advantages of targeting 
ROSA26 over other methods include its reliable success in transgene 
insertion, wide tissue expression under its own promoter and absence of 
detectable downstream effects when in the heterozygote state [189]. 
This particular strain of ROSA26 transgenic mouse contains an 
enhanced yellow fluorescent protein (eYFP) inserted into the locus. 
Constitutive eYFP expression is blocked by an upstream floxed STOP 
sequence that requires excision by active Cre before it can be transcribed. A 
mouse expressing both the ROSA26eYFP and KC transgenes would provide 
a tool for confirming the induction of PTC-specific iCre expression using 
exogenous testosterone. 
A male ROSA26eYFP heterozygous mouse on a mixed B6/129 
background was a kind gift from Professor Graham Williams, Imperial 
College, London. Animal genotyping was performed using two separate 
primer mixes; one for KC, a second for ROSA26eYFP transgene (primer 
sequences are listed in the Appendix). 
4.4.1 Gross phenotype 
4.4.1.1 Breeding 
Mice heterozygous for ROSA26eYFP (mixed B6/129 background) and 
KC (C57BL/6J background) were successively bred to produce offspring that 
were normal in size, behaviour and fertility with litter genotype ratios 
consistent with Mendelian inheritance. First generation female mice 
heterozygous for both KC and ROSA26eYFP were used at 6-10 weeks of 
age. 
88 
4.4.2 Generalised effects of exogenous testosterone 
Administration of a subcutaneous testosterone pellet for a minimum of ten 
days was necessary to induce functional KC expression and subsequent 
floxed gene deletion. Mice treated with testosterone gained more weight and 
displayed more aggressive behaviour to handling than their untreated 
counterparts.  
4.4.3 Kidney-specific induction of KC transcription 
Following testosterone treatment, significant KC mRNA transcription was 
detected in kidney tissue (p=0.02) from mice containing the KC allele but not 
in the absence of testosterone or the KC transgene (Figure 22). KC 
transcription was undetectable in organ tissue apart from the brain, although 
this was statistically insignificant (p=0.06).  
 
Figure 22. Testosterone induction of KC mRNA transcription 
Values are corrected for genomic DNA (gDNA) using a non-reverse transcribed control of the 
same sample. This was necessary to discriminate transcribed KC messenger RNA (mRNA) 
from KC sequences in contaminating genomic DNA. Corrected values obtained in KC- tissue 
represent non-specific or contaminant polymerisation (occurring at Ct values >35). Significant 
KC transcription was observed only in KC+ mouse kidney tissue (1.89 AU; 95%CI -2.1-5.8) 
when compared to other KC+ organs; Two-way ANOVA with Bonferroni’s post test, n=4, 
**p<0.01.  
4.4.4 Kidney-specific induction of YFP protein expression 
YFP has significant amino acid sequence homology with green fluorescent 
protein (GFP) to allow detection using a GFP antibody. Western blot analysis 
revealed YFP in kidney tissue from testosterone treated double transgenic 
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mice and not in other organs or kidney tissue from testosterone naïve mice 
(Figure 23). 
 
 
Figure 23. Western blot analysis of whole organ lysates for YFP expression 
YFP expression is limited to the kidney of KC-ROSA26eYFP transgenic mice treated with 
testosterone (arrows). No expression was detected in other organs or testosterone naïve 
mice. Pure GFP protein was used as a positive control (27kDa). GFP antibody performance 
was variable; non-specific bands a frequent limitation as in (C). Three different antibodies 
were used to confirm findings; A, Abcam (ab6556); B, Clontech; C, Abcam (ab290). 
 
4.4.5 Proximal tubule-specific expression of YFP in kidney sections 
4.4.5.1 Direct fluorescence microscopy  
Fluorescence microscopy was used to identify inducible YFP expression 
within tubular structures, comparing kidney sections taken from testosterone 
treated and untreated double transgenic mice.  
Figure 24. Fluorescence microscopy of KC-ROSA26eYFP kidney tissue 
Autofluorescence of tubular structures obscures any reliable detection of YFP expression in 
proximal tubules.  Sections from both testosterone untreated (A) and treated animals (B) 
appear the same. i, DAPI spectrum; ii, yellow spectrum; iii, merged image. Bars = 200 µm. 
i ii 
iii 
A untreated B testosterone 
treated 
i ii 
iii 
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Immunohistochemistry was not performed in these studies – detection relied 
upon the endogenous fluorescence of YFP. Initial assessments were 
restricted by significant yellow-spectrum autofluoresence within the tubules, 
thus regardless of testosterone treatment and successful transgene 
activation, visual detection of YFP expression was not possible (Figure 24). 
 
4.4.5.2 Fluorescent peak correction 
To remove interfering tubular autofluorescence, the emission spectra from 
multiple user-defined regions across the kidney tissue were scanned using 
Leica LAS Lite Viewer software. Two overlapping emission peaks were 
identified within the filtered yellow spectrum; one at approximately 527 nm 
corresponding to eYFP, the other at 540nm, representing the non-specific 
background autofluorescence detected in initial fluorescence imaging. The 
selectivity of the fluorescent filter limits the precision of observed emission 
spectra, however Leica software allows a more focussed window of emission 
detection to be defined digitally, subtracting unwanted fluorescence (Figure 
25). 
 
Figure 25. Digital subtraction of background auto-fluorescence in KC-ROSA26eYFP 
kidney sections 
A) Two independent, overlapping peaks are identified by emission spectra scanning: one 
representing YFP, the other representing the background auto-fluorescence (dotted plot). The 
shaded box represents the image spectral range. B) With digital subtraction, the observed 
emission spectrum is narrowed to exclude the background peak, allowing YFP to be 
distinguished.   
 
Using this method, YFP fluorescence was confirmed in kidney tissue 
sections from testosterone-treated mice and not in those untreated. 
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Furthermore, the tubular YFP expression was heterogeneous, evident in 
portions morphologically consistent with the proximal tubule and not in other 
tubular segments (Figure 26).  
Figure 26. Digital subtraction for YFP detection in kidney sections  
In each row, the same section images are displayed before and after digital subtraction of the 
background emission peak. In testosterone-treated mouse tissue, (A) YFP is difficult to 
distinguish from background autofluorescence. but after digital subtraction of background (B),  
YFP is distinguished. Kidney tissue from testosterone-naïve mice revealed no detectable YFP 
before (C), or after digital subtraction (D). Bar = 50 µm (x10 magnification). 
4.4.6 Tubule-specific YFP expression in single tubular cells 
To support the findings from microscopic examination of KC-ROSA26eYFP 
renal tissue, a single cell-imaging approach (ImageStream) was used to 
confirm successful induction of the transgene, specific to renal tubular cells. 
Renal tubular fractions were isolated from testosterone treated and untreated 
KC-ROSA26eYFP mice as previously described. Single cell imaging of 
A B 
C D 
92 
tubular cells extracted from testosterone treated mice, revealed a population 
of YFP-expressing cells that was not detectable in tubular fractions extracted 
from untreated mice (Figure 27).  
 
Figure 27. ImageStream single cell analysis of extracted tubular cells from KC-
ROSA26eYFP mice 
A, testosterone untreated. B, testosterone treated. The first gating analysis; R2, sorts cells 
according to spherical shape (discounting asymmetric, non-cellular material). The second 
gating analysis; R4, identifies cells fluorescent in the yellow spectrum. In A (untreated), no R4 
gated-YFP-expressing cells are identified. In B (treated), a population of YFP-expressing cells 
are detected and imaged in (C).  
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4.5 The proximal tubule-specific DDAH1 knock-out mouse 
(PTD1KO) 
In order to control for the effect of testosterone treatment alone, three 
experimental groups were necessary:  
1) No testosterone KAPiCre +  (T-KC+) 
2) Testosterone  KAPiCre -  (T+KC-) 
3) Testosterone  KAPiCre +  (T+KC+; PTD1KO) 
Some results are presented with two groups for clarity (2 and 3); the KC- and 
KC+ groups, where both have been exposed to testosterone. 
4.5.1 Breeding 
Male mice heterozygous for KC on a C57BL/6J background were bred with 
transgenic DDAH1-floxed mice on a mixed strain background (generated 
previously by our own group). In this construct, LoxP sites were inserted to 
flank exon 1 of DDAH1 (encoding the initiating methionine residue and the 
first 100 amino acids of the protein). 
Successive breeding achieved the breeding genotypes required for 
production of experimental animals; all homozygous for the DDAH1-floxed 
transgene (D1) but only one parent being a KC heterozygote, the other not 
possessing the KC transgene. In this way, double transgenic, KC positive 
(KC+) “test” animals were bred alongside single transgenic, KC negative (KC-
) littermate controls. Cohorts of mice for each study derived from the same 
grandparent lineage. 
4.5.2 Gross phenotype 
4.5.2.1 Untreated transgenic mice 
Mice possessing one or both of the KC or D1 transgenes were normal 
in size, behaviour and fertility with litter genotype ratios consistent with 
Mendelian inheritance. 
4.5.2.2 Generalised effects of exogenous testosterone 
For the purposes of physiological and disease model testing, PTD1KO mice 
were exposed to testosterone for longer periods than the ROSA26eYFP 
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reporter mice, which accentuated the effects of testosterone on weight gain 
and aggression previously seen with the reporter mouse (Figure 28). 
 
Figure 28. The effect of testosterone treatment on body weight 
After 21 days, body weight increased significantly more in mice treated with testosterone 
compared to those untreated; T-KC+ vs T+KC- and T+KC+, 6.6 vs 19.1 and 22.2 % (95% CIs 
4.6-8.5, 14.5-23.8 and 18.6-25.8; p<0.05 and p<0.01 respectively). There was no statistical 
difference between T+KC- and T+KC+ mice. One-way ANOVA with Bonferroni’s post test, 
n=6 for each group, *p<0.05 **p<0.01. 
 
After a minimum of 2 weeks of testosterone treatment, ~10% (8 of 81) 
of mice developed utero-vaginal (UV) prolapse necessitating sacrifice, whilst a 
further proportion developed variable degrees of genital hypertrophy that did 
not require intervention (Figure 29). These testosterone treatment effects 
have been reported previously [190] and were unaffected by genotype. 
 
Figure 29. Genital hypertrophy (A) and UV prolapse (B) in female mice treated with 
testosterone. (UV, uterovaginal). 
4.5.3 Kidney-specific induction of KC transcription 
Kidney-specific induction of KC mRNA transcription previously seen in the 
reporter mouse was confirmed in PTD1KO mice, with no expression in other 
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organs. Within whole kidney, testosterone treatment induced KC transcription 
4000-fold (p<0.01) in KC+ mice compared with background signal in KC- 
mice. The transcription of KC in mice naïve to testosterone was detected but 
29-fold less than treated mice (p<0.001) and statistically insignificant when 
compared to KC- controls (Figure 30). 
 
Figure 30. Whole kidney KC mRNA transcription in PTD1KO mice 
Values are corrected for genomic DNA (gDNA) using a non-reverse transcribed control of the 
same sample. This was necessary to discriminate transcribed KC messenger RNA (mRNA) 
from KC sequences in contaminating genomic DNA. Corrected values obtained in KC- tissue 
represent non-specific or contaminant polymerisation (occurring at Ct values >35). KC+ mice 
showed induction of KC transcription in response to testosterone; T-KC+ vs T+KC+, 0.02 vs 
0.63 AU (95% CIs -0.03-0.07 and 0.27-1.0; p<0.01). Testosterone naïve mice (T-KC+) did not 
express significantly more KC mRNA than KC- counterparts; 0.02 vs 0.0002 (95% CI -0.0002-
0.0004). One-way ANOVA with Bonferroni’s post test, n=6 in each group, **p<0.01. 
4.5.4 Kidney-specific induction of DDAH1 deletion 
Examination of kidney tissue from KC+ mice treated with testosterone 
revealed evidence of DDAH1 gene deletion and subsequent reductions of 
mRNA, protein and enzymatic activity. Tissue from KC- mice showed no 
evidence of DDAH1 deletion. 
 
4.5.4.1 Gene 
Following testosterone treatment, qualitative end-point PCR (epPCR) 
analysis of whole kidney tissue confirmed genetic DDAH1 deletion in KC+ 
mice with evidence of deletion to a lesser extent, in the liver and brain (Figure 
31A).  
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Figure 31. Organ-specific DDAH1 gene deletion in testosterone-treated mice 
(A) End-point PCR. Primer sets were designed to identify the presence of KC and floxed 
DDAH1 transgenes, but also recombined sequences, signifying DDAH1 deletion. Only KC+ 
mice exhibited evidence of floxed DDAH1 excision in the kidney and to a lesser extent, the 
liver and brain. (B) RT-qPCR. Reduced DDAH1 mRNA transcription was confined to the 
kidney; KC- vs KC+, 2.57 vs 1.22 AU (95% CIs 1.91-3.23 and 0.36-2.08; p<0.05). 
Comparisons between KC- (white bars) and KC+ (black bars) within in each organ (DDAH1 
expression is organ specific). Mann-Whitney U test, n=6 in each group, *p<0.05. 
 
Quantitative (RT-qPCR) analysis revealed a ~50% reduction of DDAH1 
mRNA transcription in KC+ mice, significant only in kidney tissue (p<0.05) and 
not other organs (Figure 31B).   
 
4.5.4.2 Protein 
Western blot analysis of whole kidney tissue revealed ~80% less DDAH1 
protein in KC+ mice compared to KC- mice (p<0.001; Figure 32A). 
 
4.5.4.3 Enzyme 
DDAH1 enzyme activity measured in whole kidney homogenates was 
reduced by ~70% in KC+ mice compared to KC- mice (p<0.05; Figure 32B).  
 
236bp 
568 bp 
670 bp 
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Figure 32. Kidney DDAH1 protein expression and enzyme activity  
(A) Whole kidney DDAH1 protein expression was significantly reduced in KC+ mice; KC- vs 
KC+, 0.22 vs 0.04 AU (95% CIs 0.17-0.27 and 0.02-0.06; p<0.001). (B) Whole kidney lysate 
incubated with deuterium-labelled ADMA allowed LC-MS/MS measurement of enzymatically 
produced deuterium-labelled citrulline. DDAH1 activity was reduced in KC+ mice; KC- vs 
KC+, 991 vs 286 TIC (95% CIs 432-1550 and 7-565; *p<0.05). (GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; D7 citrulline, 7-deuterated citrulline; TIC, total ion count). Mann-
Whitney U test, n=6 (KC-) and n=8 (KC+), *p<0.05 ***p<0.001. 
4.5.5 Tubular-specific DDAH1 deletion 
Quantification of KC and DDAH1 mRNA transcription in tubular fractions 
isolated from mice treated with testosterone reflected findings from 
examination of whole kidney: significant KC induction (p<0.01) with 
consequent ~75% reduction of DDAH1 mRNA transcription (p<0.05) (Figure 
33). 
 
Figure 33. KC and DDAH1 mRNA transcription in isolated renal tubules 
Tubules were isolated from transgenic mice using magnetic bead separation as described in 
Chapter 10. (A) KC transcription was induced in KC+ mice; KC- vs KC+, 0.01 vs 3.56 AU 
(95% CIs -0.003-0.03 and 0.83-6.29; p<0.01). (B) DDAH1 mRNA transcription was reduced; 
KC- vs KC+, 14.5 vs 3.45 AU (95% CIs 5.1-23.9 and 1.6-5.3; *p<0.05). Mann-Whitney U test, 
n=6 for both groups, *p<0.05 **p<0.01. 
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4.6 Discussion 
 
4.6.1 Successful PT-specific gene-targeting  
In response to testosterone treatment, activation of KAPiCre (KC) resulted in 
PT-specific YFP expression in the reporter mouse and DDAH1 deletion in the 
PTD1KO mouse.  
To investigate the role of DDAH1 activity in the kidney during health 
and disease, this novel transgenic mouse has considerable advantages over 
previously created experimental animals that possess global DDAH1 deletion 
or overexpression. Global DDAH1 KO mice have elevated circulating ADMA 
and systemic BP rendering them impractical in a study aimed at differentiating 
between effects of systemic and local renal perturbations of the NO-ADMA-
DDAH axis. Similarly, genetic overexpression is not tissue-specific and 
includes cells that do not normally express DDAH1 such as macrophages, 
which may well impact upon their responses to inflammation [102]. In addition, 
genetic or viral over-expression of DDAH1 activity to supra-physiological 
levels will not be subject to normal regulatory and adaptive responses, which 
may confound results further. 
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This novel transgenic mouse allows DDAH1 deletion that is not only PT 
cell-specific, but is conditional, thus avoiding adaptive changes that result 
from constitutive gene deletion from an early developmental age. 
4.6.2 Limitations 
Evidence of floxed DDAH1 recombination was detected in brain and liver 
tissue through qualitative PCR analysis, although quantitative RT-qPCR 
analysis demonstrated this to be statistically insignificant. These findings are 
consistent with previous reports from the original developers of the transgenic 
construct which describe KC expression in brain and liver tissue using RNA-
protection assays, however only a negligible proportion of hepatocytes (<1%) 
stained positive in their LacZ reporter mouse [172]. As will be seen, in the 
absence of baseline alterations to BP or circulating ADMA, it is unlikely that 
negligible neuronal or hepatic DDAH1 deletion would impact upon renal 
function or disease progression. 
Ideally, evidence of YFP expression or DDAH1 deletion would be 
demonstrated alongside cell markers that define the PT cell type. 
Immunological counter-staining in kidney sections or FACS analysis was 
attempted using Aquaporin-1 and megalin antibodies although these were 
unsuccessful despite numerous attempts. However, the PT constitutes the 
majority (~65%) of total renal mass [191] and the largest proportion of tubular 
cell mass. Fluorescence microscopy of kidney cortex identified YFP 
expression in a majority of tubules that morphologically represented PT 
segments. Further still, the technique for tubular isolation yields PT cells far in 
excess of 65% purity (see In vitro studies Chapter 10) and ImageStream 
single cell imaging identified YFP expression to suggest that the PT was 
successfully targeted.  
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5 DOWNSTREAM EFFECTS OF PTD1 DELETION 
5.1 Introduction 
Others have previously shown that global genetic DDAH1 deletion results in 
accumulation of ADMA and a subsequent fall in NO activity [105, 119]. In 
PTD1KO mice, it was anticipated that effects on the ADMA-NO axis would be 
confined to the kidney and perhaps, more specifically to the tubular 
compartment. Furthermore, if renal DDAH1 contributes significantly to renal 
tubule NO activity, its deletion would have significant downstream 
physiological effects upon tubular metabolic function and reabsorption (see 
Introduction Chapter 1.7: NO signalling in the kidney). 
5.2 Study design 
Mice used in any one study shared the same grandparent ancestry. In order 
to control for the effect of testosterone treatment and DDAH1 deletion, three 
experimental groups were necessary:  
1) No testosterone KAPiCre +  (T-KC+) 
2) Testosterone  KAPiCre -  (T+KC-) 
3) Testosterone  KAPiCre +  (T+KC+; PTD1KO) 
Some results are presented with two groups for clarity (2 and 3); the KC- and 
KC+ groups, where both have been exposed to testosterone. 
Cohorts of PTD1KO mice and controls were treated with testosterone 
pellets for 10 - 17 days and plasma, urine and kidney tissue was analysed for 
MAs, NOx and biochemical composition. Urinary proteomics provided an 
additional approach to phenotype analysis whilst a separate study measured 
the haemodynamic effects of PTD1 deletion using invasive blood pressure 
monitoring under terminal anaesthesia. 
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5.3 Results 
5.3.1 Methylarginine (MA) and NO content 
5.3.1.1 Isolated tubules 
Comparison of tubular fractions isolated from KC- and KC+ mice 
revealed almost 7-fold higher intracellular ADMA (p<0.05) with PTD1KO and a 
corresponding 2.5-fold reduction in stable end products of NO activity (nitrites 
and nitrates; NOx; p<0.05) (Figure 34).  
 
 
Figure 34. Effect of PTD1KO on tubular MA and NO 
Tubules were isolated from transgenic mice using magnetic bead separation as described in 
Chapter 10. (A) Isolated tubules from PTD1KO mice (KC+) had significantly raised ADMA; 
KC- vs KC+, 14.0 vs 93.52 pM/mg (95% CIs 3.6-24.39 and 10.4-176.7 respectively; p<0.05) 
whilst (B) NOx was lower; 4.55 vs 1.82 µM/mg (95% CIs 1.93-7.17 and 0.38-3.26 
respectively, p<0.05). SDMA is not a substrate for DDAH1 and consistent with this, was 
unaffected by DDAH1 deletion. Mann-Whitney U test, n=6 in each group, *p<0.05. 
 
5.3.1.2 Whole kidney, urine and plasma 
MAs and NOx levels in whole kidney lysates, urine and plasma were not 
significantly altered following PTD1KO (Figure 35). 
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Figure 35. Effect of PTD1KO on systemic MA and NOx  
Examination of whole kidney lysates (A, B), urine (C, D) and plasma (E, F) revealed no 
significant (ns) alteration in MA or NOx concentrations between KC- and KC+ animals. Mann-
Whitney U test, n=6 in each group. 
5.3.2 Kidney NO signalling enzymes 
PTD1KO did not lead to significant compensatory alterations of other NO 
signalling enzymes; DDAH2, AGXT2 and NOS isoforms (Figure 36).  
5.3.3 Urinary profiles 
NO signalling influences renal tubular cell re-absorptive and secretory function 
(Chapter 1.7.2). Tubular dysfunction in humans can be detected in the clinical 
setting with urinary leak of essential metabolites including phosphate, calcium, 
glucose, amino acids, low molecular weight proteins and lactate [192, 193]. 
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The effect of PTD1KO upon these metabolites was assessed. Given the initial 
findings of a direct effect of exogenous testosterone upon urine volume and 
proteinuria, the untreated group (T-KC+) is also represented.  
 
 
Figure 36. NO signalling enzyme mRNA transcription 
Isolated tubular fragments revealed that transcription of other NO signalling pathway 
enzymes was not altered as a consequence of DDAH1 deletion. Comparisons between KC- 
(white bars) and KC+ (black bars) mice. Mann-Whitney U test, n=6 in each group. 
 
5.3.3.1 Volume and proteinuria 
Urinary volumes were elevated in mice treated with testosterone but only to 
statistical significance in PTD1KOs (p<0.05; Figure 37A). Testosterone 
treatment reduced urinary creatinine 2-fold (p<0.01) and increased proteinuria 
4 to 5-fold with no additional effect from DDAH1 deletion (Figure 37 B, C). 
These changes were reflected in calculated urine protein : creatinine ratios 
(Figure 37D). 
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Figure 37. Effect of testosterone and PTD1KO upon urine volume and proteinuria 
Urine was collected over 24 hours in metabolic cages. Comparisons made between T-KC+ 
and other groups. (A) Urine volume T-KC+ vs T+KC- and T+KC+; 37 vs 57 and 64 µL/g/24hrs 
(95% CIs 24-50 vs 42-75 and 49-78); p>0.05 and p<0.05 respectively). Urinary creatinine (B) 
and protein (C) was measured by NHS laboratory biochemical automated analysis and 
verified by LC-MS/MS and Bradford’s assay respectively. UPCR was calculated from these 
results (D). Testosterone treatment increased UPCR with no additional effect of DDAH1 
deletion; T-KC+ vs T+KC- and T+KC+; 0.36 vs 3.1 and 2.83 g/mM (95% CIs 0.21-0.5 vs 1.6-
4.6 and 2.3-3.4; both p<0.001). One-way ANOVA with Bonferroni’s post test. T-KC+ n=7; 
T+KC- n=8; T+KC+ n=20. *p<0.05 **p<0.01 ***p<0.001. 
 
 
5.3.3.2 Urinary electrolytes 
With the exception of sodium in testosterone treated mice, there were no 
significant changes detected in urinary electrolyte concentrations. DDAH1 
deletion tempered this effect rendering it non-significant (Figure 38). 
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Figure 38. Urinary electrolytes following testosterone treatment and PTD1KO  
(A) Only urinary sodium was statistically different (elevated) in testosterone treated mice. 
DDAH1 deletion made this non-significant. T-KC+ vs T+KC- and T+KC+; 34 vs 56 and 49 
mM/mM (95% CIs 26-43 vs 42-70 and 40-52; p<0.05 and >0.05). One-way ANOVA with 
Bonferroni’s post test. T-KC+ n=7; T+KC- n=8; T+KC+ n=20. *p<0.05. 
 
5.3.3.3 Urinary glucose and lactate 
Both urinary glucose and lactate were elevated in PTD1KOs (~50% and 3-fold 
respectively compared with KC- mice) although due to high variability, these 
increments did not reach statistical significance (Figure 39).  
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Figure 39. Urinary glucose and lactate following testosterone treatment and PTC 
DDAH1 deletion 
(A) Increases in urinary glucose and (B), urinary lactate were statistically insignificant. One-
way ANOVA with Bonferroni’s post test. T-KC+ n=7; T+KC- n=8; T+KC+ n=20.  
 
 
5.3.3.4 Urinary amino acids 
Urinary L-arginine was reduced by testosterone treatment alone (3-fold) but 
not in PTD1KOs. Testosterone treatment produced a non-significant rise in 
urinary concentrations of L-citrulline and L-glutamine with no effect of DDAH1 
deletion (Figure 40). 
Figure 40. Urinary amino acids 
(A) Urinary arginine decreased by 
testosterone treatment but increased by 
DDAH1 deletion. T-KC+ vs T+KC-; 0.142 vs 
0.045 AU (95% CIs 0.1-0.183 and 0.028-
0.062); p<0.05. T+KC- vs T+KC+; 0.045 vs 
0.126 (95% CI 0.049-0.204); p<0.05. Urinary 
citrulline (B) and glutamine (C) were not 
significantly altered. One-way ANOVA with 
Bonferroni’s post test. T-KC+ n=7; T+KC- 
n=8; T+KC+ n=20. *p<0.05. 
 
T-K
C+
T+
KC
-
T+
KC
+
0.00
0.05
0.10
0.15
0.20
*
*
U
rin
ar
y 
ar
gi
ni
ne
(A
U
, c
or
re
ct
ed
 fo
r I
S,
 c
re
at
in
in
e)
T-K
C+
T+
KC
-
T+
KC
+
0.0
0.1
0.2
0.3
0.4
0.5
U
rin
ar
y 
gl
ut
am
in
e
(A
U
, c
or
re
ct
ed
 fo
r I
S,
 c
re
at
in
in
e)
ns
T-K
C+
T+
KC
-
T+
KC
+
0.000
0.005
0.010
0.015
0.020
0.025
U
rin
ar
y 
ci
tru
lli
ne
(A
U
, c
or
re
ct
ed
 fo
r I
S,
 c
re
at
in
in
e)
ns
A B 
C 
107 
5.3.4 Urinary proteomics 
Urinary proteomic analysis was performed as part of a collaborative work with 
Drs Pedro Cutillas and Peter Faull in the Proteomics department of the MRC 
Clinical Sciences Centre, London. Mass spectrometry was used to determine 
the effect of PTD1KO upon peptide profiles in urine. Any effect would 
represent altered proximal tubular peptide handling in terms of; failure to 
reabsorb; increased secretion or expulsion into the urinary space. Data 
analysis was performed by Dr Cutillas and Sanjay Khadayate 
(bioinformatician, MRC Clinical Sciences Centre, London). 
A total of 1437 peptide fragments were detected and identified 
according to delta times and mass to charge ratio (m/z). Comparison of 
urinary peptide profiles in KC- and KC+ mice (PTD1KO), revealed a total of 84 
significant differences according to a p value of <0.05. Figure 41 represents 
the top twenty most altered peptide fragment abundances and the genes from 
which they originate, both decreased and increased with PTD1KO expression 
respectively. 
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Figure 41. Heat map of urinary proteomic analysis in PTD1 deletion at baseline 
82 of 1057 peptides screened were significantly altered by DDAH1 deletion. The ten most significantly down- and upregulated peptides are represented. (q 
values represent values of significance adjusted for multiple comparisons). n=4 as represented.
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5.3.5 Haemodynamics 
Invasive terminal BP recording in adult female mice (aged 8-10 weeks) 
revealed reproducible trends for elevated BP with testosterone treatment and 
reduced BP in response to PTC-DDAH1 deletion although neither effect was 
statistically significant (Figure 42). 
 
 
 
Figure 42. Systemic BP and heart rate in response to testosterone treatment and PTC-
specific DDAH1 gene deletion 
Measured by carotid artery cannulation under terminal anaesthesia. A trend for a rise in BP 
with testosterone treatment and a reduced BP in response to PTD1KO was observed but 
neither effect was statistically significant. (A) diastolic BP; (B) systolic BP; (C) mean arterial 
pressure (MAP); (D) heart rate. One-way ANOVA with Bonferroni’s post test, T-KC+ and 
T+KC- n=6, T+KC+ n=8. 
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5.4 Discussion 
 
5.4.1 A novel tool for investigating NO signalling in the PT  
As anticipated, PTD1KO deletion had direct effects upon the ADMA-NO axis 
in tubular cells that were absent systemically. Significantly elevated tubular 
cell ADMA and consequently, reduced NOx concentrations were not reflected 
in whole kidney, urine or plasma, which represents the cell-type specificity of 
PTD1 deletion. Global DDAH1 deletion has been achieved previously, but this 
is the first transgenic mouse with renal PT-specific DDAH1 enzyme deletion, 
thus providing a valuable tool with which to investigate the role of NO 
signalling in PT function.  
To date, investigation of the role of NO signalling in PT function has 
been limited to the use of pharmacological manipulation in microperfusion and 
cell culture experiments. Considerable limitations exist with these approaches. 
The highly variable and often divergent effects of NO manipulation likely 
manifest from doses of NOS inhibitors or NO donors that are non-
physiological to the PT in vivo. Furthermore, both techniques create an 
artificial environment (altering for example; temperature; oxygen tension; pH; 
neurohumoral triggers) in which normal adaptive responses may well be 
compromised if not completely abrogated. 
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5.4.2 A lack of downstream effects? 
Perversely, these same adaptive mechanisms may be in part, have 
contributed to the lack of phenotype witnessed in this series of studies. PT 
function assessed by urinary metabolites remained largely intact, albeit with 
some increase suggested in urinary loss of glucose and lactate (although not 
statistically significant). Increased urinary arginine (but not citrulline or 
glutamine) in PTD1KOs only rescued a lowering effect of testosterone 
treatment, suggesting a build-up of NO substrate rather than inhibited PT 
reabsorption of amino acids. Although a reproducible trend for lowered 
systemic BP in PTD1KOs was observed, this remained statistically 
insignificant across repeated studies. 
 The mice in this study were treated with testosterone for a minimum of 
ten days as indicated by the original developers of the KAPiCre construct 
[186], in order to ensure successful KAPiCre activation. All mice were 
sacrificed for biological phenotyping within a week (between 10-17 days’ 
exogenous testosterone treatment). This time period of treatment was chosen 
in an effort to make an assessment of the direct effects of reduced PT cell 
DDAH1 activity. Longer periods would conceivably introduce confounding 
effects of downstream adaptions and prolonged testosterone exposure 
(discussed further in Chapter 9). 
5.4.3 Urinary proteomics: uromodulin  
Interestingly, urinary uromodulin (UMOD) was reduced >8-fold in the PTD1KO 
mouse. As UMOD is known to be exclusively expressed in epithelial cells of 
the thick ascending limb [194], this effect indicates that functional changes are 
communicated from PT epithelial cells, downstream along the nephron to 
those in the Loop of Henle. What is not clear is whether increased ADMA in 
the tubules of PTD1KO mice is the chief effector molecule, or an alternative 
molecule communicates the effect. The identification of 82 significantly altered 
peptides indicates that PT-specific NO signaling has far-reaching effects upon 
epithelial cells in different segments along the course of the nephron. 
UMOD (or Tamm-Horsfall protein) is of particular interest as it has 
been associated with renal immunomodulation and the progression of CKD 
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[195].  UMOD is the most abundant mammalian urinary protein and despite 
being identified over 25 years ago [196], its function remains uncertain. 
Controversy exists as to whether UMOD is a predominantly, anti- or pro-
inflammatory protein. In vitro and in vivo studies reveal protective effects 
against nephrolithiasis [197] and urinary tract infections by inhibiting crystal 
aggregation, and trapping bacteria [198], cytokines and cellular debris, to 
facilitate their excretion [199]. However, other in vitro experiments 
demonstrate that UMOD can stimulate proinflammatory cytokine release from 
whole blood [200] and facilitate neutrophil migration across epithelial 
monolayers [201].  
The relevance of UMOD and other urinary peptides affected by 
PTD1KO is discussed further, in the final discussion (Chapter 12.6). 
5.4.4 Limitations 
Measurement of urinary total protein does not allow differentiation of 
glomerular (albumin leak) from tubular dysfunction (failure of reabsorption of 
amino acids and low molecular weight proteins). Attempts were made to 
assess failure of tubular reabsorption through measurement of urinary amino 
acids, glucose and lactate [193]. Alternative approaches to assess these 
relative effects could include measurement of both urinary total protein and 
albumin, along with retinol-binding protein [202]. Furthermore, had time 
allowed, an assessment of GFR using inulin clearance would have provided 
further insights into alterations of renal function secondary to PT cell DDAH1 
deletion. 
Many of the effects assessed in this study were reliant upon urinalysis. 
Significant limitations exist with the use of metabolic cages to collect urine. 
Urine drips down the walls of the cage into glass bottles that are cleaned only 
by water-rinsing between experiments. In addition, chow, drinking water 
overflow and faeces are unrestricted from falling into the collection vessels. 
Urine specimen contamination is therefore inevitable, producing highly 
variable results that identify only very large genotype or treatment effects.  
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5.4.5 Direct effects of testosterone 
Due to the limitations in urine collection and analysis described above, it is 
difficult to interpret the effects of testosterone upon urinary volume, creatinine 
and protein. A significant increase in body weight gain was observed in 
testosterone-treated mice suggesting oral intake of food and water was 
increased. Such increased feeding activity could feasibly exacerbate the 
likelihood of urine collection vessel contamination discussed above. 
Testosterone-related polydipsia (thirst) or increased activity would increase 
drinking water drip contamination of urine collections and could alter urinary 
results, although this is not supported by urinary electrolyte concentrations 
that remained the same, irrespective of testosterone exposure - one would 
expect these to be diluted. 
Tubular function (and particularly Na/K ATPase function, upon which 
the PT is highly dependent) is known to be under hormonal control [203]. 
Although the role of kidney androgen-sensitive protein (KAP) is yet to be 
determined, its very existence indicates that PT function is under androgenic 
influence. A recent report identified that transgenic overexpression of KAP 
developed hypertension and increased renal oxidative stress [204], although 
the KAPiCre transgenic construct used in this study does not produce 
functional KAP protein, so is unlikely to produce the same effect. 
Protein in the urine originates from either glomerular leakage or altered 
tubular reabsorption/secretion of low-molecular weight proteins. Without 
quantifying albuminuria (to identify the contribution of glomerular protein 
leakage), it is impossible to say whether the proteinuric effect of testosterone 
(if genuine) is due to increased protein leakage into the ultrafiltrate, or 
dysregulated tubular function. A direct association of testosterone exposure 
and albuminuria has been confirmed in mouse studies using both gender and 
strain comparisons, which was further demonstrated by androgen 
supplementation in female mice [205].  
Testosterone has direct effects upon NO production. Androgens have 
been demonstrated to have divergent effects on NO-independent 
vasodilatation across different vascular beds [206]. Equally confusing is the 
increased CV and renal disease in rodent models, however in human clinical 
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trials, higher androgen levels associate with better CV health [207]. The direct 
effects of oestrogens and fundamental differences between animal models of 
disease and human cohorts confound an understanding of the complex 
relationship between testosterone and NO-related disease. 
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6 SALT-FEEDING IN PTD1KO MICE 
6.1 Introduction 
PTD1KO characterisation studies demonstrated that disruption of proximal 
tubular DDAH1 elevated ADMA and in turn, reduced NO synthesis. Although 
NO signalling is known to regulate tubular sodium reabsorption and TGF [136-
139] no effects upon BP or urinary electrolytes and volume were observed at 
baseline in the PTD1KO mouse. Encouragingly, functional downstream 
effects of DDAH1 deletion were confirmed through proteomic urinalysis 
showing significantly altered peptide profiles. A salt-feeding study was 
undertaken in an attempt to expose other downstream effects of tubular 
DDAH1 abrogation in a physiologically stressed environment using a high salt 
(sodium) load.  
6.2 Study design 
Published rodent salt-loading protocols vary in dose (2-8% sodium in 
chow) and duration from one week and beyond [208]. For practical ease and 
clarity, only two groups; KC- and KC+ mice were treated with testosterone (as 
previously described) and fed low- or high-sodium chow (0.03% or 3.15%) 
with ad libitum access to normal water. Standard chow has a sodium content 
of 0.1% (Harlan Laboratories Teklad Global Diet). The group numbers were 
as follows: 
 KC- KC+ (PTD1KO) 
Low salt 3 5 
High salt 6 8 
 Total 22 
Urine was collected in metabolic cages prior to and following 8 days of 
salt feeding. Invasive blood pressures were recorded under terminal 
anaesthesia and plasma and kidney tissue were harvested as described 
previously. Samples were analysed for evidence of altered NO signalling and 
renal sodium handling. 
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6.3 Results 
6.3.1 MAME and NOS enzymes 
Consistent with findings reported in Chapter 4, PTD1KO mice exhibited 
significantly reduced whole kidney DDAH1 mRNA transcription, protein and 
enzyme activity (Figure 43A-C). High salt feeding increased DDAH1 mRNA 
transcription (>50%; p<0.05) in KC- but not KC+ (PTD1KO) mice (Figure 
43A). DDAH1 upregulation was not seen at the level of protein or enzyme 
activity however. Salt loading produced small increases in DDAH2, AGXT2 
and iNOS transcription, although (with the exception of iNOS in KC- mice 
(~60%; p<0.05)), they did not reach statistical significance and no differences 
were observed between KC- and PTD1KO mice. 
6.3.2 The NO-ADMA axis 
Whole kidney ADMA content was higher in PTD1KO mice (~30%; p<0.01) but 
no additional effect of salt feeding was observed (Figure 44A). Of note, 
previous characterisation studies did not detect higher whole kidney ADMA 
content, it was restricted only to the isolated tubular fractions in which ADMA 
was elevated by ~60% compared with KC- controls. Consistent with 
elevations in DDAH1 and iNOS in KC- animals, both whole kidney and urinary 
NOx increased in response to salt feeding. 
6.3.3 The effect of salt-feeding renal sodium handling  
A high salt diet produced small, statistically insignificant (<5mmHg) increases 
in systemic BP with no differences between KC- and PTD1KO mouse strains 
(Figure 43).  Appropriately in response to salt-loading, fractional excretion of 
sodium (FENa; the clearance of sodium adjusted for GFR) rose significantly 
(~25-fold; p<0.0001), whilst plasma aldosterone fell, which confirmed that 
significantly higher amounts of sodium were being ingested/excreted and 
serum aldosterone levels were appropriately suppressed (>2-fold; p<0.01). No 
additional effect of PTD1KO was observed. In animals fed a high salt diet, 
plasma sodium fell and plasma creatinine rose – only to a significant degree 
in animals with intact DDAH1.  
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Figure 43.  Whole kidney tissue MAME and NOS isoform transcription 
DDAH1 deletion is confirmed in these studies as previously shown. A, In DDAH1 intact (KC-) mice, salt feeding increased DDAH1 mRNA transcription by 
>50% (low vs high salt diet; 3.66 vs 6.47 AU; 95% CIs, 1.11-6.21 and 4.98-7.95 respectively; p<0.05). A high salt feed increased transcription of DDAH2, 
AGXT2 and iNOS but it did not reach statistical significance except iNOS in KC- mice (G; low vs high salt diet; 1.11 vs 1.84 AU; 95% CIs, 0.12-2.1 and 1.4-
2.29 respectively; p<0.05). Two-way ANOVA with Bonferroni’s post test. Low salt KC- n=3, KC+ n=5; high salt KC- n=6, KC+ n=8. *p<0.05 **p<0.01 
**p<0.001.
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Figure 44. Whole kidney and urinary ADMA and NOx content 
A, Whole kidney ADMA is elevated in PTD1KO animals but with no additional effect of salt 
loading. Following a salt loading, KC- mice have significantly elevated kidney tissue (B, low vs 
high salt; 0.18 vs 0.24 mM/mg; 95% CIs, 0.17-0.19 and 0.19-0.3; p<0.05) and urinary NOx (D, 
low vs high salt; 0.37 vs 1.12 mM/mM; 95% CIs, -0.39-1.11 and 0.17-1.49 respectively; 
p<0.05) whereas PTD1KO mice do not. Two-way ANOVA with Bonferroni’s post test. Low salt 
KC- n=3, KC+ n=5; high salt KC- n=6, KC+ n=8. *p<0.05 **p<0.01 **p<0.001. 
6.3.4 Tubular sodium channel expression  
Western blotting analysis of whole kidney lysates taken from salt-fed mice 
was problematic due to poorly functioning antibodies, despite numerous 
attempts to optimise their efficacy. A high-salt diet appeared to inhibit NHE3 
channel expression in all mice but no other significant effects were detected 
(Figure 46). RT-qPCR analysis was also performed to investigate sodium 
channel and Aquaporin 1 effects at the level of transcription. Although good 
replication was achieved with newly designed primers, no further insights 
were gained into diet or genotype effects (data not shown). 
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Figure 45. Systemic BP and renal sodium handling 
A and E, Systemic BP (systolic and diastolic) was marginally elevated in mice fed a high salt diet (<5mmHg; ns). B, Urinary volumes were higher in high salt 
groups although variability rendered this non-significant. F, Fractional sodium excretion was raised in both mouse strains on a high salt diet (KC- low vs high 
salt; 0.28 vs 6.37%; 95%CIs -0.11-0.67 and 4.47-8.28 respectively; p<0.0001. KC+ low vs high salt; 0.24 vs 6.99%;95% CIs 0.18-0.3 and 5.42-8.56; 
p<0.0001). G, Plasma aldosterone was lower in all high salt-fed animals (KC- low vs high salt; 1097 vs 478 pg/mL; 95% CIs -842-3036 and 318-638; p<0.01. 
KC+ low vs high salt; 1350 vs 513 pg/mL; 95% CIs 1105-1596 and 375-652; p<0.0001). Only in KC- mice did plasma sodium fall (D) and creatinine (H) rise 
significantly (plasma sodium low vs high salt; 158 vs 152 mmol/L; 95% CIs 151-166 and 148-156; p<0.05. Plasma creatinine low vs high salt; 23 vs 27.6 µM; 
95% CIs 15.7-30.1 and 24.7-30.4; p<0.05). Two-way ANOVA with Bonferroni’s post test. Low salt KC- n=3, KC+ n=5; high salt KC- n=6, KC+ n=8. *p<0.05 
**p<0.01 **p<0.001. 
Fractional sodium excretion equation:  
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Figure 46. Expression of tubular sodium channel protein in whole kidney 
A, Cartoon illustrating expression patterns of renal tubular sodium channels and Aquaporin 1. B and C, representative Western Blots (WB) of sodium channel 
protein in whole kidney lysates. D, graphical representation of WB data. NHE3, sodium–hydrogen ion exchanger type 3; Na / Pi,  sodium–phosphate 
cotransporter; NKCC, sodium-potassium-2chloride cotransporter; NCC, Na-Cl cotransporter; ENaC, epithelial sodium channel. Two-way ANOVA with 
Bonferroni’s post test. Low salt KC- n=3, KC+ n=5; high salt KC- n=6, KC+ n=8. *p<0.05. 
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6.4 Discussion 
 
 
Salt-loading increased renal DDAH1 mRNA transcription in KC- mice and to a 
lesser extent, DDAH2, AGXT2 and iNOS. Consistent with this, renal and 
urinary NOx was elevated showing that NO activity was upregulated in 
response to salt-feeding. As previously discussed, NO signalling is important 
for renal sodium reabsorption and tubulo-glomerular feedback (TGF) through 
which tubular flow regulates glomerular filtration rate. Tubular upregulation of 
NO with salt-feeding indicates an adaptive natriuretic response to excrete 
excess sodium by inhibiting tubular reabsorption. Salt-feeding in rodents has 
previously been shown to significantly affect kidney NOS enzyme expression 
[209, 210]. Similar to microperfusion studies of NO regulating tubular 
reabsorption, the results are often contradictory. Acutely (within 48 hours), a 
high salt feed can upregulate renal nNOS and iNOS expression although at 3 
weeks, this effect is reversed. The direction of shift in NO activity with salt-
loading appears to be related to time of exposure, salt dose, level of 
associated hypertension and background genotype. 
PTD1KO mice did not respond to salt-feeding by NO signalling enzyme 
upregulation like their KC- counterparts. Despite this, there was an absence of 
downstream phenotypic differences in terms of systemic BP, urinary volumes 
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or FENa. Possible explanations for a reduction in NO activity but little in the 
way of downstream effects include; no genuine difference in MAME or NOS 
gene expression or even NOx (a type I error); or a Type II error resulted and 
true genotype effects were not detected. This uncertainty originates largely 
from variable data from urine analysis (and its limitations – discussed 
previously and below) making detection of small adaptive downstream effects 
unlikely. 
6.4.1 Limitations 
6.4.1.1 Duration of exposure 
Overall, results from the salt-feeding study were disappointing. Effects of the 
high salt diet alone did not reach the degree anticipated which inevitably 
contributed to the lack of significant effects observed with PTD1 deletion. 
Published rodent salt-loading protocols vary in dose (2-8% sodium in chow) 
and duration from one week and beyond [208], however it is possible that in 
these mice, 8 days of 3.15% sodium chow was inadequate to produce 
significant BP or biochemical changes. 
In addition, gender-related effects may have contributed as only female 
mice were used in this study. In human studies at least, females exhibit 
increased salt-sensitivity compared to males when observing BP responses to 
altered dietary salt intake [211]. The administration of exogenous testosterone 
is likely to confound sex-related effects further, potentially reducing the degree 
of effect in this study. 
 
6.4.1.2 Urine collection 
Another important limitation is that of imprecise urine collection already 
discussed in the previous chapter. Urine collected in non-sterile metabolic 
cages is incomplete (evaporation, spilling) and inevitably becomes 
contaminated by the animal’s faeces and feed. This renders attempts at 
precise measurement of urinary electrolytes and volume futile, with a high 
potential for variable results and artefact for example; high sodium 
concentration from high-salt chow contamination or high urinary volumes from 
mice with polydipsia or leaking water bottles.  
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6.4.1.3 Measuring sodium channel function 
Although Western blotting has previously been used with success to 
determine adaptive sodium channel changes in the kidneys of NHE3 and 
NCC deficient mice [212], it is dependent upon effective antibodies and large 
alterations to allow successful detection. Furthermore, the degree of protein 
expression within a tissue lysate does not necessarily represent activity. Many 
post-translational modifications, including phosphorylation, protein kinase 
activation and membrane transmethylation, determine channel protein 
translocation to the apical membrane and sodium transport activity [213]. For 
identifying functional sodium transport effects of PTD1KO, microperfusion 
techniques could provide more reliable functional data that could then be 
supported by well-designed in vitro studies directly measuring channel flux 
(such as patch clamp techniques) [213]. 
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7 MICROPERFUSION EXPERIMENTS 
7.1 Introduction 
Single nephron micropuncture was pioneered in the 1920s by Wearn and 
Richards (University of Pennsylvania) using glass micropipettes to cannulate 
single superficial glomeruli in frogs [214]. They demonstrated for the first time 
that protein-free fluid was filtered from the blood at the glomerulus and 
subsequently, by showing the presence of glucose and sodium chloride in 
blood and glomerular filtrate but not in bladder urine, they confirmed tubular 
reabsorption of these constituents. 
From being restricted to sampling only superficial proximal and distal 
tubule portions, micropuncture techniques developed to access segments 
from the loop of Henle and collecting ducts through the renal papillae. A 
further advancement was microperfusion of a single tubule using oil droplets 
to isolate a segment and perfusing a prepared fluid with sample collection 
downstream [178]. This allows compounds of interest to be administered and 
their direct effects upon tubular reabsorption to be determined (Figure 47).  
 
Figure 47. Schematic aspects of micropuncture techniques 
1 demonstrates the collection of tubule fluid by a micropipette. 2 (perfusion pipettes) and 3 
(collection pipettes) illustrate the means by which tubules may be continuously perfused. 4 
illustrates the method of perfusing peritubule capillaries. These approaches may be used 
concurrently to determine tubular function in a defined artificial setting. (Reproduced from 
[178]). 
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Tubular fluid reabsorption (Jv) is calculated by the difference between 
volume (V) of artificial tubular fluid (ATF) perfusion (perf) and collection (coll) 
rates (nL/min) corrected by the length of tubule perfused (mm). The normal 
range for Jv in a rat is 2.5 – 3.0 nL/min/mm. 
 !" ! !! !"#$ ! ! !"## !! !"!!"#$%! 
 
To ensure an adequate proportion of ATF is recollected, non-
reabsorbed C14 inulin is perfused and >85% retrieval distally is deemed 
adequate.  
Professors Chris Wilcox and William Welch at Georgetown University 
(Washington, USA) run a laboratory that performs renal tubule micropuncture 
techniques for investigating mechanisms of tubuloglomerular feedback and 
control of systemic blood pressure. Previously, in Sprague-Dawley rats, they 
demonstrated inhibited tubular reabsorption using ADMA administration and 
DDAH1 gene silencing (unpublished). To develop these interesting findings 
further, a collaborative investigation was set up to test the role of renal 
DDAH1 in proximal tubular sodium and fluid reabsorption.  
Research assistant Miss Tracy Bell performed all of the microperfusion 
studies described here. The author visited the Georgetown laboratory to 
observe the technique and assist in the design of experiments using the 
specific DDAH1 inhibitor, L257 and transgenic PTD1KO mice; both developed 
and supplied by our group. 
7.2 Effect of ADMA upon tubular reabsorption 
This particular experiment was performed by members of Professor Wilcox’s 
group, with no input from the author of this thesis. They are presented here for 
means of introducing the subsequent studies using L257 and the PTD1KO 
mouse, to which the author did contribute as described above. 
Microperfusion with ADMA revealed dose-dependant inhibition of 
tubular fluid reabsorption (>30% at 10-4 M; Figure 48A). Synthetic NOS 
inhibitor, L-NG-nitro arginine methyl ester (L-NAME) was effective at lower 
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concentrations (10-6 M) but produced a similar maximal inhibition of reduction 
in Jv at higher concentrations (10-4 – 5). 
In a separate series of experiments, systemic administration of DDAH1 
silencing RNA (siRNA) reduced renal DDAH1 protein expression by ~50% 
and inhibited Jv by ~30% (Figure 48B). 
 
Figure 48. Effect of ADMA microperfusion and DDAH1 gene silencing upon tubular 
reabsorption 
(A) ADMA (10-4 M) or L-NAME (10-4 M) into the PT both reduced Jv significantly to 2.0±0.2 
and 1.8±0.2 nl/min/mm, respectively (p<0.05).  (B) siRNA was complexed with a polymer 
from TransIT in vivo gene delivery system. Rats received 100 µg of siRNA (or equivalent 
vehicle) in 6 mL of PBS via the left jugular vein as a 7-second bolus injection to mimic the 
protocol of “hydrodynamic stress” and 72 hours after IV injections micropuncture experiments 
were performed. Two-way ANOVA with Bonferroni’s post test. n=5. *p<0.05. 
7.3 The effect of pharmacological DDAH1 inhibition upon tubular 
reabsorption 
Novel selective inhibitors of DDAH were developed at UCL (London) [215]. 
NG‐(2‐methoxyethyl)‐l‐arginine (L257) and NG‐(2‐methoxyethyl)‐l‐arginine 
methylester (L291) are arginine derivatives unlike other potential DDAH 
inhibitors, as they do not exhibit interaction with the NOS or arginase 
enzymes. Both L257 and L291 inhibit DDAH activity in vitro with an IC50 
value of 20 µM (Figure 49), causing significant elevations in circulating ADMA 
levels when administered intravenously into rodents, and increase vascular 
tension when used in organ bath studies using mesenteric resistance vessels 
[105]. Successful DDAH inhibition is detected both in vivo and in vitro by 
raised ADMA levels, reduced NO, and their respective downstream functional 
effects. Additionally, in vitro DDAH activity assays can be performed in which 
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reduced L-citrulline production (from reduced ADMA metabolism) is observed. 
Because L257 and L291 inhibit DDAH through active site binding, the 
presence or expression of DDAH protein is unchanged. 
Figure 49. Pharmacological DDAH1 inhibition using L257 and L291 in vitro 
DDAH activity was measured in rat kidney lysates in the presence of L-291 (black squares) 
and L-257 (black triangles) at the concentrations indicated. n=3. Reproduced from [105]. 
 
A pilot experiment was performed by perfusing L257 into superficial PT 
segments (anatomically most likely to represent S1 and S2 segments [216]) 
for 5-10mins at 20 nL/min, but this had no effect upon Jv (Figure 50). A 
working concentration of 100µM was used - derived from previously published 
studies (discussed and referenced above) wherein circulating ADMA was 
increased whilst systemic BP was unaffected in rodents. The maximum time 
period that the PT can reliably be perfused is approximately 20 minutes. This 
may be inadequate time for; tubular cells to absorb the compound; L257 to 
transit and bind to DDAH1; intracellular ADMA to accumulate causing 
competitive inhibition at the active site of NOS and block NO synthesis to 
eventually influence tubular fluid reabsorption. 
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Figure 50. Tubular reabsorption (Jv) in response to L257 administration 
Short-term perfusion of L257 in the proximal tubule did not affect Jv; vehicle vs L257; 3.37 (± 
0.2) vs 3.35 (± 0.6) nl/min/mm. The addition of an intravenous bolus of L257 2 hours prior to 
micropuncture significantly reduced Jv to 2.3 (±0.2) nl/min/mm compared with vehicle 
(p<0.01) and PT-L257 alone (p<0.05). One-way ANOVA with Bonferonni’s post test. n=5. 
 
 Subsequently, an intravenous bolus injection of L257 (60 mg/kg) was 
administered 2 hours prior to micropuncture, which reduced Jv by ~30% 
(Figure 50). In addition, plasma and urine ADMA levels were elevated (45% 
and 10-fold respectively) with no significant change in L-NMMA or SDMA 
levels (Figures 51A and B). Concentrations were highly variable in ATF and 
although no significant differences were seen, a similar trend of increased 
ADMA was demonstrated (Figure 51C).  
Figure 51. Plasma, urinary and tubular fluid MA content 
Comparisons between PBS vehicle (white bars) and L257 (black bars) treated groups. (A) 
Plasma ADMA was increased following L257 treatment. Vehicle vs L257, 0.46 vs 0.67 µM 
(95% CIs 0.38-0.55 and 0.6-0.75; p<0.001). (B) Urine ADMA was also elevated following 
L257; vehicle vs L257, 1.06 vs 10.2 (95% CIs 1.01-1.1 and 4.4-16; p<0.01). (C) No significant 
changes were found in the MA content of ATF. Mann Whitney U test. n=5. **p<0.01 
***p<0.001. 
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In the preceding PTD1KO mouse characterisation studies, urinary 
amino acid and peptide profiles were influenced by PTD1 deletion. Urinary 
amino acid contents were measured in this study to determine the effect of 
L257 treatment on tubular handling of amino acids. Significant elevations of 
amino acids occurred in L257-treated rats; glutamine (4-fold; p<0.01), arginine 
(2-fold; p<0.05) although citrulline did not change. (Figure 52). 
 
 
Figure 52. Plasma, urinary and tubular fluid amino acid profiles  
(A) Plasma citrulline was significantly elevated (vehicle vs L257, 20.4 vs 29.2 µM; 95% CIs 
16.8-23.9 and 26-32.3; p<0.001) and glutamine was not while arginine LCMSMS identification 
in these samples did not work despite repeated efforts. (B) Urinary glutamine and arginine 
acids significantly increased with L257 treatment (vehicle vs L257); glutamine, 0.64 vs 2.68 
µM/mM creatinine (95% CIs 0.36-0.91 and 1.83-3.52; p<0.01); arginine, 0.17 vs 0.36 µM 
(95% CIs 0.04-0.29 and 0.21-0.5; p<0.05). (C) No significant changes were found in the 
amino acid content of ATF. Mann Whitney U test. n=5. *p<0.05 **p<0.01 ***p<0.001. 
 
 
By blocking DDAH1 activity with L257, ADMA accumulated and one 
would anticipate a reduction of NO activity. Renal tissue was not stored from 
these experiments, however urinary NOx was measured and found to be 
~45% lower in L257-treated animals although this did not quite reach 
statistical significance (p=0.07; Figure 53A). 
Of note, urinary creatinine increased >2-fold which again, did not quite 
reach statistical significance, however no difference in plasma creatinine was 
observed between vehicle and L257 treatment suggesting that tubular 
secretion of creatinine was enhanced (p=0.09; Figure 53B). 
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Figure 53. Urinary NOx and creatinine 
(A) Urinary NOx was reduced in L257-treated animals. Vehicle vs L257, 0.57 vs 0.32 mM 
(95% CIs 0.26-0.87 and 0.12-0.52; p=0.07). (B) Urinary creatinine was increased following 
L257 treatment. Vehicle vs L257, 30.4 vs 69.9 mM (95% CIs 24.4-36.5 and 20.6-119; 
p=0.09). Plasma NOx and creatinine were no different between treatments suggesting that 
these differences were specific to renal tubular function rather than transfer of corresponding 
concentrations from plasma to ultrafiltrate. Mann Whitney U test. n=5. 
7.4 The effect of PTD1KO upon tubular reabsorption 
Transgenic PTD1KO mice were bred as previously discussed and exported to 
Georgetown University for this series of micropuncture studies. As before, PT-
specific DDAH1 deletion was activated using testosterone pellets (22 mg) with 
90-day release, implanted subcutaneously into the mid-scapular region. After 
a minimum of 10 days’ testosterone treatment the mice were placed into a 
metabolic cages for 24hr urine collection. Microperfusion/recollection 
experiments were performed between days 11 and 17 post testosterone 
treatment. 
 
Figure 54. The effect of PTD1KO upon Jv, urine output and sodium excretion 
(A) No effect of PTD1KO was observed upon Jv; KC- vs KC+, 1.7 (± 0.21) vs 2.0 (± 0.15) 
nl/min/mm. (B) 24 hr urine output did not differ between groups; 1.1 (± 0.14) vs 1.2 (± 0.13) 
mL/24hrs and similarly, (C) sodium excretion was unchanged; 0.19 (± 0.03) vs 0.17 (± 0.02) 
mmol/day. Mann Whitney U test. n=6. 
 
PT-specific DDAH1 knockdown did not affect fluid reabsorption. 
Similarly, 24-hour urine output and urinary sodium excretion did not differ 
between groups (Figure 54).  
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7.5 Discussion 
 
 
Microperfusion techniques record real-time effects of local (tubular) and 
systemic pharmacological intervention in vivo and thus provide functional 
insights that cannot be gained using in vitro or ex vivo approaches. Tubular 
fluid reabsorption (Jv) was reduced by tubular perfusion of ADMA and 
systemic pharmacological and genetic DDAH1 inhibition. The effects of NO 
upon tubular reabsorption have been studied previously using microperfusion 
techniques and appear to show a bimodal effect dependent upon dose (see 
Introduction Chapter 1.7.2: Functional roles of NO in the kidney). 
7.5.1 DDAH1 activity regulates tubular sodium handling 
These data provide the first evidence that DDAH1 activity and ADMA 
play a regulatory role over tubular function and in these studies, ADMA 
inhibits fluid reabsorption, indicating that NO is stimulatory. Given that 
functional polymorphisms of DDAH1 are known to exist in the general 
population [116, 154, 217], renal sodium handling may well be influenced by 
DDAH1 genotype. Indeed, this is consistent with recent data from the GenSalt 
study; an ambitious study involving 7-day feeding of consecutive low sodium; 
high sodium and high potassium diets to over 3000 Chinese Han recruits with 
measurement of systemic BP responses and analysis of genotyping data 
[218]. A DDAH1 variant (rs11161637) was associated with reduced BP salt 
sensitivity, in that individuals homozygous for this genotype did not display the 
same drop in systolic BP on the low sodium diet than those with a different 
DDAH1 variant [219]. This confirms that DDAH1 genotypes can influence salt 
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sensitivity and therefore systemic BP. What this study does not provide is 
data on corresponding circulating ADMA, which would shed light as to 
whether this effect manifests from changes in the vasculature or discrete 
organ beds, such as the kidney. 
7.5.2 Limitations 
Although microperfusion allows assessment of tubular function in vivo, the 
perfusate is artificial (ATF; artificial tubular fluid) and therefore its composition 
inevitably differs from that of ultrafiltrate. If the fluid temperature, flow, pH or 
tonicity is significantly different, this may have profound effects upon tubular 
function – more so if circulating small proteins and hormones are considered.  
 
7.5.2.1 Tubular concentrations of NO and MAs 
What these studies do not allow is the determination of NO or methylarginine 
concentrations within the tubular lumen as collections are of ATF, not free 
flow ultrafiltrate. NO concentrations within tubular fluid have been measured 
real-time in rats and remain in the region of 110 nM along the length of the 
nephron [220]. 
No studies to date have reported measurement of methylarginines in 
tubular fluid. In the L257 study, ADMA concentrations in ATF were in the 
region of 10 nM and assuming no contamination had occurred, this can only 
have existed as a result of tubular secretion of ADMA into luminal fluid. 
Therefore, considering normal plasma concentrations, the approximate 
concentration range of ADMA in tubular fluid lies between 10 and 250 nM.  
Another factor, which may alter this proposed range further, is that of 
DDAH1 activity. In order to clarify this, tubular free flow collections would be 
necessary from mice treated with systemic L257; deficient in the DDAH1 gene 
globally and finally the PTD1KOs. Only when true tubular ADMA 
concentrations are known, can conclusions be drawn on the effects of 
physiological shifts in NO and ADMA upon tubular function. 
Results from microperfusion studies in the PTD1KO mouse failed to 
demonstrate an effect of genotype upon sodium and fluid reabsorption. This 
may represent the importance DDAH1 activity within renal cell types other 
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than PT cells and their influence over tubular reabsorption. In addition, the 
presence of high L257 tubular concentrations alone may overwhelm tubular 
CAT transporter and hence, reabsorptive capacity. Direct measurement of 
ADMA within the ATF collected in these experiments would be helpful to 
compare against those from ADMA treatment plus free-flow collections from 
untreated mice. 
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8 MODELS OF RENAL DISEASE: CHARACTERISATION OF 
FOLATE NEPHROPATHY 
8.1 Introduction 
8.1.1 Mouse models of CKD 
A variety of mouse disease models have been developed to mimic acute 
(AKI) and chronic (CKD) human kidney disease. Experimental approaches to 
invoke a renal injury fall into three broad categories: surgical, nephrotoxic and 
transgenic (Table 12). Whilst the specific mechanism of injury is perhaps 
more relevant for modelling human AKI, CKD models require simply that the 
final common pathway of progressive renal fibrosis is reliably established. 
With this in mind, the most relevant primary end-point for a model of CKD is 
histological assessment of tubulointersititial fibrosis over more than one time-
point. Important collateral end-points include histological evidence of 
macrophage recruitment, capillary rarefaction with activation of profibrotic 
molecules (eg, TGF! and "SMA), elevations in plasma urea and creatinine, 
proteinuria and ideally, systemic BP. 
Significant limitations exist with the use of mouse CKD models, both on 
practical terms and in reference to their application to human disease. For 
example, many mouse strains (particularly C57BL6) are resistant to modes of 
renal injury that otherwise function very well in other species such as the rat. 
Examples include streptozotocin-induced diabetic nephropathy and 5/6 
nephrectomy [221]. In addition, many common models of CKD involve 
recovery surgery, requiring appropriate resource and a degree of surgical 
expertise to ensure reproducible results.  
CKD in humans is often multifactorial and progresses over decades; 
features that are impractical to reproduce in an experimental setting. In 
addition, biological differences between mice and humans impact upon the 
natural history of CV and renal disease progression. As an example, wild-type 
mice have much higher levels of protective high-density lipoprotein (HDL),  
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Model Benefits Limitations 
   
Surgical Definitive nephron reduction / renal injury Requires expertise and facilities 
   
UUO Reproducible histological fibrosis reported in most 
strains 
Rapid progression not reflective of human disease 
Normal contralateral kidney compensates 
UNx Relative ease of surgery Often requires second injury (salt or protein-loading) 
Variable fibrotic outcomes 
5/6 nephrectomy Well-characterised historically (esp. role of RAS in 
fibrosis) 
Requires recovery surgery 
Disease severity varies between strains 
Small amount of kidney tissue to analyse 
Ischaemia-reperfusion Mimics a common human renal injury Requires recovery surgery 
Variable fibrotic outcomes 
   
Nephrotoxic Surgery not required, two kidneys to analyse 
 
Less well established and characterised than the surgical models 
   
Adriamycin  Proteinuric model Reported success in Balb/c strain, some resistance in other strains 
Nephrotoxic nephritis Mimics a specific human disease  
Well established in rabbits/rats, less so in mice 
Highly variable disease severity, antiserum not commercially available 
Technically difficult tail vein injection required 
Streptozotocin 
diabetic model 
Hyperglycaemia is predictable 
 
Renal fibrosis modest and variable 
Strain dependent (eg. CD1 and eNOS -/- susceptible) 
Folic acid; adenine; 
aristocholic acid; 
cisplatin 
Ease of administration; IP 
 
Specific nephrotoxicity less applicable to common causes of human 
renal injury 
   
Transgenic Eg. Col4!3 deletion; autosomal polycystic disease 
mutation; lupus-nephritis prone 
Lifelong exposure may provoke adaption in alternative pathways 
Interpretation is disease-specific 
Costly technology 
Often requires second injury 
Table 12. Mouse models of renal injury 
UUO, unilateral ureteric obstruction; UNx, uninephrectomy; RAS, renin-angiotensin system; 5/6 nephrectomy, fraction of renal mass removed – unilateral 
nephrectomy with two-thirds of the contralateral kidney removed; IP, intra-peritoneal; Col4!3, collagen-IV subunit. (Adapted from text [221]).
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which may in part explain the resistance to atherosclerosis frequently reported 
in mice [222]. 
8.1.2 Folate 
Folate (folic acid or pteroylglutamic acid) is an essential cofactor required for 
the synthesis of pyridines and pyrimidines to create DNA. Freely filtered at the 
glomerulus, folate is actively reabsorbed in the proximal tubule by specialised 
transport proteins (!-folate receptor proteins, !-FRs) [223]. Supplementary 
oral folate is routinely prescribed for patients with ESRD on haemodialysis, 
malnourished patients, and pregnant women. 
Administration of intraperitoneal (IP) folate is a well-established 
experimental technique to model renal injury (See Methods Chapter 3.5.8.1) 
[173, 175, 224]. When folate is administered in supra-therapeutic doses (180-
240µg/g; ~15,000-fold higher than the 5mg daily prescribed dose in 
haemodialysis patients), folate crystals precipitate within renal tubule lumina 
and induce dose-dependent nephrotoxicity.  Widespread acute tubular 
necrosis ensues within 48 hours with a concomitant rise in serum creatinine 
and BUN to mimic AKI. A period of epithelial regeneration follows, and from 2 
weeks following injury, the kidneys exhibit progressive fibrosis and loss of 
function. Folate injury thus provides a reproducible model with which to 
examine the natural history of inflammation from initiating acute tubular injury 
through to slowly progressive fibrosis characteristic of chronic kidney disease. 
Prior to adopting folate nephropathy as the model for both AKI 
(DDAH2) and CKD (PTD1KO) studies, it was necessary to characterise the 
course of folate-induced renal disease and assess the quality of data that 
could be gained using a variety of analysis techniques. 
8.2 Study design 
Forty, 10-week old female WT C57BL6 littermate mice were purchased from 
Charles River Ltd (Kent, UK) and randomly assigned to receiving a single IP 
injection of either vehicle (0.3M NaHCO3) or folate (240µg/g, dissolved in 
0.3M NaHCO3). Mice were sacrificed at 2 days, 2 weeks and 12 weeks. A 
detailed description of tissue harvesting can be found in the Methods chapter. 
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Group sizes were between 5-8 (no premature deaths were experienced in this 
study). 
8.3 Results 
8.3.1 Kidney : body weight ratio and appearance 
The kidney : body weight ratio changed appreciably over the course of the 
disease: initially increasing by 30% at day 2 (<0.0001) with a pale, swollen 
appearance (Figure 55A), followed by a return to baseline weight at 2 weeks 
(Figure 55B). At 12 weeks following folate injection, the kidneys had shrunk to 
30% less than vehicle-treated controls with a pale, shrivelled appearance 
(Figure 55C). 
 
Figure 55. Kidney : body weight and appearance in folate nephropathy 
Photographs of harvested kidneys (left-sided) following vehicle vs folate administration at (A) 
2 days; 6.2 vs 8.4 mg/g (95% CIs 5.3-7.2 and 7.7-9.1); p<0.0001. (B) 2 weeks; both 6.2 mg/g. 
(C) 12 weeks; 6 vs 4.1 mg/g (95% CIs 5.6-6.4 and 3.7-4.4); p<0.0001. Three kidneys imaged 
to represent; vehicle-treated n=5; folate-treated n=8. (D) Graphical representation of kidney : 
body weight ratios (milligrams per gram, mg/g). Two-way ANOVA with Bonferroni’s post test.  
n=5 (vehicle), n=8 (folate) ***p<0.0001. 
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8.3.2 Serum and urinalysis 
At 2 days following folate administration, serum creatinine rose significantly 
(16-fold; p<0.001) over vehicle-treated animals, falling to 3-fold higher at 2 
weeks (p<0.05) and remained 2-fold higher than controls at 12 weeks 
(p<0.05) (Figure 56). 
Figure 56. Serum creatinine (A), urine output (B) and proteinuria (C) in folate 
nephropathy 
Serum creatinine was quantified by LC-MS/MS. (A) Serum creatinine (vehicle vs folate) at 2 
days; 17 vs 276 µM (95% CIs 11-24 and 249-302); p<0.001. 2 weeks; 24 vs 65 µM (16-31 
and 43-87); p<0.05. 12 weeks; 19 vs 34 µM (15-24 and 20-47); p<0.05. (B) Urine output was 
elevated at 2 weeks; 1.8 vs 9.9 mL/g/hr (1.2-2.5 and 6.5-13.3); p<0.001. (C) Proteinuria was 
raised at 2 weeks and fell by 12 weeks (not statistically significant between treatment groups). 
Two-way ANOVA with Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05 ***p<0.001. 
 
For humane reasons, housing mice in metabolic cages was avoided 
during the period of acute inflammation hence urinary data at 2 days are not 
available. Mice treated with folate displayed significant polyuria at 2 weeks (5-
fold; p<0.001), which reduced to a level marginally above vehicle-treated 
controls at 12 weeks (non-significant). Proteinuria, reported as urinary protein-
creatinine ratio did not significantly change at either time point.  
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8.3.3 Acute inflammatory cytokines 
Pro-inflammatory and pro-fibrotic cytokine mRNA transcription was up-
regulated in whole kidney lysates with specific patterns over the three time-
points (Figure 57). The most acute responses were exhibited by ET-1 and IL6, 
with transcription peaks at 2 days (5-fold and 25-fold respectively; p<0.001) 
before falling towards baseline at 2 and 12 weeks. TNF! mRNA transcription 
was delayed in comparison, with no change at 2 days and a 7-fold peak at 2 
weeks (p<0.001) with a reduced but significant elevation persisting at 12 
weeks (p<0.01). Housekeeper Pol2a transcription did not significantly change 
at any time point.   
8.3.4 Pro-fibrotic cytokines 
Pro-fibrotic cytokines; TGF" and Col1 2! were up-regulated acutely at 2 days 
but peaked at 2 weeks (3- and 12-fold respectively) and mRNA transcription 
remained significantly elevated at 12 weeks (Figure 57D-E). 
 
8.3.5 MAME expression, MAs and NO activity 
Kidney tissue mRNA transcription of DDAH2 and AGXT2 was altered during 
the course of folate-induced kidney disease (Figure 58). DDAH1 transcription 
was reduced at 2 and 12 weeks although this was not statistically significant. 
DDAH2 transcription did not change until 2 weeks with ~3-fold upregulation 
(p<0.001), persisting at 12 weeks (p<0.01). AGXT2 transcription fell 37-fold at 
2 days following folate in comparison to vehicle treatment (p<0.001), 
recovering to baseline by 12 weeks.  
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Figure 57. Whole kidney tissue mRNA transcription of pro-inflammatory (A-C) and pro-
fibrotic (D, E) cytokines in folate nephropathy 
mRNA transcription measured by RT-qPCR. Vehicle vs folate: (A) ET-1 (endothelin-1); 2 
days 0.5 vs 4.6 AU (95% CIs -0.09-1.1 and 3.3-5.9); p<0.001. 2 weeks 0.4 vs 2 AU (0.3-0.5 
and 0.8-3.2); p<0.05. 12 weeks 0.4 vs 0.9 AU (0.3-0.5 and 0.7-1.1); p<0.001; (B) IL6 
(interleukin-6); 2 days 0.8 vs 20 AU (-0.7-2.4 and 8.9-31.8); p<0.001. 2 weeks 0.4 vs 3.2 AU 
(-0.02-08 and 1.6-4.8); p<0.01. 12 weeks 0.2 vs 3.2 AU (0.1-0.4 and -1.8-8.2); p>0.05. (C) 
TNF! (tumour necrosis factor-!); 2 weeks 0.3 vs 2.1 AU (0.1-0.4 and 1.3-2.9); p<0.001. 12 
weeks 0.7 vs 1.6 AU (0.4-0.9 and 0.9-2.3); p<0.01. (D) TGF" (transforming growth factor-"); 2 
weeks 0.7 vs 2.2 AU (0.5-0.9 and 1.4-3.0); p<0.01. 12 weeks 0.4 vs 0.8 AU (0.3-0.6 and 0.6-
1.0); p<0.05. (E) Col12! (Collagen1 subunit 2!); 2 days 0.4 vs 1.2 AU (-0.3-1.1 and 0.7-1.6); 
p<0.05. 2 weeks 0.2 vs 2.4 AU (0.1-0.2 and 1.1-3.7); p<0.01. 12 weeks 0.1 vs 0.6 AU (0.08-
0.1 and 0.3-0.9); p<0.01. (F) Housekeeper Pol2a transcription did not change. Two-way 
ANOVA with Bonferroni’s post test. n=5 (vehicle), n=8 (folate).  *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 58. Whole kidney tissue MAME transcription in folate nephropathy 
mRNA transcription measured by RT-qPCR. (A) DDAH1 transcription did not change 
significantly although there was a trend towards downregulation at 2 and 12 weeks following 
folate. (B) DDAH2, 2 weeks 0.3 vs 0.8 AU (95% CIs 0.2-0.4 and 0.5-1.2); p<0.001. 12 weeks 
0.3 vs 0.6 AU (0.2-0.3 and 0.4-0.7); p<0.01. (C) AGXT2, 2 days 14.6 vs 0.4 AU (4.8-24.3 and 
0.3-0.5); p<0.001. 2 weeks 14.7 vs 6.7 AU (10.6-18.7 and 1.4-12.0); p<0.05. 12 weeks, non-
significant. Two-way ANOVA with Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05 
**p<0.01 ***p<0.001. 
 
In response to folate renal injury, methylarginine concentrations in 
plasma, urine and whole kidney tissue changed over time (Figure 59). At 2 
days, plasma L-NMMA and SDMA rose significantly in response to folate 
administration (8- and 4-fold respectively; p<0.001) and quickly fell towards 
baseline at 2 and 12 weeks. ADMA plasma concentrations did not alter at 2 
days and although trended towards a rise at 2 and 12 weeks, did not increase 
significantly. 
In urine, L-NMMA was elevated 2.5-fold (p<0.05) in folate-treated mice 
compared to vehicle controls but normalised at 12 weeks. Both urinary ADMA 
and SDMA were reduced in response to folate at 2 and 12 weeks (p<0.05). 
Whole kidney content of all MAs increased by 1.5 to 2-fold at 2 days 
and 2 weeks (p<0.05-0.001) and fell towards baseline at 12 weeks, at which 
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point the only MA being significantly elevated was ADMA (approximately 25%; 
p<0.05). 
 
 
 
 
Figure 59. Methylarginine (MA) content in plasma, urine and whole kidney in folate 
nephropathy 
MAs measured by LC/MSMS. (A) Plasma L-NMMA and (C) SDMA were elevated at 2 days. 
L-NMMA (vehicle vs folate), 418 vs 3356 AU (95% CIs 72-764 and 2566-4145); p<0.001. 
SDMA, 4551 vs 18290 AU (1925-22753 and 13310-23270); p<0.001. (D) Urinary L-NMMA at 
2 weeks, 209 vs 488 AU (138-280 and 266-710); p<0.05. (E) Urinary ADMA at 2 weeks, 
80415 vs 53466 AU (61529-99301 and 42868-64065); p<0.01. (F) Urinary SDMA at 2 weeks, 
36500 vs 23530 AU (26990-46010 and 16860-30199); p<0.05, similar effect remained at 12 
weeks. (G) Kidney L-NMMA was elevated at 2 days 690 vs 1707 (392-988 and 1371-2043); 
p<0.001 and fell to non-significantly elevated levels at 2 and 12 weeks. (H) Kidney ADMA was 
elevated at every time-point with a peak at 2 weeks, 5978 vs 11258 AU (3856-8100 and 
9837-12679); p<0.001. (I) Kidney SDMA was most elevated at 2 days, 321 vs 557 AU (200-
442 and 323-791); p<0.05 and fell to control levels by 12 weeks.  Two-way ANOVA with 
Bonferroni’s post test. n=5 (vehicle), n=8 (folate).  *p<0.05, **p<0.01, ***p<0.001. 
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Figure 60. NO activity in whole kidney and urine in folate nephropathy 
NOx (nitrates and nitrites; stable end-products of NO activity) were measured by ozone 
chemiluminescence. (A) Kidney tissue NOx was unchanged at 2 days but rose significantly at 
2 weeks, 0.006 vs 0.02 AU (0.0006-0.01 and 0.009-0.03); p<0.05. (B) Urinary NOx initially fell 
at 2 weeks but was increased at 12 weeks; 2 weeks 515 vs 204 AU (416-615 and 134-273); 
p<0.001.12 weeks 282 vs 800 AU (241-323 and 387-1213); p<0.05. Two-way ANOVA with 
Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05, **p<0.01, ***p<0.001. 
 
8.3.6 Histological features 
Severe tubulointerstitial disease was evident in kidney sections from folate-
treated mice (Figure 61). At 2 days; tubular dilatation and epithelial flattening, 
luminal casts; tubular atrophy. At 2 weeks; interstitial inflammatory cell 
infiltrates and 12 weeks; tubular atrophy and areas of extra-cellular matrix 
deposition. Vehicle-treated mice displayed normal histological appearances at 
all time points. 
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Figure 61. Representative histological features of folate nephropathy  
A, C and E: vehicle controls displayed normal histological appearances; dense with tubules, 
their lumina barely visible.  B, D and F: folate-treated mice at 2 days, 2 and 12 weeks 
respectively. Gross and diffuse tubular dilatation (td) with some luminal casts (lc) was visible 
at 2 days (B). Some resolution of tubular dilatation was apparent at 2 weeks (D), but with 
added presence of interstitial inflammatory cells (inc) (darker nuclei). By 12 weeks (F), some 
earlier features remained but with marked expansion of extra-cellular matrix (ecm), tubular 
atrophy and some glomerulosclerosis seen lower left quadrant. Representative of n=5 (PBS 
vehicle) and n=8 (folate). PAS stain, x20 magnification. Bars = 50 µm.  
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8.3.7 Renal fibrosis (collagen deposition) 
Collagen deposition quantified by picrosirius red immunostaining was 
significantly elevated in animals treated with folate at 2 and 12 weeks (vehicle 
vs folate: 2 weeks, 4 vs 5.7%, p<0.01; 12 weeks, 2.7 vs 6.4%, p<0.001. 
Figure 62).  
8.4 Discussion 
 
8.4.1 Folate nephropathy as a model for established CKD 
These results are consistent with previous reports that folate nephropathy is a 
valid and reproducible model of CKD [173, 175, 224]. Renal fibrosis is the 
best structural correlate and predictor of renal function decline [225], proving it 
be the most relevant outcome in CKD models. Many published animal studies 
of CKD report fibrosis at a single early time-point (eg. 7-14 days post injury) 
which is arguably too acute, reveals nothing about disease progression and 
thus limits their interpretation in the context of human CKD. 
In this study, significant degrees of progressive renal fibrosis were 
detected across two different time-points (2 and 12 weeks). Secondary 
outcome data supported that established CKD had been achieved by 
confirming; raised serum creatinine (measured by LCMS/MS), reduced kidney 
size, pro-fibrotic cytokine upregulation (TGF! and Col12") and 
tubulointerstitial histological changes. Furthermore, at 2 day and 2 week time-
points, a sharp rise in serum creatinine, inflammatory cytokine expression and  
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Figure 62. Renal collagen deposition in folate nephropathy 
Representational images of kidney sections from mice treated with (i-ii) Vehicle and (iii-iv) 
Folate. Stained with picrosirius red and viewed through circularly polarised light. A detailed 
description of this method, developed with the assistance of Dr Dorman (MRC CSC, London), 
is reported in the Methods section. Section area defined through texture thresholding (i and 
iii). Capsular collagen was excluded from the analysis by automated circumferential reduction 
of the analysed perimeter (double lines). Background is subtracted to measure percentage 
collagen per total section area (ii and iv). (G) Percentage collagen deposition is significantly 
elevated at 2 and 12 weeks. 2 weeks (vehicle vs folate); 4.0 vs 5.7% (95% CIs 3.0-5.1 and 
4.4-6.9); p<0.01. 12 weeks; 2.7 vs 6.4% (1.7-3.7 and 5.2-7.6); p<0.001. Two-way ANOVA 
with Bonferroni’s post test. n=5 (vehicle), n=8 (folate). *p<0.05, **p<0.01, ***p<0.001. 
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acute histological changes demonstrated that folate nephropathy can 
also be useful to model tubulointerstitial AKI. 
8.4.2 Quantifying renal fibrosis 
An additional method developed during this validation study was the 
quantification of renal fibrosis. A commonly used approach is picro-sirius red 
or Masson-trichrome staining of kidney sections followed by semi-quantitative 
histological evaluation of collagen content and therefore fibrosis severity. This 
is observer-dependent, introduces potential bias, and does not take into 
account regional differences in collagen content across a kidney section 
which can vary by up to 30% [221]. The method used in this study 
circumvents these limitations through automated quantification of collagen as 
a percentage proportion of the whole section area. A potential criticism is that 
this quantification method inevitably includes non-fibrotic collagen of the renal 
pelvis structures. However, this occurs consistently within each kidney section 
and would simply increase the overall scores of percentage fibrosis without 
introducing bias for relative comparisons. 
8.4.3 The NO signalling pathway in folate nephropathy 
AGXT2 expression is specific to the renal tubule and is the only MAME to 
metabolise SDMA as well as ADMA and L-NMMA. At 2 days, renal AGXT2 
mRNA transcription was profoundly suppressed by folate injury (37-fold) 
whilst in parallel, plasma SDMA rose 4-fold (and L-NMMA). In contrast, both 
DDAH isoforms and plasma ADMA were unchanged at 2 days. It is unclear 
whether this represents AGXT2 and SDMA as regulators or merely 
bystanders of tubular injury, but the actions of AGXT2 and SDMA remain 
largely unresolved and further study of their roles in acute renal inflammation 
is warranted.  
There is a general perception that CKD represents a state of NO 
deficiency, although much of this is based upon decreased arginine synthesis 
and raised circulating ADMA [44]. Some of the findings here support this 
notion, with AGXT2 suppression and elevated kidney and plasma MAs at 2 
and 12 weeks. 
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In contrast however, in this study using a folate model of nephropathy, 
elevated NOx concentrations in kidney tissue and urine suggest that labelling 
CKD as a state of NO deficiency may be inaccurate. Higher renal expression 
of inflammatory and pro-fibrotic cytokines was observed, along with enhanced 
DDAH2 transcription at 12-weeks. This likely represents macrophage 
recruitment and activation within inflamed kidney. Taken together, these 
observations indicate an ADMA-NO imbalance in favour of NO predominates 
– not a state of deficiency.  
The disparity between this study and previous reports may be 
explained by a difference of emphasis placed upon local kidney versus 
systemic NO bioavailability. Previously published conclusions that describe a 
state of NO deficiency in chronic renal disease are based not only upon low 
circulating NO and high ADMA, but also the deleterious effects of systemic 
administration of NOS inhibitors such as L-NAME. The vasoconstrictive effect 
of systemic NOS inhibition is well established, however these studies do not 
isolate the (extra-vascular) kidney tissue when making assessments of, or 
manipulating the NO-ADMA axis. This thesis and specifically, the next chapter 
aim to address this issue. 
8.4.4 Limitations 
Despite reproducibility and ease of use, the folate nephropathy model of CKD 
has limitations. The most immediate is the mechanism of injury, specific to the 
action of highly concentrated folate within the tubular lumen, which does not 
directly represent a specific human disease. However, CKD results when a 
final common pathway of progressive fibrosis is established, irrespective of 
the initiating injury. Therefore, perhaps the limitations of applicability to human 
disease are only relevant when considering its use as a model of AKI. 
Although many secondary end-points were measured to confirm 
established CKD, proteinuria did not feature and in fact, was reduced in folate 
treated mice. These differences were not statistically significant and it is more 
likely that proteinuria detection was limited by the practical issues surrounding 
urine collection - as have been discussed as a significant limitation in previous 
chapters. 
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A deficiency of this particular experiment is the omission of invasive BP 
recordings, which would have been a useful additional outcome measure of 
progressive CKD and related CV disease. However, this was performed in the 
subsequent folate nephropathy experiment using PTD1KO mice, 
demonstrating a 14mmHg increase in the systolic BP of control mice 
(testosterone naïve; Figure 69). 
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9 FOLATE NEPHROPATHY IN THE PTD1KO MOUSE 
9.1 Introduction 
As previously discussed in Chapter 1.7.3.2, data previously published from 
our own group questioned the notion that raised ADMA always correlates with 
ill-health and is directly pathogenic. In human cohorts, a DDAH1 
polymorphism (rs17384213 GG genotype) associated with higher DDAH1 
mRNA expression in kidney allografts and in two independent CKD patient 
cohorts, lower plasma ADMA levels but a steeper rate of eGFR decline [154]. 
These results were in contrast to preceding association studies that indicated 
elevated plasma ADMA causes progressive renal disease. We took a basic 
science approach to resolve this conflict by specifically disrupting the NO-
ADMA-DDAH axis within kidney tissue and not systemically.  
The proximal tubule (PT) is the principal site of renal DDAH1 
expression (Chapter 1.7.1.1). To determine the role of PT-specific DDAH1 in 
the progression of renal fibrosis, PTD1KO and control (KC-) mice were 
subjected to a folate nephropathy model of CKD. 
9.2 Study design 
All mice were homozygous for the floxed DDAH1 transgene but either 
negative or positive for the KAPiCre gene (KC- or KC+). As previously 
described, exogenous testosterone was administered for a minimum of ten 
days prior to study inclusion to activate KC and delete PT DDAH1. In order to 
control for the effect of testosterone treatment alone, three experimental 
groups were necessary:  
1) No testosterone, KAPiCre +  (T-KC+) 
2) Testosterone, KAPiCre -   (T+KC-) 
3) Testosterone, KAPiCre +   (T+KC+; PTD1KO) 
 
Mice received either folate or vehicle treatment and were culled at one 
of three time points: 2 days, 2 weeks and 12 weeks (Table 13).  
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  T-KC+ T+KC- T+KC+ Total 
2 days 
Vehicle 3 2 3 8 
Folate 5 3 10 18 
2 weeks 
Vehicle 6 3 3 12 
Folate 11 (7) 7 (1) 11 (1) 29 (9) 
12 weeks 
Vehicle 5 4 8 (1) 17 (1) 
Folate 11 (1) 9 18 (6) 38 (7) 
( ) = premature death   Total 112 (17) 
 
Table 13. Numbers of mice within each experimental group 
Three groups; T-KC+; T+KC-; T+KC+, received either vehicle or folate and were culled at 
three time-points, resulting in 18 groups (122 mice total). 16 premature deaths occurred (in 
brackets); 8 in testosterone naïve mice treated with folate likely due to severe AKI within 72 
hours (post-mortem revealed grossly enlarged, yellow kidneys); 8 testosterone-treated mice 
were sacrificed early after developing UV-prolapse. One mouse (T+KC+ group) was excluded 
from analysis due to severe bilateral hydronephrosis identified at tissue harvest. Potential 
effects of mortality rates are discussed (Chapter 9.4.3.1).  
 
The KC- group size was limited by lower breeding yields of this 
genotype. Fewer numbers were allocated to the vehicle-treated cohorts as 
little or no pathological response was expected, whereas folate-treated group 
sizes were expanded due to a higher anticipated degree of disease variability.  
9.3 Results 
9.3.1 Kidney : body weight ratio 
At 2 days following folate administration, kidney : body weight in T-KC+ 
mice had increased by 43%, whilst all testosterone-treated mice (T+KC- and 
T+KC+) exhibited a non-significant (variable) rise with no difference between 
them (Figure 63A). At 2 and 12 weeks, kidney : body weight was significantly 
lower in folate-treated testosterone naïve mice (T-KC+) mice compared with 
both testosterone treated mouse groups (T+KC- and T+KC+). Although trends 
for lower kidney : body weight ratios were observed in T+KC- mice compared 
with PTD1KOs (T+KC+), these did not reach statistical significance (Figure 
63B and C).   
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Figure 63. Kidney to body weight ratios following folate treatment 
Comparison of folate-treated groups (black bars). (A) 2 days. No significant differences. (B) 2 
weeks. T-KC+ vs T+KC-; 5.4 vs 8.2 mg/g (95% CIs 4.5-6.5 and 7.4-8.9); p<0.01 and T+KC+; 
9.6 mg/g (95% CI 8.4-10.9); p<0.001. T+KC- vs T+KC+; no significant difference. (C) 12 
weeks. T-KC+ vs T+KC-; 4.7 vs 7.8 mg/g (4.2-5.1 and 7-8.7); p<0.001 and T+KC+ 8.6 mg/g 
(95% CI 7.5-9.6); p<0.001. T+KC- vs T+KC+; no significant difference. Numbers per group 
(n): Vehicle-treated; T-KC+ 2 days n=3; 2 weeks n=6; 12 weeks n=5. T+KC- 2 days n=2; 2 
weeks n=3; 12 weeks n=4. T+KC+ 2 days n=3; 2 weeks n=3; 12 weeks n=7. Folate-treated; 
T-KC+ 2 days n=5; 2 weeks n=4; 12 weeks n=10. T+KC- 2 days n=3; 2 weeks n=6; 12 weeks 
n=9. T+KC+ 2 days n=10; 2 weeks n=10; 12 weeks n=12. Two-way ANOVA with Bonferroni’s 
post test. **p<0.01 ***p<0.001. 
9.3.2 Serum creatinine 
At 2 days following folate treatment, T-KC+ mice had an 8-fold rise (p<0.001) 
in serum creatinine over vehicle-treated controls and both testosterone-
treated groups (T+KC- and T+KC+; Figure 64A).  
At 2 weeks, folate-treated T-KC+ serum creatinine had fallen but 
remained 60% higher than vehicle-treated animals. T+KC- mouse mean 
creatinine had risen 40% following folate but this was not statistically 
significant. T+KC+ (PTD1KO) mouse serum creatinine did not change. 
At 12 weeks, T+KC- folate-treated mice, exhibited a mean 120% 
elevation in serum creatinine compared to vehicle controls and T-KC+ and 
T+KC+ mice exposed to folate (p<0.01 and p<0.001 respectively).  
9.3.3 Urinary volume 
Urine was not collected at the 2-day time-point for humane reasons (mice 
could display signs of distress 48 hours after folate injury). At 2 weeks, a 4-
fold higher urinary volume occurred in folate-treated T-KC+ compared to 
vehicle controls (p<0.001 unpaired t test, not shown on graph). At both 2 and 
12 weeks, urinary volumes in folate-treated mice did not differ significantly 
between T-KC+, T+KC- and T+KC+ groups (Figure 65).  
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Figure 64. Serum creatinine following folate treatment. 
Comparison of folate-treated groups (black bars). (A) 2 days. T-KC+ vs T+KC-; 170 vs 13.4 
µM, (95% CIs 126-214 and 2-24.7); p<0.001 and T+KC+ 16.7 µM (95% CI 13.3-20.2). T+KC- 
vs T+KC+ groups; no significant difference. (B) 2 weeks. A trend for increased serum 
creatinine in all folate treated animals vs vehicle controls but no significant differences. (C) 12 
weeks. Higher serum creatinine in folate-treated T+KC- mice; 24.4 µM (9%CI 16.9-32) 
compared to folate-treated T-KC+ mice; 16.5 µM (95% CI 12.5-20.5; p<0.01), and T+KC+ 
mice; 12.9 µM (95% CI 11.3-14.6; p<0.001). Numbers per group (n): Vehicle-treated. T-KC+ 
2 days n=3; 2 weeks n=6; 12 weeks n=5. T+KC- 2 days n=2; 2 weeks n=3; 12 weeks n=4. 
T+KC+ 2 days n=3; 2 weeks n=3; 12 weeks n=7. Folate-treated; T-KC+ 2 days n=5; 2 weeks 
n=4; 12 weeks n=10. T+KC- 2 days n=3; 2 weeks n=6; 12 weeks n=9. T+KC+ 2 days n=10; 2 
weeks n=10; 12 weeks n=12. Two-way ANOVA with Bonferroni’s post test. **p<0.01 
***p<0.001. 
 
 
 
 
 
 
Figure 65. Urinary volumes following testosterone and folate treatment. 
(A) 2 weeks. A significant increase in urinary volume in testosterone naïve mice after folate. 
T-KC+; 32.9 vs 125.8 µL/g/24hrs (95% CIs 21-45 and 95-157); p<0.001. (A and B) 2 and 12 
weeks. No significant differences in urinary volumes were detected in between folate-treated 
groups. Numbers per group (n): Vehicle-treated. T-KC+ 2 weeks n=6; 12 weeks n=5. T+KC- 
2 weeks n=3; 12 weeks n=4. T+KC+ 2 weeks n=3; 12 weeks n=7. Folate-treated; T-KC+ 2 
weeks n=4; 12 weeks n=10. T+KC- 2 weeks n=6; 12 weeks n=9. T+KC+ 2 weeks n=10; 12 
weeks n=12. Two-way ANOVA with Bonferroni’s post test. ***p<0.001. 
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9.3.4 Proteinuria 
The most significant effect upon 12-week proteinuria, was that of 
testosterone treatment which increased levels 4-fold (p<0.001) over controls 
(Figure 66). Folate produced a 2-fold (but insignificant) rise in proteinuria in T-
KC+ mice but no changes in testosterone-treated groups. Although a trend of 
reduced proteinuria was observed in PTD1KOs (T+KC+) compared to T-KC+ 
mice, this did not reach statistical significance.  
9.3.5 Acute inflammatory cytokines 
Folate injury upregulated kidney mRNA transcription of ET-1, IL-6 and TNF!, 
with a peak effect between 2 days and 2 weeks (Figure 67). The largest effect 
was seen in T-KC+ mice (approx. 10-fold increase; p<0.01) whilst 
testosterone-treated groups appeared to be protected with smaller increases 
in cytokine mRNA between 2 and 5-fold (non-significant). At 12 weeks, overall  
ET-1 and IL6 transcription following folate in PTD1KOs (T+KC+) was lower 
than T+KC- mice although this did not reach statistical significance. 
 
 
Figure 66. Proteinuric response to testosterone and folate treatment. 
Testosterone had the largest impact upon proteinuria. Comparison of vehicle-treated groups 
(white bars). Urine protein : creatinine ratio (UPCR, mg/µM). T-KC+ vs T+KC- and T+KC+; 
0.79 vs 3.6 and 3.3 mg/µM respectively (95% CIs 0.02-1.6, 1.9-5.3 and 2.4-4.2) both p<0.01. 
Comparison of folate-treated groups (black bars); no significant differences. Numbers per 
group (n): Vehicle-treated; T-KC+ n=5; T+KC- n=4; T+KC+ n=7. Folate-treated; T-KC+ n=10; 
T+KC- n=9; T+KC+ n=12. Two-way ANOVA with Bonferroni’s post test. **p<0.01. 
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Figure 67. Kidney tissue acute inflammatory cytokine mRNA transcription following folate treatment. 
mRNA transcription measured by qPCR. In testosterone naïve mice (T-KC+); endothelin-1 (ET-1, A-C) peak transcription at 2 days (vehicle vs folate); 4.1 vs 
41.9 AU (95% CIs 1.8-6.4 and 24.5-59.3); p<0.01). Interleukin-6 (IL-6, D-F) peak transcription at 2 weeks; 0.14 vs 1.3 AU (95% CIs 0.08-0.2 and 0.89-1.65); 
p<0.0001). Tumour necrosis factor-! (TNF!, G-I) peak transcription at 2 weeks; 0.13 vs 1.4 AU (0.08-0.19 and 0.22-2.5); p<0.01. In T+KC- and T+KC+ 
groups, although trends of increased transcription following folate were observed, no significant differences were detected. Numbers per group (n): Vehicle-
treated. T-KC+ 2 days n=3; 2 weeks n=6; 12 weeks n=5. T+KC- 2 days n=2; 2 weeks n=3; 12 weeks n=4. T+KC+ 2 days n=3; 2 weeks n=3; 12 weeks n=7. 
Folate-treated; T-KC+ 2 days n=5; 2 weeks n=4; 12 weeks n=10. T+KC- 2 days n=3; 2 weeks n=6; 12 weeks n=9. T+KC+ 2 days n=10; 2 weeks n=10; 12 
weeks n=12. Two-way ANOVA with Bonferroni’s post test. *p<0.05, **p<0.01, ***p<0.001. 
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9.3.6 Pro-fibrotic cytokines 
TGF! and Col12" mRNA transcription was stimulated in folate-treated mice 
with a peak effect at 2 weeks (Figure 68). Pro-fibrotic cytokines were most 
elevated in testosterone naïve (T-KC+) mice (TGF!, 3-fold and Col12", 14-
fold) whilst testosterone treated mice had a smaller, non-significant rise. 
By 12 weeks, no significant differences in TGF! were observed. 
Col12" transcription however, was significantly increased by folate treatment 
in T-KC+ mice (>2-fold) and to a lesser extent, in T+KC- mice. PTD1KOs 
(T+KC+) however, exhibited significantly less Col12" kidney tissue 
transcription than T-KC+ and T+KC- counterparts. 
 
Figure 68. Pro-fibrotic cytokine mRNA transcription following folate treatment. 
mRNA transcription measured by qPCR. In testosterone naïve mice (T-KC+); transforming 
growth factor-! (TGF!, A-C) peak expression was at 2 weeks (vehicle vs folate); 0.4 vs 1.2 
AU (95% CIs 0.33-0.44 and 0.83-1.51); p<0.001). Collagen 1 subunit 2" (Col12"; E) peak 
expression at 2 weeks; 0.05 vs 0.7 AU (95% CIs 0.03-0.06 and 0.45-0.96); p<0.001). (F) At 
12 weeks Col12" was increased 2-fold in T-KC+ (0.4 vs 1.0 AU (95% CIs 0.23-0.64 and 0.75-
1.3); p<0.01). At 12 weeks following folate treatment, Col12" transcription was significantly 
lower in PTD1KOs (T+KC+; 0.39 AU, 95% CI 0.27-0.52) than in both T-KC+ (1.0 AU, 0.75-1.3 
AU; p<0.001) and T+KC- mice (0.78 AU, 95% CI 0.49-1.1; p<0.05). Numbers per group (n): 
Vehicle-treated. T-KC+ 2 days n=3; 2 weeks n=6; 12 weeks n=5. T+KC- 2 days n=2; 2 weeks 
n=3; 12 weeks n=4. T+KC+ 2 days n=3; 2 weeks n=3; 12 weeks n=7. Folate-treated; T-KC+ 2 
days n=5; 2 weeks n=4; 12 weeks n=10. T+KC- 2 days n=3; 2 weeks n=6; 12 weeks n=9. 
T+KC+ 2 days n=10; 2 weeks n=10; 12 weeks n=12. Two-way ANOVA with Bonferroni’s post 
test *p<0.05 **p<0.01 ***p<0.001. 
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9.3.7 Haemodynamics 
Terminal systemic BP measurements were performed in all mice of the 12-
week cohort (Figure 69). At 12 weeks following folate, testosterone naïve 
mice had increased systolic BPs over their vehicle-treated controls (110 vs 
96mmHg, p<0.05). After more than 12 weeks of testosterone exposure, 
T+KC- mice had elevated systolic BPs (~112mmHg) irrespective of folate 
treatment. PTD1KO mice (T+KC+) treated with vehicle exhibited similar 
increased systolic BP (107mmHg). Folate treated PTD1KO mice had 
significantly lower systolic BPs than T+KC- controls (98 mmHg vs 112, 
p<0.01). 
Figure 69. Systolic BP responses at 12 weeks following folate treatment 
Folate treatment increased systolic BP significantly at 12 weeks. T-KC+ vehicle vs folate; 96 
vs 110 mmHg (95% CIs 90-102 and 103-117); p<0.05. Testosterone exposure increased 
systolic BP at 12 weeks; T-KC+ vs T+KC- vehicle-treated; 96 vs 113 mmHg (95% CIs 90-102 
and 93-133); p<0.05. 12 weeks after folate, PTD1KO mice had significantly lower systolic BP 
than T+KC- controls; 98 vs 112 mmHg (95% CIs 93-103 and 101-122); p<0.01. Numbers per 
group (n): Vehicle-treated; T-KC+ n=5; T+KC- n=4; T+KC+ n=7. Folate-treated; T-KC+ n=10; 
T+KC- n=9; T+KC+ n=12. Two-way ANOVA with Bonferroni’s post test *p<0.05 **p<0.01 
***p<0.001. 
9.3.8 Histological evidence of disease 
Histological analysis confirmed significant acute tubular injury two days 
following folate administration in all mice. Tubular lumen dilatation, casts and 
epithelial cell flattening were evident from the 2-day into 2-week time-points, 
at which time significant interstitial inflammatory cell infiltration was also 
observed. By 12 weeks, areas of tubular atrophy and fibrosis were clearly 
seen (Figure 70). 
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Figure 70. Histological appearances of folate nephropathy in PTD1KO mice and controls 
There were no histological differences between DDAH1 intact (KC-) and PT-specific DDAH1 deleted (KC+ PTD1KO) mice treated with vehicle (0.3M 
NaHCO3) at any time-point. At 2 days and 2 weeks following a single IP folate injection, significant disease was evident including; tubular dilatation (td) and 
epithelial cell flattening; luminal casts (lc) and more significantly at 2 weeks; tubulointerstitial inflammatory cell infiltrates (inc). There was no obvious 
difference in disease severity between KC- and KC+ mice at these time-points. At 12 weeks following folate-induced disease, tubulointerstitial fibrosis /extra-
cellular matrix (ecm) deposition was more severe in KC- mice (quantified and confirmed by automated collagen analysis described in the Methods chapter 
and following sub-chapter). 
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Figure 71. Renal collagen deposition following folate treatment 
Percentage (%) renal collagen deposition was assessed by automated image analysis of 
whole sagittal kidney sections stained with picro-sirius red (detailed in “Methods” chapter). (A) 
2 days: no change. (B) 2 weeks (vehicle vs folate); T-KC+, 3 vs 6.8% (95% CIs 2.1-3.9 and 3-
10.5); p<0.01. T+KC-, 2.1 vs 4.2% (0.6-3.5 and 2.6-5.8); p=0.055. T+KC+, 2.3 vs 4% (0.3-4.2 
and 2.8-5.3); not significant. (C) 12 weeks (vehicle vs folate); T-KC+, 3.4 vs 7.9% (95% CIs 
2.3-4.5 and 6.3-9.6); p<0.01. T+KC-, 3.8 vs 7.2% (95% CIs 2.6-5 and 5.3-9.2); p<0.05. 
T+KC+, 3.2 vs 4.5% (2-4.4 and 3-5.9); not significant. (D) The same data presented to 
highlight comparisons between T+KC- and T+KC+ (PTD1KO) mice. Numbers per group (n): 
Vehicle-treated. T-KC+ 2 days n=3; 2 weeks n=6; 12 weeks n=5. T+KC- 2 days n=2; 2 weeks 
n=3; 12 weeks n=4. T+KC+ 2 days n=3; 2 weeks n=3; 12 weeks n=7. Folate-treated; T-KC+ 2 
days n=5; 2 weeks n=4; 12 weeks n=10. T+KC- 2 days n=3; 2 weeks n=6; 12 weeks n=9. 
T+KC+ 2 days n=10; 2 weeks n=10; 12 weeks n=12. Two-way ANOVA with Bonferroni’s post 
test *p<0.05 **p<0.01 ***p<0.001. 
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Figure 72. Reduced collagen deposition in PTD1KO mice at 12 weeks following folate 
T+KC- compared to T+KC+ (PTD1KO). Representative images of kidney sections stained 
with picro-sirius red and viewed through circularly polarised light. Images taken at x25 
magnification and processed using Image J software to stitch, remove background and 
quantify collagen (yellow) as a percentage of total kidney section area. (n=3 representative of; 
T+KC- n=9 and T+KC+ n=12 experiment group numbers). 
9.3.9 Renal fibrosis (collagen deposition) 
Renal fibrosis, determined by percentage collagen deposition, did not change 
in any treatment group at the 2-day time-point (Figure 71A). At 2 weeks, 
folate-treated T-KC+ mice had a significant >2-fold rise in fibrosis (p<0.01) 
whereas both T+KC- and T+KC+ groups had a smaller, statistically non-
significant rise (Figure 71B). 
At 12 weeks following folate, percentage collagen had increased 
further in both T-KC+ and T+KC- mouse groups but not in PTD1KOs (Figures 
71 and 72). 
T+KC- T+KC+ (PTD1KO)  
i i 
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9.4 Discussion 
 
9.4.1 PTD1KO protects against progression of renal disease 
Chronic kidney disease (CKD) features progressive renal fibrosis that disrupts 
and contracts normal kidney architecture to eventually reduce organ size and 
function. Clinically, CKD is defined and classified according to serum 
creatinine and often manifests with proteinuria and elevated systemic BP. 
In this 12-week model of CKD, the PTD1KO mouse was protected from 
renal fibrosis; a reduction in renal mass; elevated serum creatinine; 
proteinuria and raised systemic BP. In addition, pro-fibrotic cytokine mRNA 
transcription in kidney tissue was significantly lower in PTD1KO mice than 
controls. These data are mutually supportive and indicate that in a folate 
model of CKD, DDAH1 disruption in the proximal tubule protects against 
kidney disease progression. 
9.4.2 Conflict with previous studies: “DDAH1 protects against renal fibrosis” 
Previously, a number of investigators have attempted to examine the impact 
of manipulating the NO-ADMA-DDAH axis in rodent models of CKD, and 
conclude that DDAH1 activity protects against renal fibrosis. For example, 
direct osmotic pump infusion of ADMA in mice exacerbated renal fibrosis 
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although this finding was accompanied by a 60mmHg elevation of systolic BP 
over controls and a similar effect with L-NAME infusion, together suggesting a 
predominant hypertensive injury [157]. 
More convincing, were studies using rodents that overexpressed 
DDAH1. Protection against renal collagen deposition was reported in both an 
angiotensin-induced and surgical nephron-reduction model of CKD (despite 
correcting for hypertension pharmacologically [158, 159]). Whilst intriguing, 
major limitations compromise their relevance to endogenous DDAH1 activity 
in human disease. DDAH1 overexpression was not tissue-specific and 
presumably included immune cells such as macrophages that do not normally 
express DDAH1, but play a crucial role in tissue inflammation [102]. In 
addition, genetic or viral over-expression of DDAH1 activity to supra-
physiological levels will not be subject to normal regulatory and adaptive 
responses. Fundamentally, the renal-specific NO-ADMA-DDAH axis in these 
animals is not characterised and cannot be separated from the systemic 
effects of DDAH1 overexpression and BP reduction. 
In the PTD1KO mouse, highly PT cell-specific DDAH1 deletion was 
confirmed with no alteration to baseline plasma ADMA and systolic BP, 
suggesting that the protection against kidney collagen deposition and 
functional decline was independent of circulating ADMA and BP – both 
intrinsic confounders in previous models. Possible mechanisms behind the 
influence of local DDAH/ADMA upon kidney fibrosis are discussed in Chapter 
12.5. 
9.4.3 Limitations 
9.4.3.1 The effects of testosterone 
Due to the extended nature of this disease model, mice were exposed to 
testosterone for longer periods of time than those in initial PTD1KO 
characterisation studies. By comparing data from vehicle-treated mice across 
all three study groups (T-KC+; T+KC-; T+KC+), physiological effects of 
exogenous testosterone were identified and included; increased kidney : body 
weight ratio (~50%, p<0.001); elevated proteinuria (4-fold, p<0.01) and raised 
systolic BP (17 mmHg, p<0.05). Mice exposed to testosterone appeared to 
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have partial protection from folate-induced acute kidney injury manifested by 
only very small increases in serum creatinine at the 2-week time-point; along 
with induced inflammatory cytokine expression and even fibrosis. 
Renal hypertrophy and proteinuria associated with testosterone have 
been reported elsewhere [190, 226]. In a rodent model of ischaemia-
reperfusion kidney injury, exogenous testosterone protected against reduced 
cortical perfusion and upregulated TNF! [227]. In this study, despite being 
initially protected from disease, testosterone-treated animals manifested 
similar degrees of fibrosis to testosterone naïve mice at 12 weeks. This may 
represent an element of hypertensive renal injury in testosterone-treated 
mice. In addition, testosterone has been reported to increase renal injury 
through exacerbating oxidative stress and pro-fibrotic angiotensinogen 
expression [228]. 
The significant effects of testosterone in this model cannot be 
overlooked and were to some extent, anticipated - demonstrated by the study 
design including two control groups. Importantly, the protective effect of PTD1 
deletion was identified through comparison of two groups exposed to 
testosterone; KC- and KC+. Unfortunately, the very nature of this transgenic 
model does not allow complete separation of the effects of testosterone 
treatment in mice with different genotypes. 
An alternative PT-specific Cre expressing transgenic mouse has been 
developed using a tamoxifen-responsive element driven by a promoter 
fragment of the (PT-specific) gamma-glutamyl transpeptidase type II gene. 
However, since tamoxifen is an oestrogen receptor antagonist and oestrogens 
are reported to reduce circulating ADMA [229], this construct would not be 
free of confounding effects. 
Below, further specific considerations of the confounding effects of 
exogenous testosterone are discussed. 
 
9.4.3.2 Mortality and testosterone effects 
The fatalities attributed to AKI or acute folate toxicity (8 in total) with 72 hours 
of folate administration all occurred within the testosterone untreated (T-KC+) 
group indicating a protective effect of androgen treatment against folate injury 
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and disease. Apart from one mouse (1 of 53) in the PTD1KO (T+KC+) group, 
all other fatalities resulted from deliberate humane sacrifice due to the 
emergence of utero-vaginal (UV) prolapse, a known side-effect of 
testosterone treatment in rodents [190] (T+KC- group 1 of 28 (4%); T+KC+ 7 
of 53 (13%)). 
Despite a disproportionate manifestation of UV prolapse in the 
PTD1KO group, it is not possible to conclude as to which way this may have 
influenced the finding of reduced renal fibrosis in PTD1KOs (ie. producing a 
type 1 or narrowly avoiding a type 2 error). If testosterone protects against 
folate nephropathy and the incidence of UV prolapse represents testosterone 
sensitivity, then one could propose that the PTD1KO mouse may have 
incurred more protection against fibrosis over their T+KC- counterparts. 
However, a theory of increased testosterone sensitivity in PTD1KOs is not 
consistent with respect to androgen-related systemic hypertension, as 
PTD1KOs had lower mean systemic BP. 
 
9.4.3.3 Serum creatinine and testosterone effects 
At 2 days following folate administration, serum creatinine was significantly 
elevated in testosterone naïve mice but not in testosterone-treated mouse 
groups (T+KC- and T+KC+). Taken in isolation, this could be interpreted as a 
failure to produce significant acute renal injury in testosterone-treated mice. In 
conflict with this is the acute histological changes witnessed in kidney sections 
taken from testosterone-treated mice at 2 days and 2 weeks. Furthermore, at 
12 weeks the presence of significant fibrosis in folate-treated mice in 
comparison to vehicle-treated controls indicates a folate-induced injury. In 
addition, albeit to a lesser extent than testosterone-naïve mice, a consistent 
elevation of serum creatinine concentrations at subsequent time intervals (2 
and 12 weeks) and furthermore, other secondary end-points reflected much 
the same pattern; acute increase and subsequent decrease in kidney : body 
weight ratios; along with increased acute cytokine transcription (including ET-
1, IL6 and TNF!). 
Serum creatinine has been reported as an imperfect measure of renal 
dysfunction in rodent models [230] and given the complexity of effects of sex 
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hormones upon renal function [231], it is difficult to predict its influence upon 
tubular creatinine handling in the presence of additional physiological 
stressors. Testosterone may well protect against nephrotoxic injury, which will 
not only affect the degree of disease but also the natural history, meaning that 
2 days may not be the appropriate time interval at which to see the most 
intense disease. Alternative approaches to confront or circumnavigate these 
issues would include using alternative measures of renal dysfunction (such as 
sinistrin and PAH method) and perhaps, plotting the natural history of renal 
injury in the presence of testosterone-treatment (eg. daily time-points within 
the first week).  
 
9.4.3.4 Proteinuria and testosterone effects 
PTD1KO mice had lower mean proteinuria and systemic BP than their 
folate-treated KC- controls. However, closer examination of the level of 
proteinuria and systolic hypertension in both KC- groups (vehicle and folate-
treated) and the vehicle-treated group of PTD1KOs reveals comparable 
results. This indicates that testosterone directly elevates proteinuria and 
systolic BP at 12 weeks and masks the added effect of folate nephropathy. 
Similar to mechanisms of human CV disease, it is most likely that proteinuria 
develops in testosterone-treated mice as a direct result of hypertension. What 
is difficult to resolve is reduced systolic BP in PTD1KO only in the presence of 
folate injury. Although the mouse was protected against many other features 
of CKD, the lower BP in these circumstances may represent significant 
tubular dysfunction with salt and water losses significant enough to produce 
relative hypotension. This unmasking of tubular dysfunction with concurrent 
physiological stress may represent what was anticipated in the salt feeding 
experiments of Chapter 6. 
 
9.4.3.5 Off-target effects of Cre activity 
Deserving of comment is the possibility of Cre toxicity leading to reduced 
fibrosis in PTD1KO mice. Although the presence of the KC transgene was 
controlled for in the testosterone untreated group (T-KC+), activated KC was 
not, due to limitations in time and resource as this would have required a 
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fourth experimental group; testosterone-treated, KC+ but DDAH1 flox 
negative. Cre toxicity has been reported to cause cardiomyopathy [232], brain 
development defects [233] and widespread apoptosis in embryos [234]. To 
date, there are no descriptions of Cre-toxicity relating to fibrosis and any 
reported effects appear to disrupt normal cellular function and architecture 
rather than preserve it, as witnessed in the PTD1KO mouse. 
 
9.4.3.6 Further experiments 
Given the emphasis made throughout this thesis upon the differentiation of 
local versus systemic DDAH1/ADMA effects, an important experiment to 
perform would a model of folate nephropathy in global DDAH1 KO mice. 
Alternatively, to circumnavigate potential confounding effects of life-long 
genetic DDAH1 abrogation, systemic DDAH1 inhibition through administration 
of L257 or silencing RNA could be performed. 
Data from alternative experimental models of CKD would strengthen 
the findings made in this study. Folate nephropathy, like many other animal 
disease models, does not directly represent a form of common human renal 
disease and its relevance to the clinical setting relies on it reaching an 
established “final common pathway” of fibrosis. Using a nephron reduction 
model of disease such as 5/6 nephrectomy, UUO model or even renal 
ischaemia-reperfusion to induce chronic renal disease and demonstrate 
protection against renal fibrosis in PTD1KO mice would inevitably add weight 
to the impact of this study.  
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10 IN VITRO STUDIES 
10.1 Introduction 
In vivo studies in Chapters 4, 5 and 9 indicated that increased tubular ADMA 
resulting from PT-specific DDAH1 gene disruption protects against the 
development of fibrosis following a folate model of kidney injury. An in vitro 
series of studies were undertaken to define specific effects of ADMA upon 
proximal tubular function. 
The direct effects of folate upon PT cell function in vitro were not 
assessed for a number of reasons. The use of folate injury in this CKD model 
is to trigger an acute inflammatory response that transitions into a phase of 
chronic, progressive fibrosis to mimic the “final common pathway” observed in 
human CKD. It is not an examination of the long-term pathophysiological 
effects of (single dose) folate on the kidney. The use of folate in vitro would 
not mimic in vivo effects due to the absence of many stimulated cytokines and 
contribution of other structures and cell types such as peritubular capillaries, 
glomeruli and infiltrating inflammatory cells including macrophages and 
neutrophils. Within the limitations of in vitro studies, the aim here was to 
define the pathophysiological effects of ADMA, either directly or through 
pharmacological DDAH1 inhibition, upon PT cell function. 
In response to injury, surviving proximal tubular cells undergo phases 
of differentiation and proliferation necessary for repair and restoration of 
function, although what determines coordinated repair from destructive 
proliferation is poorly understood [235]. A remarkable proliferative capacity 
and high metabolic strain imposed by active reabsorption, places huge energy 
demands upon the PT cell, which is met by densely packed mitochondria 
within the cell cytoplasm. Taking an in vitro approach, the impact of ADMA 
upon proximal tubular differentiation, proliferation and mitochondrial function 
were investigated.  
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10.2 Study Design 
A cell line was used for the majority of these functional studies. Normal 
Human Proximal Straight Tubular Cells (NHPSTs) were a kind gift from 
Professor Patricia Wilson (UCL, London). The cells were conditionally 
immortalized using a vector containing pZiptsU19 with the temperature 
sensitive SV40 T-antigen allele tsA58U19 and a neomycin resistance gene. 
Proliferative growth at 33°C was switched off by incubation at 37°C within 48 
hours (upon T-antigen de-activation), after which point the cells display 
normal PTC characteristics [160]. 
To support findings made in the NHPST cell line, a method for 
extraction and culture of primary mouse PT cells was learnt and developed. In 
addition, extraction of tubular fragments proved useful to: 
1. confirm that renal DDAH1 expression is principally tubular. 
2. demonstrate tubule-specific gene manipulation in both KAPiCre 
transgenic strains (ROSAYFP reporter and PTD1KO; see 
Results Chapter 4). 
The method protocol was very kindly taught and demonstrated by Dr 
Linghong Huang in Dr Tim Johnson’s laboratory at Sheffield University 
(previously published, [236]). The technique yields purified fractions of tubular 
fragments that can be used for primary cell culture or immediate analysis. 
10.3 Renal tubule isolation 
10.3.1 Methodology 
Mice were sacrificed by cervical dislocation and through a large midline 
laparotomy incision, the visceral fat and small bowel were moved aside to 
expose the abdominal aorta. Working under dissection microscopy, the renal 
arterial circulation was isolated by suture ligation superior to the renal arteries 
with additional sutures to occlude the superior mesenteric artery (SMA) and 
celiac trunk (Figure 73). 
The abdominal aorta was cleaned of encapsulating fat and fascia and a 
length of suture positioned horizontally underneath the aorta (inferior to the 
renal arteries) and left untied. A small oblique incision was made through the 
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aorta just above the iliac bifurcation to approximately half the vessel width. 
The aorta was cannulated through this incision, using a length of pre-
fashioned plastic tubing (the end was briefly heated under a light source and 
stretched prior to being cut obliquely to achieve a sharpened tip). The tubing 
within the aorta was tied in place using the pre-positioned suture. The free 
end of tubing was cannulated by a 30 gauge needle and attached to a 10mL 
syringe containing BSA-inactivated magnetic beads suspended in HBSS. 
Using a syringe driver, the bead solution was infused at a rate of 
1mL/min and kidney perfusion was confirmed by rapid blanching. 
 
Figure 73. Renal tubule isolation 
A, Cartoon of abdominal vessel anatomy with suture and cannulation sites indicated (adapted 
from Google images). B, microscopic examination of purified tubular fraction and C, 
glomerular fraction following magnetic separation. At higher (x400) magnification, the beads 
are clearly visualised within the glomerular capillary loops.  
 
Once perfused, both kidneys were removed, decapsulated and minced 
with a scalpel before incubation in collagenase solution at 37°C for 30 min 
with agitation. The resulting homogenate was pushed through successive 
sieves (100µ and 50µ pore size) using a 1mL syringe plunger and ice cold 
HBSS rinsing. Fragments retained by the 50µ sieve were collected into a 
15mL Falcon tube and a magnet was applied to the side. Sediment could be 
seen lining the side of the tube, representing glomeruli with magnetic beads 
trapped within their capillary loops (Figure 73C). The tubular fragments and 
cells remained in suspension (Figure 73B). Microscopic examination of 
tubular and glomeruli fractions confirmed purity and fractions were pelleted by 
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centrifugation at 1,000rpm for 5mins before resuspension in media and plated 
out or stored at -80°C until further use.   
 The most technically challenging aspect was correct placement of 
sutures to avoid liver and gut perfusion leading to inadequate renal bead 
entrapment. The SMA and celiac trunk (leading to the hepatic and splenic 
arteries) branches lie very close to the right renal artery especially, and care 
was required to tie ligatures around them whilst avoiding compromise to right 
kidney perfusion. All too often in early experiments, was the liver perfused 
causing inadequate bead perfusion into the glomerular capillary loops. Once 
well practiced, the surgical success rate was in the region of 95% 
(approximately 1 in 20 were inadequately perfused). 
10.3.2 Characterisation of tubular / glomerular fractions 
10.3.2.1 MAME/NOS expression 
RT-qPCR and Western blotting analysis confirmed that the tubules chiefly 
express renal DDAH1 and AGXT2 (96% and 98% more than glomeruli; 
p<0.001) whilst the glomeruli express proportionately more DDAH2 (53%), 
iNOS (99%) and eNOS (82%; all p<0.001). nNOS was equally expressed in 
both fractions (Figures 74A-D).  The glomerular fraction had 13-fold (p<0.01) 
more NOx content than the tubule. 
 
10.3.2.2 Cell surface protein expression 
Expression of E-cadherin and pancytokeratin (both epithelial (tubular) cell 
markers) and alpha smooth muscle actin (!-SMA; a marker of myofibroblasts 
and glomerular mesangial cells) were studied to assist in estimating fraction 
purity. The relative expression of each marker within the fraction it did not 
represent was between 20-28% (Figure 74F and G).  
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Figure 74. MAME and NOS expression profiles of isolated tubular / glomerular fractions. 
All data expressed as relative percentage expression between tubular and glomerular fractions. mRNA corrected by Pol2a and protein, by !-tubulin 
transcription. Successful staining with antibodies for iNOS and AGXT2 protein detection was not possible despite attempts to optimise those commercially 
supplied (iNOS, author’s own findings; AGXT2, Dr B Caplin personal communication). Mann-Whitney U test. n=5 all groups. **p<0.01, ***p<0.001. 
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10.4 The effects of ADMA upon proximal tubular cell function 
10.4.1 Differentiation: NHPSTs 
Transforming growth factor ! (TGF!) is a cytokine secreted by activated 
immune cells that stimulates cellular differentiation and proliferation. Its role in 
renal fibrosis is well recognised [237] and its use in vitro allows specific 
pathways of fibrosis to be studied. TGF! has been shown to stimulate 
epithelial to mesenchymal (EMT) in vitro and in vivo [238, 239], and despite 
the controversy over which cells of origin contribute to myofibroblasts in vivo 
[240, 241], a state of epithelial de-differentiation / differentiation following 
injury is generally accepted. 
By quantifying the expression of protein markers of epithelial (E-
cadherin) and myofibroblast or mesangial ("SMA) cell types, the 
differentiating effect of TGF! upon NHPSTs was examined and furthermore, 
whether treatment with ADMA (3µM; plasma concentrations observed in 
patients with ESRD) or DDAH1 inhibitor, L257 (100µM) altered this effect. 
Treatment with 5ng/mL TGF! produced significant phenotypic changes 
in NHPSTs at 96 hours with E-cadherin suppression (32%; p<0.05) and 
"SMA stimulation (53%; p<0.05) suggesting differentiation from an epithelial 
cell phenotype to mesenchymal (or myofibroblastic). No additional effect was 
seen with either ADMA or DDAH1 inhibitor treatment (Figure 75). 
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Figure 75. The effect of TGF! upon NHPST differentiation at 96 hours 
Using Western blotting analysis, a significant effect of TGF! upon NHPST differentiation was 
observed with no added effect of ADMA or DDAH1 inhibitor. A and B: loss of E-cadherin 
expression. Control vs TGF!; A, 0.91 vs 0.67 AU (95% CIs -0.61-2.44 and -0.19-1.53; 
p<0.05), B, 0.79 vs 0.48 AU (95% CIs 0.25-1.33 and 0.22-0.74; p<0.05). C and D: gain of 
"SMA expression. Control vs TGF!; C, 0.94 vs 1.92 AU (95% CIs -0.49-2.38 and 1.3-2.46; 
p<0.05), D, 0.29 vs 0.62 AU (95% CIs 0.09-0.49 and -0.97-2.21); p>0.05). E, Representative 
Western blot. Concentrations used; TGF! 5ng/mL, ADMA 3µM, DDAH1 inhibitor (L257) 
100µM. Results indicative of n=3 individual experiments. 4 wells per experiment. One-way 
ANOVA with Bonferroni’s post test. *p<0.05, **p<0.01. 
 
10.4.2 Proliferation: NHPSTs 
Proliferation in response to serum feeding (10%) (after 48 hours of serum-
starving) was measured using two methods; a scratch wound assay and 
Bromodeoxyuridine (BrdU) assay (see Methods). Cells treated with FCS grew 
 
Control   TGF!     ADMA3  TGF!+ ADMA3  
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>4-fold more than those in serum free media (p<0.001; Figure 76). ADMA 
treatment (3 and 10µM) reduced growth by ~35% (p<0.01) and DDAH1 
inhibitor L257 by 20% although this did not reach statistical significance. 
Mitomycin reduced growth by 63% (p<0.001). As mitomycin is a powerful 
inhibitor of proliferation, it suggests that growth of cells into the wound is 
largely proliferation rather than migration. 
 
 
Figure 76. The effect of ADMA and DDAH1 inhibition upon NHPST proliferation 
A, Representative images of the same scratch wound taken at the time of treatment (T0) and 
24 hours later (T24) reveal cellular growth into the space. B, Representative images of 
treatment groups following digital track pad demarcation. The filled (black areas) were 
quantified using Image J software and percentage growth calculated and plotted in C. 
Comparisons of FCS only vs other treatments. FCS vs serum free; 48.3 vs 11.3% (95% CI 
32.4-64.3 and 6.2-16.5); p<0.001. FCS vs ADMA; 3µM and 10µM both 32% (95% CIs 27.7-
36.3 and 9.6-54.4 respectively); p<0.01, and mitomycin 18%; p<0.001. Results indicative of 
n=3 individual experiments. 4 wells per experiment. One-way ANOVA with Bonferroni’s post 
test. **p<0.01, ***p<0.001. 
 
To confirm an inhibitory effect of ADMA upon NHPST proliferation, a 
second assay was used; a bromodeoxyuridine (BrdU) assay (Figure 77). This 
also provided further information in that the inhibitory response appeared to 
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be dose-dependent over a range of 1.0 - 10µM (p<0.001), and that the NOS-
inert methylarginine isoform SDMA had no effect (suggesting that the ADMA 
effect was through NOS inhibition). Similar to the scratch studies, DDAH1 
inhibitor L257 had a weak but statistically non-significant inhibitory effect on 
proliferation.  
Figure 77. BrdU assay in NHPST cells 
FCS only (black bar) vs FCS + other treatment comparisons. Linear trend across ADMA 
concentrations (horizontal bar). FCS only; 1.67 arbitrary units (AU, 95% CI 1.4-1.93) vs 
ADMA 1, 3 and 10µM; 1.12 (p<0.01), 0.96 (p<0.01) and 0.89 (p<0.001) respectively (95% 
CIs; 0.92-1.33; 0.86-1.07; 0.79-0.99); and for linear trend showing dose-dependent ADMA 
effects p<0.001. No significant difference with SDMA or DDAH1 inhibitor (L257) treatment. 
Results indicative of n=3 individual experiments. 8 wells per experiment. One-way ANOVA 
with Bonferroni’s multiple comparison test and post test for linear trend. **p<0.01 ***p<0.001. 
 
10.4.3 Proliferation: primary PTCs 
Studies in the NHPST cell line had confirmed an inhibitory effect of ADMA 
upon proliferation and it was desirable to confirm this in a culture of primary 
tubular cells. Renal tubules were isolated from mice (WT, C57B6 strain) as 
previously described and cultured in 96 well plates. 
In an effort to repeat the scratch wound assays, cultures of primary 
cells were attempted on numerous occasions in 6, 12 and 24 well plates with 
no success. The unresolved issue was that of patchy growth and a failure to 
reliably cultivate uniform cell monolayers necessary for the technique. For this 
reason, an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
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(4-sulfophenyl)-2H-tetrazolium) assay was used alongside the BrdU 
proliferation assay used previously. 
Results between the two assays were very similar; the dose-dependent 
inhibitory effect of ADMA upon proliferation seen in the cell line was confirmed 
(p<0.01) and furthermore, an inhibitory effect of DDAH1 inhibitor L257 seen 
only as a trend in the NHPST cell line, was found to be statistically significant 
(Figure 78; p<0.05). 
 
Figure 78. Proliferation assays in primary tubular cells 
FCS only (black bar) vs other treatment comparisons. Linear trends (horizontal bars) across 
ADMA concentrations. A, BrdU assay. FCS vs serum-free; 0.24 AU vs 0.13 (95% CIs 0.2-
0.29 and 0.11-0.15); p<0.001. ADMA 1, 3 and 10µM; 0.17, 0.16 and 0.12 (p<0.05) AU 
respectively (95% CIs 0.07-0.26; 0.08-0.21; 0.09-0.15); p<0.01 for linear trend showing dose-
dependent ADMA effects. FCS vs L257; 0.24 vs 0.14 AU (95% CI 0.07-0.22); p<0.05. B, MTS 
assay. FCS vs serum-free; 0.83 vs 0.54 AU (95% CIs 0.76-0.89 and 0.47-0.62); p<0.001. 
ADMA 1, 3 and 10µM; 0.79, 0.70 and 0.67 AU respectively (95% CIs 0.7-0.88; 0.58-0.81; 
0.57-0.77); p<0.01 for linear trend. FCS vs L257 0.83 vs 0.66 AU(95% CI 0.55-0.78); p<0.05. 
Results are indicative of n=4 individual experiments. 8 wells per experiment. One-way 
ANOVA with Bonferroni’s multiple comparison test and post test for linear trend. *p<0.05 
**p<0.01 ***p<0.001. 
 
10.4.4 Mitochondrial function in NHPSTs 
Proximal tubular (PT) cells are densely packed with mitochondria, allowing 
them to produce large quantities of ATP required to fulfil their energy-
demanding reabsorptive role. NO is known to influence mitochondrial function 
at many levels as discussed in Introduction Chapter 1.7.2.5. Both in vitro and 
in vivo studies presented in this thesis demonstrate significant ADMA-
dependent effects upon PT cell function. 
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It was hypothesised that ADMA reduces PT cell proliferation through 
disruption of mitochondrial respiration. 
To test this, the NHPST cell line was used to assess the effect of 
ADMA and the synthetic NO donor (SNAP) upon mitochondrial respiration 
using two in vitro approaches: 
1) Measurement of real-time aerobic and anaerobic respiration using the 
Seahorse XF Extracellular Flux Analyzer (Seahorse Bioscience, 
Copenhagen, Denmark).  
2) Measurement of intracellular adenosine mono-, di-, tri-phosphates by 
LCMSMS to calculate energy charge. NHPST cells were grown to 
confluence in 12-well plates and treated with ADMA (10 µM) and SNAP 
(100 µM). Each well was harvested in ice-cold perchloric acid (20%).  
 
10.4.4.1 Seahorse experiments 
This automated system quantifies the cellular respiration rate in basal and 
stressed conditions by using compounds to influence parts of the 
mitochondrial respiratory chain. NHPST cells were seeded to achieve 
confluence within 48 hours and cells were treated with ADMA 10 µM and NO 
donor (S-nitroso-N-acetyl-l,l-penicillamine, SNAP; 100 µM) for 24 and 48 
hours. 
Following ADMA treatment for 24 and 48 hours, basal oxygen 
consumption rate (OCR) significantly increased (~20%; p<0.05) whilst NO 
donor (SNAP) treatment caused a decrease (~40%; p<0.01) (Figure 
79A,B,E). These effects diminished during mitochondrial stress and there 
were no effects of ADMA or SNAP treatment upon anaerobic glycolysis (as 
measured by extracellular acidification rate (ECAR); Figure 79C,D).  
 
10.4.4.2 Energy charge 
The energy charge, or status of a cell can be determined by taking into 
account the relative abundances of ATP, ADP and AMP using the equation 
[242]: !"#$%&!!!!"#$ ! !!"#!! !!!!!!"#!!!!!!!"# ! !"# ! !"#!! 
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The normal baseline physiological range for the energy charge of a cell 
is 0.8-0.95. Lower values suggest higher metabolism, whilst higher values 
indicate lower metabolism as less ATP / ADP is being used for energy-
consuming functions. Using LCMS/MS, both ADP and AMP were optimised 
for reliable detection although this was not possible for ATP at the time of 
study (this has since been achieved). Therefore, an abbreviated version of the 
formula was used to determine energy charge (giving a lower normal range): 
 !"#$%&!!!!"#$ ! !"#!!"# ! !"#! 
 
When the energy charge was quantified in NHPST cells, treatment with 
ADMA significantly reduced the energy charge (13%; p<0.05), whilst SNAP 
treatment caused an increase (74%; p<0.001) (Figure 79F).  
 
10.5 Discussion 
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Figure 79. Mitochondrial function in NHPSTs 
Media and compounds (1-4) were added sequentially to modulate mitochondrial function and 
their effect on oxygen consumption rate (OCR) was measured. (1) control medium; (2) 
oligomycin to inhibit ATP synthase; (3) FCCP (carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone), an uncoupler to short-circuit the proton circuit and allow maximal 
respiration; (4) rotenone to inhibit total mitochondrial respiration. Production of lactic acid 
(hydrogen ions; extracellular acidification rate (ECAR)) was also measured to quantify 
anaerobic glycolysis. A and B, following 24 and 48 hrs of treatment, consistent trends were 
observed for increased basal OCR with ADMA treatment (the difference was subsequently 
lost following the addition of compounds 2-3). Consistently, a decrease in OCR was seen with 
SNAP (NO donor) treatment. Although these differences did not reach statistical significance 
according to two-way ANOVA testing, focussed analysis of basal OCR (E) revealed 
significant effects of ADMA (46.6 pM/min; 95% CI 40-53.2; p<0.05) and SNAP (23.1 pM/min; 
95% CI 16.6-29.1; p<0.01) when compared to control (38.4 pM/min; 95% CI 34.9-41.9). F, in 
separate in vitro studies, LCMS/MS quantification of ADP and AMP in NHPST cells treated 
with ADMA and SNAP produced a significant decrease and increase respectively, in cellular 
energy charge; Control 0.39 AU (95% CI 0.35-0.43) vs ADMA 0.34 AU (95% CI 0.32-0.36; 
p<0.05) and SNAP 0.68 AU (95% CI 0.65-0.72; p<0.001). One-way ANOVA with Bonferroni’s 
post test. All n=4 (6 wells per group per experiment). *p<0.05 **p<0.01 ***p<0.001. 
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10.5.1 Renal tubule isolation 
10.5.1.1 Tubular purity and protein characterisation 
In this study, the magnetic bead perfusion technique for separating and 
purifying fractions of tubules was successful, achieving degrees of purity (80-
99%) similar to previously published reports [236, 243]. Assessments of 
tubule purity were made according to relative expressions of proteins specific 
to epithelial (E-cadherin and pancytokeratin) or glomerular mesangial cells 
and myofibroblasts (!SMA). In the case of primary cell culture, the media 
composition positively selected epithelial cell growth thereby suppressing the 
growth of any non-tubular cells. 
Highly tubule-specific DDAH1 and AGXT2 expression demonstrated 
here is not only consistent with previous reports [70, 98, 99], but suggests 
limited contamination of tubular fractions by other renal cell types. There 
remains uncertainty as to the nature and site of iNOS expression in the 
kidney. Some investigators have been unable to detect iNOS in untreated 
human, rat or mouse kidney tissue [244], whilst others have identified iNOS 
expression at various points along the tubule in basal conditions [71] and in 
the glomerulus during acute inflammation [245]. Interestingly in these studies, 
iNOS mRNA transcription was detected and predominant in the glomerular 
fraction (99%) and barely detectable in tubular fractions. This may represent 
glomerular disruption and induced iNOS expression resulting from mechanical 
trauma during the extraction process. In addition, much of the renal iNOS 
expression data derives from rat studies [70] [[246] and may reflect 
differences between species. 
 
10.5.1.2 Proximal tubule purity 
Using this method, isolated tubular fragments pertain to different regions of 
the entire nephron – not solely the proximal region. Attempts were made to 
quantify proximal tubule cells using FACS analysis (with Aquaporin 1 and 
Megalin antibodies) without success, largely due to difficulties in liberating 
single cell suspensions from tubular fragments. However, the majority of 
kidney mass is composed of proximal tubule and in studies using 
stereological histology, the estimated proportion of total kidney mass was 
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approximately 65% [191]. The remaining components (connective tissue, 
vasculature and glomeruli) are extracted through sieving and magnetic 
separation, which would result in proximal tubule purity far in excess of the 
initial 65%. In the instance of primary culture, media components positively 
select PT growth over other cell types thus increasing PT cell purity further 
still. 
10.5.2 ADMA inhibits PT cell proliferation 
The most prominent observation was that ADMA inhibited proliferation of 
NHPST and primary PT cells at concentrations comparable to those 
measured in the plasma of patients with CKD (1-10 µM). This is the first 
demonstration of ADMA inhibiting renal PT cell proliferation, however similar 
effects have been shown in cultured alveolar epithelial cells, in which both 
ADMA and a DDAH1 inhibitor (L291) inhibited proliferation and induced 
apoptosis [127]. The anti-proliferative effect of ADMA appears to be specific to 
the epithelial cell sub-type. Previously, investigators have reported that ADMA 
inhibits VEGF-induced motility in HUVECs but it did not alter endothelial cell 
proliferation [247]. In activated macrophages, ADMA inhibits migration and 
phagocytic function but similarly, proliferation was unaffected (Ahmetaj and 
Leiper, personal communication). 
Renal tubular cell de-differentiation and proliferation occurs following 
acute kidney injury [235]. Dysregulation of these processes has been 
implicated in the pathogenesis of the ensuing chronic and progressive fibrosis 
[248]. Supporting folate nephropathy as a model that is representative of 
human renal disease, tubular epithelial cell de-differentiation and proliferation 
has been observed following experimental folate administration in mice [249, 
250]. In the studies presented here, ADMA inhibits tubular cell proliferation in 
vitro. In mice with PT-specific DDAH1 gene disruption, tubular cell ADMA was 
elevated and consequently, were found to be protected from progressive renal 
fibrosis at 12 weeks following folate injury. Taken together, these findings 
indicate that tubular ADMA may confer protection against fibrosis through 
limiting the pathological proliferation that can ensue following acute kidney 
injury. Further studies, such as comparing the transcription or protein 
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expression of proliferating cell nuclear antigen (PCNA) in KC- and KC+ 
(PTD1KO) mice would be useful to confirm this.  
Tubular cell apoptosis is critical to renal tubule responses in acute 
injury and the transition to chronic fibrosis [248]. The folate nephropathy 
model of renal disease has been shown to manifest tubular apoptosis in 
experimental mice [250, 251]. Some preliminary in vitro studies were 
designed to investigate the effects of ADMA in TGF!-induced apoptosis with 
limited success (data not shown); largely due to inadequate caspase 3 
induction and/or detection using Western blotting. Further in vitro studies 
would be useful to further investigate this, along with supportive data of kidney 
caspase induction from in vivo studies presented in Chapter 9. 
10.5.3 ADMA alters mitochondrial respiration 
These data demonstrate that ADMA increases OCR and decreases cellular 
energy charge in NHPSTs. Logically, NO donor SNAP had the opposite 
effect. This is consistent with the current dogma suggesting NO inhibits 
mitochondrial respiration by binding to cytochrome c oxidase [252]. 
Given that ADMA-treatment increased PT cell oxygen expenditure but 
reduced energy charge, an uncoupling effect of ADMA upon mitochondrial 
ATP generation is suggested. A previous study of hepatic mitochondrial 
dysfunction in diabetic rats demonstrated that ADMA caused mitochondrial 
dysfunction, reduced ATP with evidence of increased oxidative stress. These 
findings were replicated in hepatocyte in vitro experiments along with 
enhanced transcription of uncoupling protein 2 (UCP2) [253]. The uncoupling 
of mitochondrial function may underlie the effect of ADMA treatment inhibiting 
PT cell proliferation and potentially, explain some of the effects seen on 
tubular reabsorptive function, which clearly require further study to confirm. 
10.5.4 Limitations 
10.5.4.1 Quantifying PTC purity 
Prior to adopting the magnetic bead technique, a number of different 
approaches for renal tubule purification were attempted, involving multiple 
sieving steps or Percoll centrifugation to separate fractions [254, 255]. 
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Magnetic bead perfusion was by far the most successful, but despite almost 
complete separation of glomeruli from tubules, the purity of proximal 
segments was difficult to quantify. As discussed previously, attempts at using 
FACS analysis of tubular fractions failed, however an alternative approach 
could involve growing the PTCs out in culture first, to generate a cell 
monolayer from which it is easier to gain a single cell suspension. Subsequent 
incubation with antibodies against PTC-specific (Megalin, Aquaporin 1) and 
non-PT proteins (NCC and Aquaporin 2; characteristic of distal tubule and 
collecting duct) prior to FACS analysis would give quantitative data on purity. 
A consideration for this strategy however, is the phenotypic changes invoked 
in cells that are taken out of their normal environment altering characteristic 
protein expression, such as reduced megalin production for example. 
 
10.5.4.2 Mitochondrial metabolism 
Results of the investigation into effects of ADMA upon mitochondrial activity 
were intriguing, however they are only preliminary, requiring further study 
before conclusions can be drawn. A limitation to Seahorse analysis is the 
requirement for a uniform cell monolayer – something that can be achieved in 
the NHPST cell line but not in primary PTCs. This obviously precludes primary 
cells from being used to replicate and support effects seen in the cell line. 
At the time of study, LCMS/MS detection of adenosine phosphates was 
not fully optimised, with ADP detection being sub-optimal and ATP detection 
completely absent. Although the results presented here were robust and 
reproducible, they require repeating now that detection of all three subtypes 
has subsequently been optimised. Furthermore, demonstrating a dose 
response relationship of ADMA and SNAP would add further strength to these 
findings, plus an investigation into UCP mRNA transcription (using RT-qPCR) 
would help to confirm or refute the hypothesis of an uncoupling effect of 
ADMA. 
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11 THE ROLE OF DDAH2 IN AKI 
This project was run in parallel to, and independent of the renal DDAH1 
studies.  
11.1 Introduction 
The second DDAH isoform (DDAH2) was identified a decade after DDAH1 
[101, 256] and has been much more difficult to characterise. Data from 
transgenic overexpression experiments suggest that DDAH2 can have a 
lowering effect on circulating ADMA, however demonstration of its activity in 
humans has been difficult to detect. Technical difficulties in producing a 
soluble, active recombinant DDAH2 protein have halted enzyme 
characterisation studies and prevented screening of compounds that may 
enhance or inhibit activity. Studies investigating rodent overexpression [124] 
or human polymorphisms of DDAH2 [257] suggest that DDAH2 can determine 
plasma ADMA concentrations. Both DDAH isoforms are strongly expressed in 
visceral organs including the liver, kidney and pancreas but distinct 
expression patterns exist in other tissues, with high DDAH2 expression often 
co-localising with eNOS in vascular endothelium, heart, lung, placenta and 
most exclusively, in immune cells [102]. 
11.1.1 DDAH2 in macrophage activation and disease 
Recent observations within our group identify DDAH2 as a critical 
enzyme in macrophage-driven inflammation. Both DDAH2 gene deletion and 
exogenous ADMA, inhibit macrophage migration and phagocytic burst activity 
(unpublished, Ahmetaj and Leiper), whilst global DDAH2 gene deletion 
appears to protect against joint inflammation in a rodent model of rheumatoid 
arthritis (unpublished, Leiper). To date, the effect of DDAH2 gene 
overexpression or deletion in inflammatory disease has not been reported 
although DDAH2 overexpression in mice appears to reduce ADMA-induced 
vascular oxidative stress and hypertension [124].  
Macrophage activation and infiltration are prominent features of various 
experimental models of renal disease including; ischaemia [258], 
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glomerulonephritis [259] and folate nephropathy [224, 250]. Furthermore, 
studies presented in this thesis (Chapter 8.3.5) identified a 3-fold increase in 
kidney tissue DDAH2 transcription at 2 and 12 weeks following folate injury; 
which likely represents macrophage activation and infiltration. 
11.1.2 Hypothesis 
Given the evidence for the contribution of DDAH2 in macrophage 
activation and inflammatory disease, we tested the hypothesis that DDAH2 
null (knock-out; KO) mice would be protected from acute renal inflammation. 
11.2 Nephrotoxic nephritis model 
The nephrotoxic nephritis (NTN) model of disease was originally selected to 
test the hypothesis. As glomerular and interstitial macrophage infiltration is a 
hallmark feature of the NTN model [260], it seemed an ideal method to use. 
The model was performed with assistance and nephrotoxic serum provided by 
Dr Ruth Tarzi, Imperial College, London, and is described in detail in the 
Methods chapter. 
A pilot experiment involved 5 female DDAH2 KO mice and WT 
littermate controls aged between 8-12 weeks. 7 days following pre-
immunisation, 5mg of nephrotoxic serum (NTS) was administered via the tail 
vein and mice were checked daily for 10 days until sacrifice and tissue 
harvesting. Mortality was higher in the WT group (3 of 5) than the DDAH2 KO 
group (1 of 5). Although the small remaining numbers made statistical testing 
impossible, histological findings were promising – revealing more severe 
disease in WT kidney tissue (Figure 80). 
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Figure 80. Representative kidney PAS-stained histology following NTN induction 
(A) WT tissue revealed tubule dilatation (TD), some with luminal casts, tubular cell flattening 
and evidence of glomerular crescents (arrow, bottom left). (B) DDAH2 KO tissue appeared 
unaffected. Representative of 2 in the WT group, 4 in the DDAH2 KO group. Bars = 50 µm. 
The model was repeated using 10 mice in each group and, given the 
unacceptable mortality experienced in the pilot experiment, the interval 
between pre-immunisation and NTS administration was reduced from 7 to 5 
days. The second experiment caused no mortality but also failed to produce 
any significant disease according to histological appearances. A third 
experiment was performed, again using 10 mice in each group but this time 
using a new batch of NTS at an increased dose of 10mg (from 5mg). Yet 
again, this failed to produce significant disease according to histology. 
At this point, the NTN model was abandoned due to such variable 
disease – a finding previously reported by others [221]. Results in parallel 
studies using folate nephropathy as a model of CKD suggested that it yielded 
much more reproducible disease and that it could also be used to model the 
acute phase of renal inflammation. 
11.3 Study design 
Female mice, both DDAH2-/- and WT littermates (8 - 10 weeks old) were 
treated with a single IP dose of folate as previously described. To illustrate the 
dose-sensitivity of different strains, these mice developed significant disease 
at a lower dose of 180 µg/g (240 µg/g in the PTD1KO strain). Mice were 
culled 2 days later and tissues harvested. Baseline urine and post treatment 
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plasma and kidney tissue were collected and stored at -80°C. The experiment 
was repeated four times in total with 5-12 in each treatment group. 
11.4 Results 
11.4.1 Baseline plasma and urine MA concentrations 
Plasma MA concentrations did not differ between WT and D2KO mice at 
baseline whereas in urine, levels were significantly higher in D2KOs; L-NMMA 
>4-fold (p<0.05) and ADMA >2-fold (p<0.001; Figure 81).  
 
Figure 81. Plasma and urine MA concentrations 
(A) No differences in plasma MA levels were observed. (B) Urinary MA concentrations were 
significantly higher in D2KO mice. WT vs D2KO; L-NMMA, 0.077 vs 0.338 µM (95% CIs 0.04-
0.11 and 0.15-0.52 respectively), p<0.05; ADMA, 18.8 vs 44.4 µM (95% CIs 12.7-24.9 and 
37.1-51.8), p<0.001. Mann-Whitney U test, n=7 (WT) and 11 (D2KO). *p<0.05 ***p<0.001. 
 
11.4.2 Renal gene expression 
As anticipated, DDAH2 mRNA expression in kidney tissue from D2KOs was 
absent whereas in WT mice, it doubled at day 2 post folate treatment (p<0.01; 
Figure 82A). Additionally at 2 days, induced expression of acute inflammatory 
cytokines (iNOS, TNF! and IL1") was significantly lower in D2KO renal tissue 
and measurement of urinary NOx suggested that renal NO activity was also 
reduced (Figure 82).   
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Figure 82. Renal tissue gene expression and urinary NOx; 2 days post folate 
(A) DDAH2 mRNA expression was detected at levels 50-fold lower in D2KO mouse kidney 
tissue and deemed insignificant (95% CI 0.004-0.045AU). Folate treatment increased renal 
DDAH2 expression in WT mice from 0.95 to 1.94 AU (95% CIs 0.89-1 and 1.47-2.4; p<0.01). 
(B) urinary NOx was reduced in D2KO mice; WT vs D2KO, 1.4 vs 0.59 mM (95% CIs -0.49-
3.29 and 0.33-0.84; p<0.05). Cytokine expression was also reduced with the exception of IL6; 
(C) iNOS, 35.1 vs 1.97 AU (95% CIs 5.8-64.3 and 1.0-2.9; p<0.001); (D) TNF!, 14.9 vs 0.48 
AU (95% CIs -3.1-32.9 and 0.27-0.69; p<0.01); (E) IL1", 2.05 vs 0.67 AU (95% CIs -1.5-5.6 
and 0.46-0.88; p<0.05); (F) IL-6 transcription was not significantly different. n=7 (WT) and 11 
(D2KO). WT comparisons in folate vs vehicle-treated groups (A); two-way ANOVA with 
Bonferroni’s post test, **p<0.01. WT vs D2KO comparisons (B-F); Mann-Whitney U test. 
*p<0.05 **p<0.01 ***p<0.001. 
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11.4.3 Macrophage recruitment 
Immunohistochemistry using a Mac-2 antibody revealed significantly more 
macrophages in WT mouse renal tissue than D2KOs at 2 days following folate 
administration (14 vs 5; p<0.01; Figure 83).  
 
 
Figure 83. Renal macrophage recruitment at 2 days post folate 
(A) WT vs D2KOs, 14.2 vs 5.2 (95% CIs 3.5-25 and 2.9-7.6; p<0.01). Representative kidney 
tissue images from (B) WT mice showing evidence of macrophage infiltration (arrows) with 
significantly lower numbers observed in renal tissue taken from D2KO mice (C). Sections 
stained with anti-Mac-2 antibody (Abcam). Means derived from counts within 4 randomly 
selected cortex fields for each section. Values verified by a second independent blinded 
observer. n=4 (WT), n=10 (D2KO). Mann Whitney U test. *p<0.05. 
 
11.4.4 Plasma creatinine and mortality 
Renal function according to plasma creatinine was preserved in D2KO and 
significantly elevated in WT mice at 2 days following folate administration 
(p<0.01), In the initial study, overall mortality was 43% in WT and only 9% in 
D2KO mice (Figure 84). 
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Figure 84. Plasma creatinine and mortality 
(A) Plasma creatinine was significantly elevated from baseline in WT and not in D2KO mice; 
WT vs D2KO, 125.1 vs 26.5 µM (95% CIs 63.7-186.5 and 16.4-36.6; p<0.01). (B) In a pilot 
study using 240µg/g of folate, mortality was 43% compared to only 9% in D2KO n=4 (WT), 
n=10 (D2KO). The folate dose was reduced to 180µg/g for subsequent experiments to reduce 
mortality and allow the experiment to run to term (2 days). n=7 (WT) and 11 (D2KO). Mann-
Whitney U test. **p<0.01. 
11.5 Discussion 
 
 
In this folate model of AKI, DDAH2 null mice were protected against renal 
macrophage infiltration, cytokine expression and decline in renal function 
according to serum creatinine. Furthermore, in an initial study using a higher 
240µg/g dose, mortality was 34% lower in DDAH2 deficient mice (for 
subsequent experiments, 180 µg/g was used). 
This is the first such study to demonstrate a role of DDAH2 in renal 
inflammation and is consistent with previous observations made by our group 
in studies of macrophage function and rheumatoid arthritis. Evidence 
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suggests that the effect of DDAH2 is mediated through NO regulation. 
Through comprehensive in vitro studies of macrophages taken from WT, 
macrophage-specific and global DDAH2 KO mice, Dr Ahmetaj (Leiper group) 
demonstrated that NO synthesis was reduced in DDAH2 KO strains when 
stimulated with an inflammatory cocktail (LPS, TNF!, IFN"). The addition of 
iNOS inhibitor 1400W almost completely abrogated nitrite production 
suggesting that DDAH2 activity is required for complete iNOS activation 
during inflammation (Figure 85). 
 
Figure 85. Macrophage NO activity in response to LPS stimulation 
NO activity according to nitrite production. ddah2 +/+, WT; ddah2 m-/-, macrophage-specific 
DDAH2 KO; ddah2 -/-, global DDAH2 KO; 1400W, iNOS inhibitor. Comparisons between 
DDAH2 +/+ and other genotypes. One way ANOVA, *p<0.05. Courtesy of Dr B Ahmetaj, 
MRC, London. 
 
In this folate model of AKI, urinary NOx was also reduced in DDAH2 
KO mice in support of the protective effect against inflammation manifesting 
through reduced NO synthesis. 
A requirement for tonic NO activity to achieve iNOS activation has 
been described elsewhere [261]. Organ bath studies of rat aortic rings 
denuded of endothelium and hence eNOS activity, were resistant to iNOS 
activation (within the medial layer) in response to LPS stimulation. A similar 
phenomenon may explain the findings in DDAH2 KO mice. Increased ADMA 
in the macrophages of DDAH2 null mice would suppress basal NO production 
and subsequently, limit iNOS activation in response to inflammatory stimuli. 
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Using non-selective pharmacological NOS inhibition (L-NMMA) to 
reduce the deleterious effects of NO activity in human sepsis, unfortunately 
increased mortality in clinical trials [75]. This indicates that therapeutic non-
selective NO reduction is unlikely to be of benefit and therapies are required 
to effect a targeted manipulation of the NO signalling pathway. DDAH2 is 
expressed across specific cell types and represents a target for selective 
pharmacological inhibition of NO production, theoretically providing clinical 
benefit of reduced inflammation but tolerable side effects. At present, a 
specific DDAH2 inhibitor is not available for use – largely due to the current 
technical limitations in producing a soluble recombinant DDAH2 protein 
required for enzyme kinetic and screening studies. Encouragingly however, 
selective inhibitors of DDAH1 have been developed and show therapeutic 
promise in protecting against circulatory collapse seen in bacterial sepsis 
[262]. This indicates that a selective inhibitor of the second DDAH isoform is 
not an unrealistic expectation.  
11.5.1 Limitations 
An obvious limitation to this study is the use of folate nephropathy to model 
AKI. Renal folate toxicity does not occur in humans and therefore the 
relevance of the model relies upon comparisons made between this and 
forms of tubulointerstitial renal disease seen in patients such as drug toxicity 
(cisplatin, aminoglycoside or ethylene glycol) or multiple myeloma 
(characterised by casts within tubular lumina causing obstruction with 
interstitial inflammation). Similar to folate nephropathy and these human 
conditions of acute tubular necrosis (ATN) are histological features including; 
tubular casts and dilatation with epithelial cell flattening; inflammatory cell 
infiltrates and disruption of normal cortical architecture. Folate nephropathy 
has previously been recognised as an experimental model of AKI [263] and 
like any other model of human disease, results have to be considered in the 
context of disease- and species-related limitations. 
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11.5.2 Further work 
Further studies will be useful to confirm a protective effect of DDAH2 
abrogation in inflammatory disease is a) effected through macrophages and 
their activation, and b) replicable in other forms of renal inflammation and 
species. Macrophage-specific DDAH2 KO mice have previously been created 
and characterised by Dr Ahmetaj within our own group (unpublished; under 
the LysMCre promoter [264]). Repeating a folate model of AKI or perhaps an 
alternative injury, such as ischaemia-reperfusion in this mouse strain would 
determine whether the protective effect of DDAH2 abrogation is conferred 
through effects on the macrophage cell type.  
As discussed above, the nephrotoxic nephritis (NTN) model is highly 
variable in the mouse. In the rat however, NTN is an established model of 
crescentic glomerulonephritis and is much more reproducible [265]. Additional 
advantages of working with the rat in preference to the mouse exist in terms 
of handling, administering compounds, obtaining plasma and urine along with 
the relative ease in performing surgical procedures. For these reasons, 
creation of a global DDAH2 gene KO rat would be a valuable resource for 
developing the findings made in these preliminary studies. 
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12 SUMMARY AND CONCLUSION 
 
The overall aim of this thesis was to test the hypothesis: “Reduced renal 
DDAH1 activity protects against kidney function decline”. To achieve this, a 
novel transgenic mouse was generated and characterised before subjecting it 
to a folate model of CKD. Supportive in vivo microperfusion and in vitro 
studies provided mechanistic data evaluating the direct effect of ADMA upon 
proximal tubular cell function. 
12.1 Development of the PTD1KO mouse 
A large proportion of this thesis focussed upon the generation and 
characterisation of a proximal-tubule specific DDAH1 knock-out mouse 
(PTD1KO). Given that the PT cell is the principal renal cell-type to express 
DDAH1 and plays key roles in CKD progression, this transgenic strain was 
vital in testing the original hypothesis.  
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Experiments in Chapter 4 demonstrate that the KC construct confers 
PT specificity in the YFP reporter and PTD1KO mouse. Although KC activity 
was detected in the liver and brain, DDAH1 expression was not significantly 
reduced in these organs so however doubtful their influence over fibrosis in 
distant organs such as the kidney, it was even less likely to confound 
experiment results. Consequently, tubular-specific effects of PTD1KO upon 
reduction of ADMA and NO synthesis were confirmed, whilst levels in plasma, 
urine and even whole kidney were unaffected. Such cell-specific manipulation 
of DDAH1 has not been reported previously and for this study, provides clear 
advantages over previously developed models that exhibit global gene 
disruption [105, 119, 266, 267]. 
12.1.1 Influence of gender in mouse studies 
The use of only female mice may have impacted upon the outcomes in salt 
feeding and folate nephropathy experiments. Gender-related effects upon 
kidney disease have been reported in both humans and mice [268]. Female 
mice have previously been demonstrated to manifest significant acute and 
chronic renal disease in response to folate administration [175].  Female mice 
appear to be protected in other experimental disease models of metabolic and 
cardiovascular disease [269], but appear to suffer more adverse outcomes in 
autoimmune disease models [270] (personal communication for Dr Ruth 
Tarzi, Imperial College, London; mouse nephrotoxic nephritis model). In 
cardiovascular and renal disease, gender differences are thought to reflect the 
androgen-oestrogen axis [207]. For this study, it is difficult to anticipate the 
overall contrasting effects of exogenous testosterone in female mice, however 
this has to be considered when interpreting the results.  
12.2 Limited biochemical effects of PTD1KO 
Despite data confirming successful disruption of PT-specific NO-ADMA-DDAH 
axis in vivo, biochemical evidence of disrupted PT reabsorption in PTD1KOs 
was lacking. The effects of NO signalling over mitochondrial activity and PT 
reabsorptive function are well described and therefore, a phenotype was 
anticipated to resemble Fanconi’s syndrome; a condition of PT cell 
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dysfunction manifesting inadequate reabsorption of glucose, electrolytes and 
amino acids [271, 272]. A non-significant but reproducible trend for lower 
systolic BPs in PTD1KO mice was observed along with elevated urinary 
amino acids, glucose and lactate. This indicated a possible Fanconi-like 
effect, however due to the high variability in urinary data, any differences 
according to genotype were rendered statistically insignificant. 
The limitations of urine biochemistry profiling are discussed at the end 
of individual chapters 5 and 6, and pertain to issues surrounding 
contamination of urine collected in metabolic cages. Further still, the effects of 
testosterone upon body weight, urinary volumes, creatinine and proteinuria 
confound results; altogether making small effects of PTD1KO upon tubular 
function impossible to confirm using these methods. 
In addition, the design of some experiments in terms of time intervals 
may have limited observed effects. For example in the salt-feeding studies, 8 
days’ of salt-feeding may not be long enough to manifest physiological effects. 
Consistent with this, a trend for increased systemic BP was observed in the 
high salt groups, although this did not reach statistical significance. Further 
studies would be undertaken to optimise the salt exposure through higher 
concentrations and extended time periods beyond 2 weeks. 
12.2.1 Limitations of testosterone use 
As previously discussed (Chapters 5 and 9), the confounding effects of 
testosterone cannot be overlooked. The effects seen in these studies, 
including total body weight gain, kidney hypertrophy, proteinuria and after 
long-term exposure, increased systemic BP have all been reported with 
exogenous testosterone use previously [190, 205, 226]. The renal tubule is 
known to be hormone sensitive [185], which is an insurmountable issue that 
needs to be considered here in the use of KAPiCre as a means of achieving 
transgenic PT cell selectivity. For this reason, key comparisons to isolate the 
effects of DDAH1 deletion were made between two groups, both treated with 
testosterone (T+KC- and T+KC+). 
Alternative transgenic constructs to target the PT cell are available but 
fail to offer significant advantages over the KAPiCre construct. A PT-specific 
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Cre using a tamoxifen-responsive element driven by a promoter fragment of 
the (PT-specific) gamma-glutamyl transpeptidase type II gene has been used 
[273]. Since tamoxifen is an oestrogen receptor antagonist and oestrogens 
are reported to reduce circulating ADMA [229], this construct would not be 
free of confounding effects. Others have targeted the Na+/H+ exchanger to 
achieve PT cell gene disruption, but this also has profound effects upon fluid 
and electrolyte flux across the gastrointestinal mucosa where it is also 
expressed [274]. 
12.3 Urinary proteomics – an alternative approach 
Urinary profiling using a proteomic approach was much more fruitful, 
identifying 84 significantly altered peptides out of a total of 1437 measured. 
Explanations as to why this type of analysis unveiled significant differences 
whilst biochemical profiling did not, arise from the aforementioned issue of 
contaminated urine collections. Many of the peptides identified in the 
proteomic study are specific to plasma (albumin) or even urine (UMOD, 
MUPs, KAP) and not present in mouse chow, water or faeces. Their presence 
therefore, is likely to reflect true content as opposed to detection of 
contaminating salts for example – an inherent problem in the biochemical 
assays. 
A screening approach such as this is useful for hypothesis-generation, 
and despite the majority of identified peptides originating from proteins of 
unknown or uncertain function, has identified far-reaching downstream effects 
of tubular DDAH1 deletion. Intriguingly, UMOD and Col1a1 were the two most 
significantly down-regulated peptides in PTD1KO mouse urine, which may 
represent particular significance in the context of progressive renal fibrosis, as 
discussed in more detail below. 
An observation worthy of mention is the detection of urinary albumin 
peptide. Although clinical dogma implies that the glomerulus is impermeable 
to albumin, microperfusion studies in normal rats confirm quantities exist in 
the ultrafiltrate (20-30µg/mL) but are almost completely reabsorbed through 
endocytosis within the PT - hence albumin is not usually found in urine [275]. 
Recently, testosterone has been shown to directly increase albuminuria in 
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mice [205]. The two groups compared in the urinary proteomic study (KC- and 
KC+ or PTD1KO) were both treated with testosterone and while each had 
significantly elevated proteinuria over testosterone-naïve controls, PTD1KO 
mice had almost 6-fold less albumin peptide in the urine. Albuminuria can 
result from hypertensive glomerular injury as witnessed by mice exposed to 
testosterone for 12 weeks, however these mice were normotensive after only 
~10 days of treatment, thus making a direct inhibitory effect of testosterone 
over PT endocytic reabsorption much more likely as the cause of urinary 
albumin leak. The 6-fold reduction in PTD1KO mice indicates that DDAH1 
deletion in part, reverses or compensates for testosterone-dependent 
endocytic dysregulation, in the PT; providing further evidence that DDAH1 
influences PT reabsorption. 
12.4 PTD1KO mice are protected from renal fibrosis and 
functional decline 
The severity of renal fibrosis is the most valuable predictor of functional 
decline in human CKD [225]. Data presented in Chapter 9 indicate that 
PTD1KO protects against renal fibrosis at 12 weeks following folate injury. 
Furthermore, secondary outcomes of disease included lower proteinuria, 
systolic BP, serum creatinine and renal tissue pro-fibrotic cytokine expression 
(TGF! and Col12"). Together, these data form a convincing argument for 
PTD1KO limiting kidney fibrosis and functional decline but they do not reveal 
the mechanism(s) through which this occurs. 
12.5 Proposed mechanisms of protection against fibrosis 
12.5.1 ADMA inhibits PTC proliferation 
In vitro studies presented in Chapter 10 demonstrate that ADMA inhibits PTC 
proliferation. Taken in isolation, this can be interpreted in either direction: that 
ADMA reduces normal proliferative responses to injury (and therefore 
harmful), or that it limits pathological, unmeasured proliferation that persists in 
CKD (and therefore beneficial). In the context of results from the folate 
nephropathy model in PTD1KO mice, one can postulate the latter to be true, 
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that PT DDAH1 disruption protects against destructive PT cell proliferation, 
deposition of interstitial collagen deposition and ultimately, preserves kidney 
function. Indeed, the same protective effect of pharmacological DDAH1 
knock-down in a rodent model of pulmonary fibrosis has been previously 
reported, where proliferation of primary alveolar epithelial cells was inhibited 
by a selective DDAH1 inhibitor (L291) whilst rodents overexpressing DDAH1 
had more severe pulmonary fibrosis following bleomycin injury [127].  
Furthermore, preliminary data presented here suggests an uncoupling 
effect of ADMA upon mitochondrial respiration, which could underlie the 
suppressed proliferative capacity of PT cells and altered reabsorptive 
function, however this requires confirmation with further study.  
12.5.2 ADMA inhibits PTC reabsorption 
Microperfusion studies found that both ADMA and synthetic non-selective 
NOS inhibitor L-NAME, inhibited PTC sodium and water reabsorption (Jv) 
when perfused directly into the tubular lumen. Furthermore, DDAH1 inhibitor 
(L257) reduced Jv, although this was required to be infused systemically for it 
to have an effect. Unfortunately similar effects were not replicated in 
microperfusion studies using the PTD1KO mouse (discussed in Chapter 7). 
If the effect of tubular ADMA is to selectively inhibit reabsorption of 
sodium and other molecules, this may provide the PTD1KO mouse with 
protection from renal fibrosis for a number of reasons. Like many ultra-filtered 
substances, folic acid is reabsorbed in the PT using specific folate-binding 
proteins expressed at the apical surface [276]. Supra-physiological 
concentrations of folate administered to mice in this model crystallise in the 
tubular lumen causing obstruction and possibly, direct cytotoxicity [277]. 
Inhibited reabsorption of folate and sodium (and therefore water) would thus 
protect PTD1KO mice from intracellular folate accumulation and even luminal 
crystallisation due to conservation of water within the ultrafiltrate. 
By inhibiting tubular reabsorption overall, ADMA may confer protection 
against fibrosis by lowering metabolic demands upon the PT, with reduced 
free radical production and subsequently, suppressed stimulation of pro-
inflammatory pathways. 
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Finally, ADMA inhibiting tubular reabsorption would also limit renal salt 
and water retention, suppress elevations in systemic BP and thus avoid a 
“second-hit” hypertensive renal injury. 
12.6 The role of UMOD in renal fibrosis and CKD 
Urinary proteomic data present alternative mechanisms of protection against 
renal fibrosis in PTD1KO mice. Urinary peptides Col1a1 and UMOD were 
lower in urine from PTD1KO mice at baseline (8.5- and 6.5-fold respectively). 
Collagen type 1 predominates in renal fibrosis [278]. Reduced production of 
collagen type 1 subunits by tubular cells and fibroblasts at baseline in 
PTD1KOs may be extended or even accentuated in a pro-inflammatory 
environment, thus conferring protection against tubulointerstitial fibrosis. 
More intriguing, is the reduction of urinary UMOD in PTD1KO mice. 
The immunomodulatory effects of UMOD have already been discussed in 
Chapter 5 but in summary, studies show considerable conflict as to whether 
UMOD behaves as a pro- or anti-inflammatory protein. Initial observations in 
humans are equally contentious. Rare monogenetic UMOD-related tubular 
diseases are characterized by defective urinary concentrating ability, low 
urinary UMOD levels, progressive tubulointerstitial fibrosis with UMOD 
aggregates visible within TAL epithelial cells suggesting defective protein 
transport [195]. However a recent review of UMOD biology identifies that; low 
urinary UMOD is often a feature in genetic disease; either low or high 
concentrations are demonstrated across an impressive array of renal 
conditions; but in established CKD, UMOD levels are elevated [279]. 
Genome-wide association studies (GWAS) support this and provide 
insights into the significance of urinary UMOD in a general population. A 
number of UMOD polymorphisms have been described to associate with 
hypertension, CKD and kidney function [195]. A recent case control study 
revealed that elevated urinary UMOD preceded the development of CKD over 
a ten-year follow-up. In addition, they identified a protective UMOD C allele 
that correlated with lower urinary UMOD levels in a dose-dependent manner 
[280]. 
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The correlation of reduced urinary UMOD with DDAH1 deletion in the 
PTD1KO mouse may represent an element of tubular dysfunction and 
impaired protein trafficking, although rather than pre-disposing to fibrosis as 
seen in UMOD-related genetic disease, it conferred protection against fibrosis 
in the folate experiment. These findings indicate that UMOD turnover (and 
perhaps TAL cell function) is strongly influenced by upstream DDAH1 activity 
and consistent with the GWAS data, UMOD contributes to kidney disease 
progression. 
12.6.1 Human evidence of an association between DDAH1 and UMOD  
Independent to this thesis, work undertaken by Dr Ben Caplin confirms an 
association between renal DDAH1 expression and urinary UMOD in a human 
renal transplant cohort (unpublished; UCL, London). Analysis of renal biopsy 
tissue and urine from recipients of live kidney transplant graft reveals a strong 
correlation between renal DDAH1 expression and urinary UMOD.  When 
extended to the whole cohort (live and deceased donors), the association was 
rendered insignificant. This likely reflects the heterogeneity of organs from 
deceased donors and relatively small sample number (Figure 86). 
The study described at the start of this thesis, implicating a DDAH1 
gene variant that associated with higher kidney tissue mRNA expression, 
lower circulating ADMA, and faster rate of progressive kidney function decline 
was also published by Dr Ben Caplin [281]. The in vivo work presented in this 
thesis supports his human cohort findings and taken together, indicate that 
renal DDAH1 activity and UMOD expression contribute to progressive renal 
function decline independent of circulating ADMA. 
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Figure 86. Relationship between DDAH1 gene expression and urinary UMOD in 
recipients of live donor transplants 
12.6.2 Conflict with published data: does DDAH1 prevent or cause disease? 
These human cohort and animal model studies are mutually supportive and 
suggest that renal DDAH1 activity exacerbates kidney function decline. On 
perfunctory examination, they stand in contrast to the wealth of human 
observational data indicating that elevated circulating ADMA exacerbates, 
whilst DDAH1 protects against, CV and renal disease [106, 108-111]. Even 
recently, reduced DDAH1 activity has been implicated in human disease 
through identification of loss-of-function DDAH1 polymorphisms that associate 
with elevated plasma ADMA and an increased risk of CV events [116, 117]. 
The critical issue to reconcile this controversy is that of tissue-
specificity. The majority of studies implicating ADMA in disease do so by 
reporting circulating ADMA, whereas here, focus upon ADMA levels within the 
kidney produces contrary results. The interpretation of associations found 
between plasma ADMA and disease is limited; in that risk factors for CV and 
renal disease are themselves reported to have relationships with plasma 
ADMA, so defining a direction of causation is confounded [91]. Using 
circulating ADMA as a marker of disease across specific tissue beds can 
therefore be misleading, as indeed suggested by a study exposing DDAH1 
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overexpressing mice to angiotensin II induced hypertension, which revealed 
variable hypertensive injury between the heart, vasculature and kidney [282]. 
Given the ubiquitous nature of NO signalling, it is plausible that 
competitive inhibition of NOS by ADMA can be both protective as well as 
destructive, determined by the disease conditions according to site, chronicity 
and magnitude of responses. It appears that at least in pulmonary [127], and 
now kidney fibrosis, reduced NO availability through DDAH1 disruption and 
elevated ADMA, is protective.  
12.6.3 Relevance to human disease 
12.6.3.1 Therapeutics 
Tissue-specificity, a major strength in this study, presents challenges to the 
direct transfer of results towards a therapy for CKD. Pharmacological DDAH1 
inhibition using compound L257 shows tissue selectivity and protection 
against circulatory collapse in a mouse model of bacterial sepsis [262]. The 
same study demonstrated that L257 inhibited NO production in LPS-treated 
aortic tissue but not macrophages. This reflects relative expression of DDAH1 
in vascular and macrophages (which do not express DDAH1), explaining the 
systemic BP benefit of both genetic and pharmacological DDAH1 inhibition 
during sepsis, whilst macrophage function is unaffected. 
Unfortunately, the pattern of DDAH1 expression cannot be exploited for 
the treatment of CKD. Chronic administration of L257 is likely to increase 
systemic blood pressure or at least, alter autoregulation of organ perfusion, 
which would clearly have a negative impact upon renal function and 
progressive fibrosis. Furthermore, acute kidney injury was not obviously 
attenuated in PTD1KO mice suggesting that timed or pulsed DDAH1 inhibition 
at an early stage of renal disease is equally unlikely to hold therapeutic 
promise. (As discussed in Chapter 11 however, such acute disruption of the 
DDAH2 isoform is an intriguing possibility). Indeed, unless targeted 
manipulation of the NO-ADMA-DDAH axis is achieved, many therapies are 
likely to fail as exhibited by previous human clinical trials in peripheral 
vascular disease [93] and bacterial sepsis [75], in which outcomes actually 
worsened with intervention. 
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Rather than proposing a direct therapeutic intervention for progressive 
renal fibrosis (CKD), this thesis provides important insights into the role of 
DDAH1 and ADMA in disease and serves as a caution to therapies aimed at 
non-selective ADMA reduction. Pharmacological agents already used for 
alternative indications have been shown to enhance DDAH1 activity and 
increased ADMA clearance. Rosiglitazone, an agent for the treatment of 
diabetes has been reported to help reduce plasma ADMA levels [283]. 
Additionally, a functional promoter element of Farnesoid X receptor exists 
within intron 1 of DDAH1 gene. When FXR agonists are administered to rats, 
DDAH1 transcription increases with subsequent reduction of plasma ADMA 
[284]. Furthermore, administration of an FXR agonist (INT-747) was also seen 
to reduce plasma ADMA and enhanced insulin sensitivity in Dahl-sensitive 
rats [285]. These findings have led investigators to propose potential benefits 
of enhancing DDAH1 activity to treat diseases that feature elevated ADMA, 
such as CV disease. Results from this body of work indicate that such an 
approach could have deleterious consequences, at least in the kidney. 
 
12.6.3.2 Risk stratification 
As previously discussed, genetic variants of DDAH1 can increase the risk of 
CV disease, determine BP responses to dietary salt and accelerate the 
progression of kidney function decline in CKD. As we are only just emerging 
into the post-genome era, personalised medicine according to genotype and 
even metabolic make-up is a far-off, yet attractive possibility [286]. Knowledge 
of an individual’s DDAH1 genotype or intra-renal activity for example, prior to 
renal transplantation or at the time of diagnosing CKD, would guide supportive 
therapies and improve longer-term outcomes. 
12.6.4 Further work 
A number of observations made in this thesis deserve further study. The 
transgenic PTD1KO mouse represents a valuable resource for investigating 
the effects of NO signalling in proximal tubular cells. Although initial 
microperfusion studies were disappointing in terms of demonstrating an effect 
of PTD1KO upon sodium and fluid reabsorption, the experimental design had 
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certain limitations and urinary proteomic studies suggested significant 
changes in tubular function. Future micropuncture experiments in PTD1KO 
mice would be of interest and should include; analysis of free flow tubular fluid 
(for MAs, NOx, amino acids and electrolytes), perfusion of different ATF 
compositions (electrolytes, amino acids, low molecular weight proteins) or 
compounds to profile the features of tubular reabsorption in PTD1KO mice. 
Furthermore, comparison with global DDAH1-/- mice would help to separate 
the local versus systemic effects that have been frequently emphasised in this 
thesis.  
The role of DDAH1 activity and ADMA in regulating PTC mitochondrial 
activity also represents a further avenue of investigation. Preliminary results 
indicate that ADMA uncouples mitochondrial respiration, which may represent 
the mechanism underlying inhibited PTC reabsorption or proliferation. In vitro 
studies using the NHPST cell line and primary PTCs from WT and PTD1KO 
mice would allow LCMS/MS analysis of adenosine phosphates and thus 
estimation of their energy charge. RT-qPCR analysis would also determine 
whether cellular respiration effectors such as uncoupling proteins (UCPs) are 
implicated in NO-dependent effects. 
The association of urinary UMOD with renal DDAH1 expression is 
intriguing, as both are reported to associate with renal function decline. 
Confirmation in both the PTD1KO mouse and a human renal transplant cohort 
suggest that this warrants further study with regard to; direct influence of NO 
and ADMA upon TAL cell UMOD production and handling; confirming the 
same association in larger cohorts of CKD patients; defining a urinary 
proteomic profile that could predict kidney function decline. 
12.7 Conclusion 
The overall aim of this thesis was to test the hypothesis: “Reduced renal 
DDAH1 activity protects against kidney function decline”. Using a novel 
transgenic mouse with proximal tubule-specific DDAH1 deletion, protection 
against renal fibrosis and functional decline was demonstrated in a folate 
model of chronic kidney disease. 
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Characterization studies of the PTD1KO mouse employed a variety of 
experimental techniques and provided novel insights into the role of renal 
DDAH1 activity in health and disease. Furthermore, collaborative in vivo 
studies involving microperfusion, and in vitro studies provided additional 
insights into the role of ADMA and DDAH1 regulating NO in the proximal 
tubule. 
 This work emphasizes the importance of considering local versus 
systemic ADMA and DDAH1 activity, along with the potential pitfalls of 
accepting circulating ADMA as a marker or therapeutic target in organ-specific 
disease.  
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15 APPENDIX 
LCMS/MS fragment detection data 
 
Compound Detector 
mode 
Intact m/z Fragment 
m/z 
Collision 
energy (CE) 
Retention 
time (RT; min) 
ADMA pos 203 46 12 2.1 
D7-ADMA pos 210 46 24 2.1 
SDMA pos 203 172 24 2.6 
LNMMA pos 189 70 24 1.8 
Arginine pos 175 60 8 1.2 
Citrulline pos 176 86 16 1.4 
Glutamine pos 147 56 0 1.5 
Creatinine pos 114 44 8 2.1 
AMP neg 348 136 6 2.5 
ADP neg 428 136 8 2.1 
Lactate neg 89 43 10 2.1 
 
 
Primer Sequences: genotyping 
Gene Forward Reverse 
DDAH1 floxed CCTCCCATTGCTAATGAAACGG TCAGTTGGAGTGTGAGTGAC 
DDAH2 CCTGGTGCCACACCTTTCC AGGGTGACATCAGAGAGCTTCTG 
KAPiCre AGATGCCAGGACATCAGGAACCTG ATCAGCCACACCAGACACAGAGAT 
ROSAYFP AAGACCGCGAAGAGTTTGTC AAAGTCGCTCTGAGTTGTTAT 
 
Primer Sequences: quantitative PCR 
Gene Forward Reverse 
DDAH1 TCTCATAGACCTTTGCGCTTTC CACAGAAGGCCCTCAAGATCA 
DDAH2 CCTGGTGCCACACCTTTCCC AGGGTGACATCAGAGAGCTTCTG 
KAPiCre AGATGCCAGGACATCAGGAACCTG ATCAGCCACACCAGACACAGAGATC 
AGXT2 TGCTGAATGCAAATGCACA CACTTGAATTGGCTCTGCAA 
eNOS AAGACAAGGCAGCGGTGG GCAGGGGACAGGAAATAGTT 
iNOS CAGCTGGGCTGTACAAACCTT ATGTGATGTTTGCTTCGGACA 
TNF" CAAACCACCAAGTGGAGGAG GTGGGTGAGGAGCACGTAGT 
IL1! GCTGCTTCCAAACCTTTGAC TGTCCTCATCCTGGAAGGTC 
IL6 CCGGAGAGGAGACTTCACAG TTCTGCAAGTGCATCATCGT 
Renin  AGGGGGTGCTAAAGGAGGAA TCGCTACCTCCTAGCACCAC 
Pol CCGCTCATGAAATGCTCCTT CGGGTCACTCTCCCCATGT 
229 
Tub GCCTTCTAACCCGTTGCTATCA CGGTGCGAACTTCATCGAT 
tonEBP GAAGAGCCCTATGTTGTGGCG TGTTGCAGGTATTTGTGGGC 
SIK1 ACAGGTGCTAGGGATCATGC AGCAGTCTGGAGGTTCCTCA 
AQP1 GCTGTCATGTATATCATCGCCCAG AGGTCATTTCGGCCAAGTGAG 
NaK CTGGCGAGTTCTATCACGCT GCCCACAGTCAATTCCATGC 
NHE3 AACCGAGCAGTGATGGGAGC GTGGGACAGGTGAAAGACGATT 
NaP CATCCTCCGTAAGGCAGATCC TTTGTCAAAGCCCAGCAACG 
TGFb AGACATTCGGGAAGCAGTGCCAG CATGAGGAGCAGGAAGGGTCGG 
ET1 CTGCTGTTCGTGACTTTCCA AGCTCCGGTGCTGAGTTC 
Col1a2 GCAGGTTCACCTACTCTGTCCT 
 
CTTGCCCCATTCATTTGTCT 
 
 
